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Abstract 
 
The first-order degradation rate constant (kdeg) of drug metabolising enzymes 
(DMEs) is a known source of uncertainty in the prediction of time-dependent drug-
drug interactions (DDIs) in physiologically-based pharmacokinetic (PBPK) 
modelling. There is a large disparity or paucity of published kdeg and related half-life 
(t1/2) values for DMEs. Physiologically-relevant kdeg values should ideally be derived 
in vivo to facilitate accurate DDI predictions. However, direct measurement of DME 
degradation in humans is not routinely possible and indirect measurements utilising 
changes in levels of specific endogenous substrates have only been described for a 
few DMEs. This thesis aims to develop an in vitro method of measuring DME protein 
degradation rates to improve the prediction accuracy of time-dependent DDIs. 
One in vitro approach of measuring protein degradation rates involves 
inhibiting de novo protein synthesis, followed by tracking residual protein or activity 
decline over time. Pharmacological protein synthesis inhibitor agents are commonly 
used for this purpose but may cause cytotoxicity. Four commonly used inhibitor 
agents were assessed for their capacity to inhibit protein synthesis without overt 
cytotoxicity. However, all selected compounds were too cytotoxic for subsequent use 
in kdeg studies. Small-interfering ribose nucleic acid (siRNA) can be added to in vitro 
systems to initiate gene-specific silencing by inhibiting messenger RNA (mRNA) 
translation. It was hypothesised that siRNA would inhibit de novo protein synthesis 
with less cytotoxicity owing to its specificity. CYP3A4 is the most widely studied 
cytochrome P450 (CYP) enzyme in terms of DDIs because of its well-recognised role 
in xenobiotic metabolism. Primary human hepatocytes were treated with CYP3A4-
specific siRNA to suppress mRNA translation, followed by the tracking of enzyme 
activity and protein loss over time to derive kdeg. CYP3A4 kdeg was calculated at 
0.019 (± 0.044) and 0.020 (± 0.0003) h-1 from protein and activity loss, respectively. 
These values were in good agreement with existing published values. The siRNA 
approach was subsequently applied to determine CYP2B6 kdeg. The CYP2B6 kdeg 
values derived from siRNA-treated hepatocytes were 0.081 (± 0.009) h-1 from protein 
loss and 0.058 (± 0.010) and 0.062 (± 0.006) h-1 from activity loss, which were 
assessed by different methods. The CYP2B6 kdeg values derived from untreated 
hepatocytes were similar to values in literature. This novel approach can now be used 
for other less well-characterised DMEs that are associated with time-dependent DDIs.  
Cellular protein abundance is a balance between synthesis and degradation. 
Dysregulation of the lysosomal or proteasomal protein degradation mechanisms 
affects steady-state protein levels and impacts on overall cellular functions. It was 
hypothesised that single nucleotide polymorphisms (SNPs) in the CYP3A4 protein 
degradation machinery could affect CYP3A4 protein abundance and downstream 
activity. Five SNPs were investigated for associations with plasma atazanair (ATV) 
concentrations, which was a surrogate measure for CYP3A4 activity. No associations 
were found and this was likely due to the lack of clear understanding of the specific 
mechanisms that commits CYP proteins for degradation. Further work in this field 
will identify targets that may be exploited in the future for more accurate 
measurements of DME kdeg. 
The data presented in this thesis enhances the understanding of methods used 
to study protein degradation and this can be applied to multiple fields of cellular 
research. Importantly, work herein has generated a novel approach to measuring kdeg 
of proteins that can be applied to other less-well characterised enzymes for better 
prediction of time-dependent DDIs.  
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1. INTRODUCTION 
 
Drug-drug interactions (DDIs) occur when two or more drugs are co-administered 
and the perpetrator drug(s) causes changes in exposure of the concomitant (victim) 
drug(s), which can lead to therapeutic failure or adverse drug reaction (ADR). This is 
particularly relevant for treatments in cancer, human immunodeficiency virus (HIV) 
and psychiatric disorders, and often in elderly patients where treatments require 
polypharmacy and also when drugs have narrow therapeutic windows (Scripture & 
Figg 2006). Mathematical modelling and simulation of DDI potential are becoming 
increasingly important to the drug discovery and development process. Regulatory 
agencies such as the US Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) have advocated for such approaches to be applied for 
predicting the risk and magnitude of DDIs for new molecular entities (NME) as well 
as approved drug compounds in the pre and post-licensing stages of drug 
development. This has been useful for optimising drug candidates, informing dosing 
regimens and clinical trials, and reducing costs of drug discovery.  
Drug metabolising enzymes (DME) are amongst some of the most important 
components in the complex interplay of factors giving rise to DDIs. Characterising 
drug-induced alterations to their activity via inhibition or induction is an important 
focus during drug development. Reliable predictions depend on accurate kinetic drug 
and system parameters that are incorporated into mathematical prediction algorithms. 
Several sources have indicated that the uncertainty of DME degradation rate constants 
(kdeg) gives rise to error in DDI predictions when incorporated into mechanistic static 
and dynamic physiologically-based pharmacokinetic (PBPK) modelling to predict in 
vivo effects (Obach et al. 2006; Wang 2010; Rowland Yeo et al. 2011; Mao et al. 
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2013). There is a large disparity in reported kdeg values of DMEs and currently no 
consensus as to the best method of obtaining kdeg. This thesis aims to address this 
issue with the optimisation of a novel and robust method of measuring kdeg.  
 
 
1.1. Drug-drug interactions 
DDIs can be pharmacokinetic (PK), whereby alterations in drug disposition, 
governing processes of absorption, distribution, metabolism and/or excretion 
(ADME), can lead to changes in drug exposure with consequential pharmacological 
effects. They can also be pharmacodynamic (PD) where the effects of the 
administered drugs in combination can be synergistic or antagonistic. DDIs occur 
through PK, PD or a combination of both mechanisms. PD interactions occur when 
drugs or substances have similar molecular targets but do not affect the PK 
parameters of each other. In synergistic PD interactions, two drugs may result in 
better response or exacerbated toxicity through separate mechanisms of action. An 
example of such a reaction is in the co-administration of warfarin and aspirin where 
both drugs’ anticoagulant activity in combination can increase the risk of spontaneous 
bleeding through distinct drug targets (Chan 1995).  
DDIs can have various outcomes: interactions between drugs can increase or 
decrease therapeutic and adverse effects, or result in a completely unique response 
that does not occur when the agents are given individually. Various other substances 
and factors can alter the PK and PD of medications for example, food, drug 
formulation excipients, nutritional supplements, genetics and environmental factors. 
Drugs with narrow therapeutic windows, such as antiretrovirals, anticoagulants, 
carbamazepine, oestrogens and aminoglycoside antibiotics, are particularly 
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susceptible to DDIs because relatively small changes in drug exposure will result in 
increased risk of ADRs or therapeutic failure (Wienkers & Heath 2005).  
PK interactions are characterised by the alteration of the disposition (ADME) of 
one drug by another. If the alterations to ADME are of sufficient magnitude then a 
significant change in exposure of the victim drug occurs leading to altered 
pharmacological effects. An example of PK interactions is when multiple drugs 
compete for the same metabolic pathway and when the pathway is inhibited the 
substrate drugs undergo partial metabolism at a slower rate, which results in reduced 
clearance and increased exposure. An example of this is in the co-administration of 
CYP3A4 substrates clarithromycin and simvastatin, where clarithromycin inhibition 
of CYP3A4 leads to increased exposure of simvastatin that in turn could potentially 
cause rhabdomyolysis (Lee & Maddix 2001).  
Drug exposure is quantified in PK terms by the maximum plasma concentration 
(Cmax) and by AUC (area under the curve); this is the area of the curve in a plasma-
concentration versus time response plot. Changes in Cmax reflects the rate and extent 
of absorption of an orally-given drug; therefore encompassing the effects of first-pass 
metabolism. AUC corresponds to overall plasma exposure and changes in AUC are 
dependent on the rate of elimination. If AUC is significantly increased by DDI then 
pharmacological effects may become exaggerated and risk of ADR potential also 
increases. A significant decrease in AUC can result in reduction of pharmacological 
effects and risk of therapeutic failure. Quantifying changes in AUC can give 
indication as to whether DDIs are likely to occur (Bachmann 2009a).  
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1.2. Cytochrome P450 enzymes 
Cytochrome P450 (CYP) are functionally diverse haemoprotein enzymes found 
ubiquitously in nature, including bacteria, yeast, plants, fish and mammals (Danielson 
2002). Human CYP enzymes constitute a major enzyme family of 57 putatively 
functional genes and 59 pseudogenes grouped into 18 families and 44 subfamilies and 
these have specific functions such as biosynthesis of steroid hormones, prostaglandins 
and bile acids, degradation of endogenous compounds such as fatty acids, steroids, 
retinoic acids as well as exogenous compounds that include drugs and carcinogens, 
mostly through an oxidative transformation process (Williams et al. 2000). CYP 
enzymes can be found in a wide variety of tissues including the intestine, kidney, 
lung, brain, adrenal gland, testes, heart, nasal and tracheal mucosa and skin, but the 
highest abundance with the largest number of isoforms occurs in the liver causing it to 
be the major site of xenobiotic metabolism (Pelkonen et al. 2008). The small 
intestines constitute the next largest site of metabolism and the relative contributions 
of these sites to xenobiotic biotransformation depend on its route of administration. 
For intravenously administered drugs the liver is likely to be the major site of 
biotransformation bypassing the alimentary canal, whereas orally administered drugs 
will first undergo intestinal absorption where a proportion of the dose is metabolised 
by locally present DMEs, before reaching the liver. The solubility and lipophilicity of 
the drug compound, as well as the interplay between uptake and efflux transporters on 
enterocytes and hepatocytes are some of the factors that account for the differences in 
drug concentrations achieved in the gut and liver, which ultimately affect the 
proportion of administered dose that is able to reach systemic circulation and into 
target sites to elicit therapeutic effects. 
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CYP enzymes are classified according to their genetic information and sequence 
homology. About a dozen enzymes belonging in the CYP- 1, 2 and 3 families and are 
well characterised for the metabolism of xenobiotics. An estimated 70% of all 
commercially used drugs undergo CYP metabolism as the main route of clearance 
and ten isoforms of CYP enzymes carry out the majority of CYP-mediated 
metabolism, these include CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4 
and 3A5 (Williams et al. 2004; Guengerich 2008). CYP3A family accounts for >30% 
of CYP abundance in the liver, of which the most abundant isoform is CYP3A4 that 
is responsible for metabolising 50% of all currently used drugs. The CYP2 family 
accounts for around 60% of hepatic CYPs and they also catalyse a significant number 
of oxidative drug biotransformation reactions (Pelkonen et al. 2008).  
All CYP enzymes contain a prosthetic group consisting of a ferric Fe3+ 
chelated to an aromatic polypophorin IX ring or haem, which is linked to the protein 
structure via a sulphur atom from a proximal cysteine ligand. They are potent 
oxidants and are called monooxygenases due to their mechanism of oxidation by 
inserting one oxygen atom into the oxidised substrate. CYP uses molecular oxygen 
(O2) by inserting one oxygen atom into a substrate (S) and reducing the second atom 
to a water molecule, utilising two electrons (e-) provided by donor reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) via a reductase protein such 
as cytochrome b5 (cyt b5) as shown in equation A (Meunier et al. 2004): 
 
 
The major pathway of elimination of toxic and pharmacological agents 
involves the biotransformation of lipophilic compounds to readily excreted water-
soluble forms. The two distinct steps involved are traditionally described as phase I 
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(oxidation) and phase II (conjugation) and each step is catalysed by different 
metabolic enzymes. CYP enzymes catalyse the majority of phase I reactions, but 
other enzymes in this class include esterases, hydrolases, alcohol dehydrogenase and 
monoamine oxidases (MAOs). The main phase II conjugating enzymes include UDP-
glucuronyltransferase (UGT), sulfotransferases (SULTs) and glutathione S-transferase 
(GST) (Pelkonen et al. 2008). Compounds undergo either phase I or phase II, or more 
commonly both stages, in the pathway of elimination.  
Within the liver, CYP enzymes are embedded in the endoplasmic reticulum 
(ER) region and the orientation of the CYP within the ER is important for their 
activity. The hydrophobic region in the N-terminal end forms the monotopic 
membrane-spanning domain anchoring the protein to the ER. The haem containing 
catalytic part of the CYP is oriented towards the cytoplasm. The CYP redox partners 
NADPH, cytochrome P450 reductase (CPR) and cyt b5 are also anchored to the ER 
orientated to the cytosolic side of the membrane, readily donating electrons to CYP 
catalytic centre (Bachmann 2009b). 
 
1.2.1. CYP3A4 
It is estimated that CYP3A4 is involved in metabolising 50% of all currently used 
drugs (Zhou 2008). It is the predominant CYP isoform in the gut and constitutes over 
30% of all CYPs in the liver and therefore plays a critical role in xenobiotic 
metabolism at both sites (Pelkonen et al. 2008). The enzyme has large substrate 
variability, is highly inducible and allows catalysis of multiple compounds 
simultaneously, rendering it the most important and widely studied in the context of 
DDIs. The kinetic interactions between CYP3A4 and its substrates are complex, 
which complicates predictions of CYP3A4-mediated DDIs (Pelkonen et al. 2008; 
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Galetin et al. 2005), for example the HIV protease inhibitor drug ritonavir is reported 
to be both an inhibitor and inducer of CYP3A in a dose and time-dependent manner 
(Hsu et al. 1997; Foisy et al. 2008). Moreover, CYP3A4 has a large substrate overlap 
with other CYP enzymes and major transporters such as P-glycoprotein (P-gp) that 
further incriminates its association to many clinically significant DDIs. A list of 
CYP3A4 substrates, inhibitors and inducers are given in Table 1.1. 
Many studies collectively refer 3A4 and 3A5 isoforms as CYP3A. CYP 3A4 and 
3A5 isoforms have high structural homology and substrate specificity, however 
expression of CYP3A5 can vary widely between populations. Over 80% of the 
Caucasian population carry the CYP3A5*3 variant in the 3A5 isoform rendering it 
inactive, whereas over 90% of Sub-Equatorial African populations carry the 
functional CYP3A5*1 allele (Lamba et al. 2012; Bains 2013). The majority of 
clinically relevant CYP3A4/5 inhibitors are established as mechanism-based enzyme 
inhibitors (Grimm et al. 2009).  
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Table 1.1 CYP3A substrate, inhibitor and inducer compounds, * denotes time-dependent inhibitors (FDA, 2016) 
Substrate Inhibitor Inducer 
Sensitive Moderate Weak 
(<2-fold  éAUC; 
20-50%ê 
clearance) 
Moderate 
(>2 and >5-fold  
éAUC; 50-
80%ê clearance) 
Strong 
(>5-fold  éAUC; 
>80%ê clearance) 
Weak 
(20-50% 
êAUC) 
Moderate 
(50-80% 
êAUC) 
Strong 
(>80%êAUC) 
Alfentanil 
Avanafil 
Budesonide 
Buspirone 
Conivaptan 
Darifenacin 
Darunavir 
Dasatinib 
Dronedarone 
Ebastine 
Eletriptan 
Eplerenone 
Everolimus 
Felodipine 
Ibrutinib 
Indinavir 
Lomitapide 
Lovastatin 
Lurasidone 
Maraviroc 
Midazolam* 
Naloxegol 
Nisoldipine 
Quetiapine 
Saquinavir 
Sildenafil 
Simvastatin 
Sirolimus 
Tacrolimus 
Testosterone 
Ticagrelor 
Tipranavir 
Tolvaptan 
Triazolam 
Vardenafil 
 
Alprazolam 
Aprepitant 
Atorvastatin 
Colchicine 
Elugistat 
Pimozide 
Rilpivirine 
Rivaroxaban 
Tadalafil 
Chlorzoxazone 
Cilostazol 
Fosaprepitant 
Istradefylline 
Ivacaftor 
Lomitapide 
Ranitidine 
Ranolazine 
Tacrolimus 
Ticagrelor 
Aprepitant 
Amiodarone* 
Amprenavir* 
Azamulin* 
Cimetidine 
Ciprofloxacin 
Clotrimazole 
Crizotinib 
Cyclosporine 
Delavirdine* 
Dronedarone 
Erythromycin* 
Fluconazole 
Fluvoxamine 
Fosamprenavir 
Imatinib 
Miconazole 
Tofisopam 
Verapamil*  
 
 
Atazanavir 
Bocepravir 
Clarithromycin* 
Conivaptan 
Corbicistat 
Danoprevir 
Darunavir 
Diltiazem* 
Elvitegravir 
Grapefruit juice* 
Idelalisib 
Indinavir 
Itraconazole 
Ketoconazole* 
Lopinavir* 
Nefazodone* 
Nelfinavir* 
Paritaprevir 
Posaconazole 
Ritonavir* 
Saquinavir* 
Telithromycin 
Telaprevir 
Tipranavir 
Troleandomycin* 
Voriconazole 
Armodafinil 
Fufinamide 
Bosentran 
Efavirenz 
Etravirine 
Modafinil 
Carbamazepine 
Enzalutamide 
Mitotane 
Phenytoin 
Rifampicin 
St John’s Wort 
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1.2.1. CYP2B6 
Until just over a decade ago, CYP2B6 was regarded as a minor human hepatic CYP 
accounting for <1% of total content. However, studies since conducted with improved 
detection methods have indicated that the isoform is highly variable between individuals, 
accounting for 2-10% of overall CYP abundance and an estimated 8% contribution to 
metabolism of all clinically used drugs (Wang & Tompkins 2008; Hedrich et al. 2016). 
CYP2B6 is considered highly inducible by phenobarbital-type compounds and CYP3A4 
inducing drugs such as rifampicin, dexamethasone and carbamazepine (Lindley et al. 2002; 
Kharasch et al. 2012; Faucette et al. 2004). CYP2B6 shares mechanisms of transcriptional 
regulation (discussed in 1.3.2) with several other DMEs, consequently inducers of CYP2B6 
have also been found to induce CYP3A4 (Kharasch et al. 2012) and UGT1A1 as well as 
transporters such as P-gp (Tolson et al. 2009).  
Compared with CYP3A4, there has been less significant enzyme inhibition interactions 
identified for CYP2B6. Walsky et al. (2006) evaluated 227 clinically used drugs for their 
ability to inhibit CYP2B6 in vitro. They found that 30 of the 227 compounds displayed 50% 
or greater inhibition at 30 µM and identified clopidogrel and ticlopidine as potent inhibitors. 
However, even with this significant in vitro finding, these inhibitors do not fit the FDA 
classification of a potent inhibitor. A list of CYP2B6 substrates, inhibitors and inducers are 
given in Table 1.2. 
CYP2B6 is highly polymorphic with over 100 single nucleotide polymorphisms (SNPs) 
and 63 alleles identified. Most significant is the CYP2B6*6 (516G>T and 785A>G) allele 
which occur in 15-60% of various populations, the homozygous phenotype results in a non-
functional allele (Zanger & Klein 2013). This variant allele has been linked to central nervous 
system (CNS) toxicity of efavirenz by significantly increasing plasma levels (Rakhmanina & 
van den Anker 2011). Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) 
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used widely for treatment of HIV-1; it has a narrow therapeutic index that renders the drug 
particularly susceptible to therapeutic failure or toxicity with altered exposure. The highly 
inducible and polymorphic nature of the CYP2B6 gene contribute to the large inter-individual 
variability observed with PK of substrate drugs and up to 250-fold expression difference 
between individuals (Hedrich et al. 2016).  
To date, CYP2B6 has not been implicated in causing clinically-relevant DDIs, however 
combining its highly inducible potential, significant impact of genetic regulations and a 
likelihood of interactions with other CYP enzymes and transporter proteins, there is an 
increased likelihood of uncovering DDIs mediated by this enzyme in the future.  
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Table 1.2 CYP2B6 substrate, inhibitor and inducer compounds, * denotes time-dependent inhibitors (Collated from FDA, 2016 and 
Hedrich et al 2016) 
 
  
Substrate Inhibitor  Inducer 
Sensitive Moderate Weak 
(<2-fold  éAUC; 20-
50%ê clearance) 
Moderate 
(>2 and >5-fold  
éAUC; 50-80%ê 
clearance) 
Strong 
(>5-fold  éAUC; 
>80%ê clearance) 
Weak 
(20-50% 
êAUC) 
Moderate 
(50-80% êAUC) 
Strong 
(>80%êAUC) 
Aminopyrine 
Artemether 
Artemisinin 
Bupropion 
Clotiazepam 
Coumarins 
Cyclophosphamide 
Diazepam 
Efavirenz 
Ifosfamide 
Lidocaine 
Mephenytoin 
Mephobarbital 
Methadone 
Nevirapine 
Pethidine 
Piclamilast 
Propofol 
S-mephobarbital 
Selegiline 
Temazepam 
Antipyrine 
Ketamine 
Mexiletine 
Nicotine 
Tamoxifen 
Tazofelone 
Testosterone 
Valproic acid 
 
Clopidogrel* 
Tenofovir 
Ticlopidine* 
Voriconazole 
Phencyclidine*  
Sertraline 
Thiotepa * 
- Nevirapine Efavirenz* 
Rifampicin 
Ritonavir 
Carbamazepine 
Phenobarbital 
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1.3. Relevance of cytochrome P450 enzyme turnover in drug-drug 
interaction predictions 
CYP enzymes are estimated to metabolise over 70% of all drugs on the market 
(Williams et al. 2004) and they tend to have broad and overlapping substrate 
specificity, which renders specific CYPs particularly relevant in causing DDIs. Most 
drugs cleared by the CYP system are metabolised by several isoforms but drugs that 
are metabolised by a single isoform are more likely to be victims of DDIs compared 
to those with multiple metabolic pathways (Pelkonen et al. 2008). Activities of CYP 
enzymes are affected by genetic, endogenous and environmental factors, which 
causes drug metabolism to be exceedingly variable between individuals. The EMA 
and FDA have issued specific guidelines on characterising inhibitory and induction 
potential of seven major CYP isoforms, 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A, by 
new molecular entities (NMEs) as part of the drug development process to assess 
potential of ADRs caused by DDIs and to recommend dosing regimens and clinical 
trials (EMA 2012; FDA 2012; FDA 2017).  
 
1.3.1 Categories of CYP inhibition interactions 
Inhibition of CYP enzymes is the most common cause of clinically relevant DDIs 
and has been the reason for withdrawal of several drugs from the market over the 
years. For example, the antihistamine terfenadine was removed from market due to 
causing QT prolongation, torsades de pointes and sudden cardiac death in patients 
receiving CYP3A4 inhibitors (Woosley et al. 1993; Dresser et al. 2000). Inhibition of 
CYP function by a perpetrator compound can lead to the reduced metabolism of a 
victim drug that uses the same inhibited CYP enzyme in its metabolic clearance 
pathway. This increases the risk of accumulation of the parent drugs leading to ADRs 
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or a risk of therapeutic failure if the concomitant parent drug requires 
biotransformation into active metabolites to exert pharmacological effects.  
CYP enzyme inhibition interactions are categorised into direct and time-
dependent inhibition (TDI). Direct inhibition involves the rapid reversible association 
and dissociation of drugs and enzymes and this can be further divided into 
competitive, non-competitive, uncompetitive and mixed inhibition. Competitive 
inhibition occurs when a substrate (inhibitor) binds to a single active site that is also 
the active binding site for another substrate or the inhibitor itself and the binding of 
the inhibitor can be reversed with increased substrate concentrations. Non-
competitive inhibition occurs if the inhibitor binds at a site that is distinct from the 
substrate-binding site, but the binding of which slows the product formation and 
addition of substrate cannot overcome the inhibition. Uncompetitive inhibition occurs 
when a drug can only bind to the enzyme-substrate complex when a substrate is 
present and then cause a slowing of product formation. Finally, mixed inhibition 
involves a combination of competitive and non-competitive inhibition to different 
degrees of affinity (Zhang & Wong 2005; Bachmann 2009a).  
Direct inhibition has been the most widely studied; progress in this area has 
led to a push to study TDI (which includes mechanism-dependent inhibition) in CYP 
interactions (Riley & Wilson 2015). TDI generally results from irreversible or quasi-
irreversible inhibition reactions. Irreversible inhibition refers to the covalent, whereas 
quasi-irreversible refers to the non-covalent, binding of a chemically reactive 
intermediate to the enzyme that catalyses its formation, resulting in an irreversible 
loss of enzyme function. TDI can also result from reversible inhibition, therefore the 
difference between TDI and mechanism-based inhibition (MBI) ought to be 
recognised (Grimm et al. 2009). TDI is defined as a compound that displays an 
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increase to the extent of inhibition it causes when incubated with the enzyme prior to 
addition of substrate, therefore TDI is a definition based on the kinetics of the 
interaction. Whilst all MBI are quasi-irreversible and irreversible inhibition 
interactions, MBI can only be defined after specific biochemical studies are 
conducted to prove that the enzyme forms a chemically reactive metabolite as part of 
the inhibition mechanism (Riley & Wilson 2015).  
 CYP inhibition interactions can also be categorised based on the agent that is 
inhibiting the enzyme in question. Inhibition can occur directly from the parent 
compound or from its metabolite(s). Metabolism-dependent inhibition (MDI) 
describes inhibition interactions caused by metabolite(s) of the investigated 
compound and can be further divided into reversible, irreversible and quasi-
irreversible MDI (Parkinson et al. 2011).  
 
1.3.2 Relevance of enzyme turnover in time-dependent interactions 
At steady-state (Ess) the rate of change of active enzyme concentration (d[E]/dt) is 
considered to be a balance between de novo protein synthesis (ksyn) and protein 
degradation, the rate of which is called kdeg (enzyme degradation rate constant) and 
this relationship is depicted in A (Yang et al. 2008): 
𝐤𝐬𝐲𝐧  𝐄 𝐤𝐝𝐞𝐠   (A) 
![!]!! = k!"# −  (k!"# x [E])  (1) [E]!! =  !!"#!!"#  (2) 
When equilibrium between enzyme ksyn and kdeg is disturbed, such as in the 
case of irreversible inhibition or induction interactions, the abundance of active 
enzyme will change and reach a new steady-state. The ESS level and the time taken to 
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reach the new steady-state level are determined by enzyme ksyn and kdeg (as described 
by equation 2). Induction and time-dependent DDIs are mediated by a change in 
enzyme level; therefore accurate estimation of enzyme turnover will affect the 
accuracy of predictions of these interactions (Yang et al. 2008; Almond et al. 2009). 
Accordingly, the predictions of time-dependent DDIs (such as MBI and time-
dependent induction) are most sensitive to inaccuracies in enzyme kdeg (Hutzler et al. 
2011).  
 
1.3.3 Mechanism-based inhibition 
A mechanism-based enzyme inhibitor is a compound that undergoes a 
biotransformation catalysed by the enzyme to a reactive metabolite, which in turn 
inactivates the enzyme by binding covalently (irreversible inhibition) or non-
covalently (quasi-irreversible inhibition) (Silverman 1995). This interaction is also 
referred to as MDI and suicide inhibition. Mechanism-based inhibition (MBI) results 
in a permanent inactivation of the enzyme that can only be overcome with the 
synthesis of new enzyme proteins (as depicted in figure 1.1), as such, interactions 
often manifest as slow-onset, long-lasting and cumulative in clinical scenarios 
(Venkatakrishnan & Obach 2007).  
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Predictions of DDIs based on in vitro models of competitive inhibition are 
known to underestimate the magnitude of interactions in the presence of a time-
dependent inhibitor (Obach et al. 2006; Hemeryck et al. 2001). Therefore TDI require 
different models of kinetic interactions and TDI-specific parameters. MBI reactions, a 
subset of TDI, can be modelled as: 
E+ I !!  EI !!"  EI!  !!"  E!"#$%                     (B) ↓ k!" E+ P 
Where E is the active enzyme and Einact is the inactive forms of the enzyme; I, 
metabolite-dependent inactivator; P, product and EI and EI’ are enzyme-inhibitor 
complexes. CYP enzymes catalyse the conversion of a mechanism-based inactivator 
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Figure 1.1 Schematic for the change in enzyme activity from baseline levels 
after multiple doses of a mechanism-based inhibitor. Upon removal of the 
inhibitor, enzyme recovery to basal levels will depend on resynthesis of the enzyme. 
Accordingly, the time taken to reach basal levels will depend on the rate of enzyme 
synthesis and degradation (that is interchangeable with t1/2).  
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to the reactive form EI’ with rate constant kp1 and this reactive metabolite is either 
released as a product (via kp2) or react and further inactivate more enzyme, Einact.  
Evaluation of MBI can be divided into two categories: 1) high-throughput 
screening assays that rank compounds based on their TDI potential, 2) kinetic assays 
constructed to characterise the potency (KI, inactivator concentration that produces 
50% rate of maximal inactivation) and maximum inactivation rate (kinact). These 
parameters are then incorporated into steady-state mechanistic or dynamic PBPK 
modelling to assess the potential of DDIs (Yang et al. 2005). 
The in vitro two-step dilution approach is used to experimentally determine KI 
and kinact. The first step involves pre-incubating a hepatic CYP system with NADPH 
and a range of inactivator concentrations over varying amounts of time to determine 
the decrease of active enzyme over time. The second step includes a dilution of the 
pre-incubation mixture to quench inactivation, followed by an activity assay with an 
enzyme-specific probe substrate at saturating concentration (Vmax) to track the 
remaining active enzyme. For each inhibitor concentration, natural log CYP activity 
versus pre-incubation time are plotted and the slope used for the calculation of the 
inactivation rate constant (kobs). This is turn is fitted to the Michaelis-Menten model 
where the array of kobs values are then plotted against inactivator concentrations to 
determine KI and kinact (Wong et al. 2016). The relationship between these parameters 
is given in the following equation: k!"# =  !!"#$% ! [!]!!![!]   (3) 
The R value is calculated based on kobs and kdeg and is used as an indicator for MBI 
potential: R =  !!"#! !!"#!!"#    (4) 
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The FDA draft guidance for industry regarding irreversible inhibitors recommended 
the use of equation 2 to assess DDI potential. If R > 1.1 (or 11 for CYP3A inhibition 
in the gut) then the test compound is considered likely to elicit considerable CYP 
MBI (FDA 2012) and warrants further investigation with a full mechanistic static 
model or dynamic PBPK model to predict in vivo DDI potential (Fujioka et al. 2012). 
Other methods such as the progress curve have also been suggested for assessing MBI 
potential (Burt et al. 2012). 
 
1.3.3.1. Relevance of kdeg in mechanism-based inhibition 
In the presence of an irreversible inhibitor in vivo, the levels of enzyme will 
decrease due to inactivation (described by equation 5), reaching a new steady-state 
level (equation 6). In steady-state CYP enzyme abundance is a balance between the 
rate of synthesis (ksyn) and rate of degradation (kdeg) (described by A). However, MBI 
will cause a secondary mechanism for loss of functional enzyme (rate constant λ) in 
addition to its endogenous degradation (kdeg), as depicted:              𝐤𝐬𝐲𝐧  𝐄 𝐤𝐝𝐞𝐠                    (C) ↓ 𝛌 
Kobs is the inhibitory rate constant can be substituted into equations 5 and 6 to account 
for λ: 
![!]!! =  k!"# − k!"# x E − k!"# x E   (5) [E]!! =  !!"#!!"#! !!"#   (6) 
Therefore by substituting inactivation constants, the mechanistic equation for MBI is: 
![!]!! =  k!"# x E! −  E! x (k!"# + !!"#$% ! !!!! ! )  (7) 
Where, ksyn = kdeg x Eo and E0 is the initial enzyme level.  
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From this principle, Mayhew et al. (2000) developed the following 
mechanistic static model equation to quantitatively assess the potential for an 
inactivator to cause increased exposure by MBI in vivo: δAUC =  !!",!"#!! !!"#$% ! ! !" !"!#!! ! !!"# !(!! !"!"#)
    (8) 
Where δAUC is the AUC ratio of in vivo exposure in the presence of inactivator 
compared to control state; fmcyp, fraction metabolised by CYP isozyme and [I]invivo, in 
vivo Cmax concentration of inactivator.  
Accurate predictions of DDIs arising from MBIs rely on four main 
parameters: 1) the in vivo enzyme kdeg, 2) in vivo concentration of inactivator drug 
available to the enzyme, 3) in vitro inactivation parameters kinact and KI and 4) the 
fraction of clearance of the affected drug mediated by the inactivated enzyme (Obach 
et al. 2006). Each of these parameters are potential sources of prediction errors and 
require further investigation.  
 
1.3.4 Enzyme induction 
Induction occurs when a perpetrating chemical compound causes an increase 
in the expression of enzymes in the metabolising tissue. This can result in increased 
CYP activity thereby enhancing clearance and reducing exposure of the victim drug 
and can also potentially lead to reduced therapeutic effect and/or increase in exposure 
to metabolites, which can in turn cause ADRs. These interactions can be clinically 
significant, for example in rifampicin induction of CYP3A that results in reducing the 
in vivo AUC of co-administered drug verapamil by up to 52-fold (Fromm et al. 1996), 
causing contraception failure if administered with oral contraceptives, organ rejection 
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when given with cyclosporine and failure of protease inhibitors in HIV treatments 
(Almond et al. 2009). 
Several forms of CYP expression occur through transcription that is regulated 
by nuclear transcription factors including the aryl hydrocarbon receptor (AhR), 
pregnane X receptor (PXR) and the constitutive active receptor (CAR); the 
mechanisms of which are depicted in Figure 1.2. In the absence of an agonist AhR is 
located in the cytosol in complex with chaperone proteins Hsp90, ARA9 and p23. 
Upon binding, AhR undergoes conformational change that causes dissociation from 
chaperone proteins and nuclear translocation. Within the nucleus AhR dimerises with 
the AHR nuclear translocator (ARNT) and forms a DNA-binding complex. The 
AHR:ARNT heterodimer complex binds xenobiotic response element (XRE) and 
initiates transcription. CYPs 1A1, 1A2 and 1B1 are induced by this mechanism 
(Hewitt et al. 2007).  
CYP3A induction is mediated by PXR and CAR. Following binding of an 
inducer to PXR, the complex translocates into the nucleus and forms a heterodimer 
with retinoid X receptor (RXR). The PXR:RXR heterodimer binds distal and 
proximal response elements in the ER6 regulatory region of the CYP3A gene, also 
referred as xenobiotic response enhancer module (XREM), to initiate transcription. In 
the absence of an activator, CAR resides in the cytosol in complex with cytoplasmic 
CAR retention protein (CCRP) and Hsp90. During induction, CAR pathway is 
activated upon binding an inducer and CAR forms a heterodimer with RXR and binds 
to many DNA-binding elements that are shared with PXR (Handschin & Meyer 
2003).  
In CYP2B6 induction, the CAR:RXR heterodimer binds to the phenobarbital-
responsive enhancer module (PBREM) in the regulatory region of the CYP2B6 gene 
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and facilitates gene transcription. PXR has also been implicated in CYP2B6 
regulation as the PXR:RXR complex is able to bind the PBREM eliciting 
transcription but selective activation of CAR over PXR provides preferential 
induction of CYP2B6 over CYP3A (Wang & Tompkins 2008; Pelkonen et al. 2008; 
Almond et al. 2009). 
 
 
Figure 1.2 Schematic showing the activation of AhR, CAR and PXR nuclear 
receptor regulation pathways leading to induction of CYP enzymes. Adapted 
from Handschin & Meyer (2003)  
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CYP induction is a time and substrate concentration-dependent process. 
Induction occurs through binding of drugs to nuclear receptors which then activate the 
protein expression of a specific enzyme through an endogenous signalling pathway, 
therefore in vitro induction studies are conducted in living cells, as opposed to 
microsomal fractions, where these signalling mechanisms are intact. In vitro studies 
typically involve the plating and culturing of cells for 1-2 days prior to addition and 
incubation with a positive control and test compounds over a range of concentrations 
for a further few days. The magnitude of CYP increase can be detected by measuring 
specific enzyme activity and preferably mRNA and compared to untreated controls 
(Fahmi & Ripp 2010).  
Several mathematical models were developed incorporating in vitro 
parameters derived from induction experiments, to assess whether a NME or drug 
compound is likely to cause induction DDIs. One such an approach is the relative 
induction score (RIS) that combines in vitro potency and efficacy induction 
parameters (Emax and EC50, respectively) with the efficacious plasma inducer 
concentrations that is correlated to a calibration curve generated from known 
induction response: RIS =  !!"# ! [!"#]!"!"![!"#]   (9) 
Where Emax is the maximum induction response; EC50, concentration at 50% of 
maximal induction and [Ind] is the concentration of inducer. If RIS > 0.1 then the 
compound is likely to lead to clinical DDI (Fahmi & Ripp 2010; Riley & Wilson 
2015).  
Another approach that is advocated by the 2012 draft FDA recommendations 
is the R3-value, which is calculated by the following equation where d is the 
calibration factor (taken as 1): 
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R! =  !!! ! ! !!"# ! [!"#]!"!"![!"#]   (10) 
If the R3 value is < 0.9 then the investigated compound is likely to be an inducer and 
will require further incorporation into mechanistic static or dynamic models to assess 
likely magnitude of DDIs. 
 The RIS approach can be used where a known induction response, such as in 
the case of CYPs in hepatocytes, are available to generate a calibration curve to which 
the investigated inducer can be compared with. The R3 approach conversely, requires 
generation of the entire profile of the concentration-induction curve (Kuramoto et al. 
2017). 
 
1.3.4.1 Relevance of kdeg in time-dependent induction 
Increased abundance of enzyme levels in response to an inducer can result 
from either increased de novo protein synthesis (ksyn) or decrease in degradation (kdeg) 
by protein stabilisation. There will be a delay in both cases before the new 
equilibrium is reached and the time taken to reach this will depend on enzyme kdeg 
(depicted in Figure 1.3), therefore accurate estimation of enzyme turnover will affect 
the accuracy of predictions. 
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The time taken to reach the new equilibrium is longer when kdeg is decreased 
compared to when enzyme synthesis is increased, thus enzyme kdeg is critical in the 
evaluation of time-dependent induction interactions (Almond et al. 2009). Enzyme 
levels will increase as described by the following equations: 
! ! !!! =  k!"# +  k!"# x E ! −  k!"# x E !   (11) =  k!"# + k!"# −  k!"#  x [!"#]!"!"![!"#] −  k!"# x [E]′  (12) 
A new steady state will be reached: [E]′!! =  !!"#!(!!"#! !!"#)!!"#  x [!"#]!"!"![!"#]   (13) 
Figure 1.3 Schematic for the change in enzyme activity from baseline levels 
after multiple doses of an inducer. Upon removal of the inducer, the time taken to 
return to basal enzyme activity levels will be dependent on the rate of enzyme 
degradation (that is interchangeable with t1/2). 
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Where kind is the enzyme induction rate constant; Kmax, maximum rate of enzyme 
synthesis; EC50, concentration of inducer at 50% of maximal induction and [E]’SS is 
the enzyme content at steady state in the presence of an inducer and [Ind] is the 
inducer concentration (Shou et al. 2008).  
 If the inducer only causes an increase in enzyme synthesis then the enzyme 
turnover (kdeg) does not determine the overall extent of induction. However, in the 
majority of time-dependent interactions the inducer is not given over sufficient time 
for the system to reach maximal induction and in this case the impact of 
interindividual variability in kdeg on the observed magnitude of induction will be 
apparent, therefore giving rise to variable DDI estimates.  
 
 
1.4 Mathematical modelling for in vivo drug interaction predictions 
Quantitative in vitro data describing ADME processes can be incorporated into 
computer-based algorithms to predict AUC changes and potential for DDIs. However, 
whilst many disposition interactions can be predicted qualitatively based on 
knowledge of ADME of interacting drugs, these quantitative changes in AUC are 
often insubstantial to bring about clinically-significant interactions in practice. 
Therefore, caution must be employed when using these prediction models because 
exaggeration of DDI potential can cause unnecessary attrition of potentially useful 
compounds (Bachmann 2009a).  
 
1.4.1. Static mechanistic model 
Fahmi et al. (2008) developed a mechanistic static model to predict the net 
potential for all DDIs simultaneously. This model accounts for metabolic 
 40 
contributions of both the liver and the gut wall and is applicable to compounds that 
can act as both inhibitors and inducers of DMEs. For example, ritonavir has been 
demonstrated to be a potent time-dependent inhibitor of CYP3A4 as well as an 
activator of the PXR induction pathway (Hsu et al. 1997). Prediction of DDIs for such 
agents are difficult due to the challenge to determine which interaction phenomena 
will dominate the in vivo response. As such, the combined or net effect model was 
developed for compounds that exhibit combinations of reversible direct inhibition, 
TDI and/or induction (Fahmi & Ripp 2010). In this model, the AUC ratio (δAUC) can 
be described by: δAUC =  !!! ! !! ! !!  ! !!"#$!(!! !!"#$)  x !!! ! !! ! !!  ! !! !! ! !!       (14) 
Where, A =  !!"#!!"#! !!"#$% ! !!!! !   B = 1+  ! ! !!"# ! [!"#]!"!",!"#![!"#]   C =  !!! [!]!!  
Where fmcyp is the fraction metabolised by CYP enzyme; FG, fraction of drug that 
escapes intestinal extraction. A, B and C are terms for TDI, induction and reversible 
inhibition, respectively. Subscript H and G are hepatic and gut interactions, 
respectively.  
The FDA categorisations for changes to substrate drug are: > 5-fold increase 
in AUC or >80% decrease in clearance suggests a strong inhibitor, >2 but <5-fold 
AUC increase and 50-80% clearance decrease is a moderate inhibitor and >1.25 but 
<2-fold AUC increase and 20-50% clearance decrease is considered a weak inhibitor. 
The advantage of this model over basic models is that it incorporates both hepatic and 
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intestinal components as well as different mechanisms of DDIs that can improve 
prediction accuracy. However, predictability of the model relies on accurate 
estimations of additional parameters such as FG, fmcyp, dose and kdeg, which can 
introduce sources of error to the model (Fahmi & Ripp 2010).  
 
1.4.2. Dynamic modelling 
As more comprehensive compound and biological systems data have become 
available through the maturation of the methods of attaining them, there has been 
increased confidence in DDI prediction accuracy using dynamic modelling and 
therefore growing interests for incorporating the use of them during drug development 
(Riley & Wilson 2015). These simulations use PBPK and in vitro-in vivo 
extrapolation (IVIVE) methods to evaluate the relevance of inhibition and induction 
interactions observed in vitro to predict in vivo clinical scenarios. The FDA and EMA 
have advocated the use of dynamic simulations alongside the net effect model during 
drug development (FDA 2012; EMA 2012).  
Static models assume a constant inhibitor/inducer concentration throughout 
the course of DDI prediction; they simply predict the change in overall exposure of 
victim drug from a constant concentration of perpetrator drug. However, many 
substrates are known to simultaneously display multiple forms of interaction 
including inhibition, inactivation and/or auto-activation, thus a comprehensive 
dynamic approach addressing the temporal changes in drug concentration as well as 
active enzyme levels and exposure to victim substrate should in theory improve 
predictions. As such, enzyme kdeg remains an important component in the dynamic 
modelling process. These models can also be semi- or whole-body PBPK and provide 
a physiologically-relevant framework enabling the incorporation of multiple ADME 
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processes, such as active transport and protein binding, as well as processes that are 
not yet fully characterised. However, predictability of such models relies on 
adequately characterised compound and biological parameters and prediction 
accuracy can be hampered by incorporating incorrect parameter values (Jones & 
Rowland-Yeo 2013).  
Proprietary software programmes with in-built PBPK algorithms, such as 
Simcyp®, PK-Sim®, AcslXtreme® and GastroPlus™, are the most commonly used 
for dynamic predictions. Semi-physiological models encompassing fewer 
compartments provide a useful tool to examine effects within a specific tissue of 
interest, for example the liver or gut, and these models are simpler and less reliant on 
multiple accurate physiological parameters. In contrast, software such as Simcyp® 
requires more comprehensive input data to incorporate into the complex in-built 
algorithms, but the software offers the distinct advantage of incorporating parameter 
variability to allow for predictions of DDI magnitude in specific patient populations 
(Fahmi & Ripp 2010).  
 
1.4.3. Uncertainty of kdeg in DDI predictions 
Several sources have highlighted the sensitivity of DDI predictions in both 
static and dynamic models to kdeg values when enzyme levels change as a result of 
TDI or induction (Venkatakrishnan et al. 2007; Grimm et al. 2009; Fahmi & Ripp 
2010; Galetin et al. 2006). Obach et al. (2006) demonstrated sensitivity of in vivo kdeg 
effects for accurate predictions of MBI interactions with contour mapping. Table 1.3 
summarises some published studies that assessed the impact of different CYP3A kdeg 
values on DDI predictions. Different kdeg values have yielded varied prediction 
accuracies, therefore it is apparent that the choice for kdeg is deemed as very important 
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for the generation of DDI predictions. This is particularly relevant for compounds that 
display time-dependent mixed inhibition/induction reactions, where complex dynamic 
modelling is needed that relies heavily on accurate incorporation of systems 
parameters (Grimm et al. 2009; Prueksaritanont et al. 2013). 
 
 
Table 1.3 Studies utilising different CYP3A4 kdeg values for DDI predictions 
 
Study Tested 
CYP3A4 kdeg 
(h-1) values 
Outcome Reference 
37 in vivo irreversible 
inhibition interactions with 
macrolides (erythromycin, 
clarithromycin and 
azithromycin) and diltiazem 
0.0048 - 0.03 89% of studies predicted 
within 2-fold using kdeg of 
0.0096 h-1 
(Galetin et al. 
2006) 
MBI with clarithromycin 
and erythromycin  
0.0231, 
0.0077 and 
0.0026 
Predicted clarithromycin 
inactivation rates were more 
sensitive to changes in kdeg 
compared with erythromycin 
(Ghanbari et al. 
2006) 
45 in vivo inhibition 
interactions with diltiazem, 
erythromycin, fluconazole, 
fluoxetine, itraconazole, 
ketoconazole, paroxetine 
ritonavir, terbinafine and 
verapamil 
0.0077 and 
0.0193 
Improved predictions of AUC 
for seven of nine trials when 
0.0193 h-1 was used 
(Einolf 2007) 
Sensitivity analysis of 
erythromycin/midazolam 
inhibition interactions in 
rats 
0.006 – 0.15 10-fold variation in kdeg 
resulted in midazolam AUC 
change from 8.3-18.8 
(Zhang et al. 
2010) 
54 clinical interactions with 
clarithromycin, diltiazem, 
erythromycin, ritonavir, 
saquinavir, verapamil and 
fluoxetine 
0.0077 and 
0.03 
Better prediction accuracy 
and less error relative to 
observed values when in kdeg 
of 0.03 h-1 was used with 
Simcyp. 
(Wang 2010) 
29 in vivo MBI interactions 
with azithromycin, 
clarithromycin, diltiazem, 
erythromycin and verapamil 
0.0193 and 
0.0077 
Better prediction accuracy of 
83 versus 59% of AUC 
within 1.5-fold when 0.0193 
h-1 CYP3A4 kdeg was used 
compared to 0.0077 h-1. 
(Rowland Yeo 
et al. 2011) 
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Table 1.3 Continued. 
 
Study Tested 
CYP3A4 kdeg 
(h-1) values 
Outcome Reference 
Simcyp simulations of 
plasma concentration-time 
profiles of diltiazem and 
midazolam interactions 
0.03 and 
0.0077 
Accurate Simcyp predictions 
(within 2-fold) were only 
observed when a hepatic 
CYP3A value of 0.03 h-1 was 
used.  
(Friedman et al. 
2011) 
Sensitivity analysis of 
crizotinib-midazolam 
interaction predictions 
0.000693 – 
0.693 
CYP3A4 t1/2 of 25-35 h 
yielded the best prediction of 
crizotinib plasma 
concentrations whereas a t1/2 
of 30-40 h yielded the best 
midazolam AUC prediction. 
Hepatic kdeg of 0.019 h-1 
yielded reasonable crizotinib 
interaction predictions.  
(Mao et al. 
2013) 
Pioglitazone/midazolam 
and troglitazone/simvastatin 
DDI predictions 
0.008, 0.03 
and 0.019 
Improved DDI predictions for 
both interactions with kdeg of 
0.03 h-1 compared with 0.019 
h-1 and 0.0008 h-1.  
(Prueksaritanont 
et al. 2013) 
Prediction of midazolam 
AUC following 28 day once 
daily oral administration of 
rifampicin 
0.008 and 
0.03 
Better prediction of observed 
midazolam AUC with kdeg of 
0.08 h-1 compared to 0.03 h-1.   
(Prueksaritanont 
et al. 2013) 
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1.5     Methods of measuring CYP protein degradation rates 
CYP kdeg is a physiological rather than drug-dependent parameter and cannot 
easily be directly measured in vivo; therefore it is often associated with uncertainty. 
The turnover of CYP enzymes is determined by protein degradation and, what is 
particularly relevant for DDI predictions, active site haem degradation. Depending on 
the approach of estimating kdeg, it is feasible that previous studies have generated t1/2 
estimates based on the protein component rather than the catalytic haem site. This will 
result in less relevance in terms of DDI kinetics thus introducing more uncertainty in 
the physiological relevance of kdeg for DDI predictions.  
There have been several approaches used to estimate CYP kdeg and the most direct 
method is using pulse-chase tracer kinetic studies of a specific protein of interest in a 
living organism (Correia 1991). However, such an approach requires multiple 
invasive sampling of hepatic tissue over time, thus it is unsuitable for humans and has 
only been applied to rodent models. Half-lives of rat CYPs 1A2, 2E1 and 3A have 
been estimated to be 10 (Correia 1991), 6-7 (Roberts et al. 1995) and 14 hours 
(Watkins et al. 1985), respectively in this way. However, rat CYP enzymes have 
shorter half-lives compared to humans resulting in under prediction of human DDI 
risk when rat half-lives are used in prediction models (Iwano S 2015; 
Venkatakrishnan et al. 2007).  
The approaches used for human estimates of human CYP kdeg fall into two main 
categories: 1) direct methods using in vitro models of the human liver and 2) indirect 
PK-based estimations based on in vivo animal or human systems.  
Liver slices and primary cultured hepatocytes have traditionally been used as in 
vitro models to estimate human kdeg. Pichard et al. (1992) used a radiolabelled pulse-
chase kinetic approach to estimate CYP3A4 kdeg in primary human hepatocytes and a 
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t1/2 of 44 hours was derived. Renwick et al. (2000) derived kdeg estimates for several 
CYP enzymes through characterising the rates of loss of CYP apoprotein and CYP-
specific metabolic activities in cultured human liver slices. The latter study, where 
pulse-chase was not conducted, is limited by the assumption that the CYP loss 
detected is solely due to enzyme degradation negating any de novo CYP synthesis that 
might occur during the analysis period. In both studies, the observed rate of loss of 
CYP may be confounded by cell death or differentiation during culture. Such caveats 
can result in uncertainty and lack of consensus on the optimum approach of 
measuring kdeg.  
Analysis of the time-course of enzyme induction followed by tracking the de-
induction profile upon removal of the inducer, or recovery profile following 
inactivation, may provide an indirect in vivo estimate of kdeg (as depicted in Figures 
1.3 and 1.1, respectively). This is based on the assumption that steady-state enzyme 
levels comprise of a balance between synthesis and degradation and that CYP 
induction, de-induction and recovery from inactivation are all first-order processes 
with a rate constant equivalent to kdeg. The inactivator or inducer utilised in such 
studies must have a shorter t1/2 than the enzyme turnover. If the inducer or inactivator 
has a t1/2 longer than that of the enzyme, the t1/2 of the drug will need to be 
deconvoluted from the overall process of induction, de-induction or recovery from 
inactivation to provide an estimate of kdeg. This can be done using physiologically-
based modelling on the clinical PK data or via non-compartmental deconvolution 
(Venkatakrishnan & Obach 2007; Venkatakrishnan & Obach 2005; Venkatakrishnan 
et al. 2007).  
Faber & Fuhr (2004) estimated human CYP1A2 t1/2 to be 39 h from tracking the 
recovery of CYP1A2 activity from induced state to basal conditions following abrupt 
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cessation of heavy smoking. Venkatakrishnan & Obach (2005) utilised non-
compartmental deconvolution of the t1/2 of paroxetine, which was originally generated 
by Liston et al. (2002) who tracked the recovery time-course of CYP2D6 upon 
cessation of treatment of paroxetine inactivator. The deconvoluted t1/2 of CYP2D6 
was estimated to be 51 h. For CYP2E1, tracking de-induction during withdrawal 
phase in alcoholics derived a t1/2 of 60 h (Lucas et al. 1995) and recovery of metabolic 
activity following inactivation by disulfiram have found the t1/2 to be 51 h (Emery et 
al. 1999).  
CYP3A (comprising 3A4 and 3A5) t1/2 are the most extensively studied amongst 
CYP enzymes using indirect PK based estimations. Greenblatt (2003) tracked the 
recovery of midazolam oral clearance following CYP3A inactivation by grapefruit 
juice, which estimated the in vivo intestinal t1/2 to be 23 h. For hepatic CYP3A4, the 
reported t1/2 values range from 10 to 140 h (Yang et al. 2008) and these have been 
derived from many studies utilising a range of in vitro and in vivo approaches (Table 
1.4). Earlier studies with in vivo rodent models estimated CYP3A t1/2 to be 14 h 
(Watkins et al. 1985). At the opposite end of the spectrum, Von Bahr et al. (1998) 
estimated CYP3A4 t1/2 to be 140 h from measuring nortriptyline metabolite formation 
in vivo in human subjects after dosing with pentobarbital. However, the accuracy of 
this estimate is likely to be limited by the fact that nortriptyline is metabolised by 
other CYP isozymes, primarily by CYP2D6, and the extent of metabolism can be 
highly variable between individuals. Several other estimates have found CYP3A4 t1/2 
to be in the region of 26 to 96 h. Table 1.4 shows a summation of the estimated 
turnover t1/2 of human hepatic CYPs.  
There are several caveats associated with the in vivo methods of deriving CYP 
kdeg. In vivo approaches characterise CYP activity through substrate drug turnover and 
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measurement of metabolite in urine or blood samples; and thus presents an indirect 
method of measuring kdeg. Such studies make the assumption that the probe substrate 
metabolites are produced by a single CYP isoform. However in practice, substrates 
such as ritonavir and midazolam are known to be metabolised by both CYP 3A4 and 
3A5 (Soars et al. 2006) and chlorzoxazone has also been found to be metabolised by 
both CYP 1A2 and 2E1 (Ono et al. 1995). Where probe substrate compounds are used 
to estimate the kdeg for a specific CYP enzyme, the validity of kdeg estimate is put into 
question when the probe substrate is metabolised by multiple CYP isoforms. 
Furthermore, drugs such as ritonavir produce simultaneous auto-induction and MBI of 
CYP3A and therefore confounds the interpretation of kdeg estimates when using the 
model-based analysis of solely auto-induction kinetics. Estimates of kdeg based on in 
vivo de-induction profiles are limited by the assumption that there was no de novo 
enzyme protein synthesis during the de-induction period. Another consideration is 
that in vivo estimates of hepatic CYP kdeg should take into account the relative 
contributions of gut disposition and metabolism of inducer/inactivator and probe 
substrate drug, when using PK based models for estimations with orally-dosed 
compounds. A combination of these caveats may give rise to the large difference 
between kdeg estimations across and within studies.  
Considering the uncertainty of CYP kdeg, several CYP3A DDI studies have used 
an approach of selecting reasonable estimates of kdeg (for example, between 24-72 h 
range) for incorporation into the prediction model, followed by examining the 
sensitivity of the predicted interaction magnitude around the range of values used, as 
shown in Table 1.3 (Galetin et al. 2005; Ghanbari et al. 2006; Venkatakrishnan & 
Obach 2007). The sensitivity of DDI predictions to varying kdeg values is related to 
fmcyp of the object drug. Prediction accuracy was found to be less sensitive to CYP 
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kdeg values when drugs had alternate clearance mechanisms (relating to a smaller 
fmcyp) compared to those with exclusive clearance by the inactivated enzyme. As 
such, fmcyp is incorporated into the static mechanistic models given by equations 8 
and 14 (Venkatakrishnan et al. 2007; Obach et al. 2006). 
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Table 1.4 Human hepatic CYP turnover half-lives and corresponding kdeg 
(Updated from Yang et al. 2008) 
 
 
CYP 
Enzyme 
Source Method n Half-life 
(h) 
kdeg  
(h-1) 
Reference 
1A2 In vitro Pulse-chase 1 51 0.014 (Diaz et al. 1990) 
 In vitro Tracking degradation over 
time in cultured hepatocytes 
N/A 43 0.016 (Maurel 1996) 
 In vitro Tracking apoprotein over 
time in cultured liver slices 
5 36 (8-58) 0.019 (Renwick et al 
2000) 
 In vivo Tracking recovery profile 
following inactivation by 
heavy smoking 
12 39 (19-143) 0.018 (Faber & Fuhr 
2004) 
 In vivo Tracking autoinduction 
profile from carbamazepine 
using caffeine metabolism as 
probe 
7 105 0.0066 (Magnusson et al. 
2007) 
2A6 In vitro Tracking apoprotein loss over 
time in cultured liver slices 
2 26 (19-37) 0.027 (Renwick et al 
2000) 
2B6 In vitro Tracking apoprotein loss over 
time in cultured liver slices 
1 32 0.022 (Renwick et al 
2000) 
 In vitro De-induction profile in 
HepatoPac following 
rifampicin induction 
2 68 (67-70) 0.010 (Dixit et al. 2016) 
2C8 In vitro Tracking apoprotein loss over 
time in cultured liver slices 
5 23 (8-41) 0.030 (Renwick et al 
2000) 
 In vivo Tracking recovery profile 
after gemfibrozil inactivation 
using repaglinide as probe 
9 22 (16-28) 0.032 (Backman et al. 
2009) 
2C9 In vitro Tracking apoprotein loss over 
time in cultured liver slices 
5 104 0.0067 (Renwick et al 
2000) 
2C19 In vitro Tracking apoprotein loss over 
time in cultured liver slices 
3 26 (7-50) 0.027 (Renwick et al 
2000) 
2D6 In vitro Tracking apoprotein loss over 
time in cultured liver slices 
4 70 0.0099 (Renwick et al 
2000) 
 In vivo Tracking recovery after 
MDMA inactivation using 
dextromethorphan as probe 
12 37 (14-60) 0.019 (Yubero-lahoz et 
al. 2000) 
 In vivo Tracking recovery profile 
after paroxetine inactivation 
followed by non-
compartmental deconvolution 
13 51 0.014 (Liston et al 2002; 
Venkatakrishnan 
& Obach 2005) 
 In vivo Tracking recovery profile 
after MDMA inactivation and 
using dextromethorphan as 
probe 
15 47 (35-58) 0.015 (O’Mathúna et al. 
2008) 
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Table 1.4 continued  
 
CYP 
Enzyme 
 
Source Method n Half-life 
(h) 
kdeg 
(h-1) 
Reference 
2E1 In vivo Tracking de-induction profile 
after alcohol induction 
6 60 0.012 (Lucas et al 1995) 
 In vivo Tracking of enzyme recovery 
after disulfiram inactivation 
using chlorzoxazone as probe 
13 50 (±19) 0.014 (Emery et al 
1999) 
 In vitro Tracking apoprotein loss over 
time in cultured liver slices 
5 27 (7-40) 0.026 (Renwick et al 
2000) 
4A11 In vitro Tracking apoprotein loss over 
time in cultured liver slices 
5 75 (56-77) 0.0092 (Renwick et al 
2000) 
3A4 In vivo Tracking of auto-induction  6 96 (53-154) 0.0072 (Pitlick et al. 
1976) 
 In vivo Tracking de-induction profile 
after carbamazepine 
induction 
7 72 (20-146) 0.0096 Lai et al (1978) 
 In vivo Tracking de-induction profile 
after carbamazepine 
induction 
3 (85-806) - (Warren et al. 
1980) 
 In vitro Induction by rifampicin 
followed by pulse-chase 
tracking of de-induction in 
hepatocytes 
1 44 0.016 (Pichard et al. 
1992) 
 In vivo Tracking of auto-induction 
and interpreted by Yang et al 
2008 
13 10 (2-158) 0.069 (Boddy et al. 
1995; Yang et al. 
2008) 
 In vitro Tracking degradation over 
time in cultured hepatocytes 
N/A 26 0.027 (Maurel, P 1996) 
 In vivo De-induction profile 
following rifampicin dosing 
with verapamil as probe 
8 36-50 - (Fromm et al 
1996) 
 In vivo Tracking of auto-induction by 
ritonavir 
16 85 (±61) 0.0082 (Hsu et al. 1997) 
 In vivo De-induction profile 
following phenobarbital 
dosing 
6 140 (48-
284) 
0.0050 Von Bahr, C et al 
(1998) 
 In vivo Tracking of auto-induction by 
methadone 
35 94 (62-205) 0.0074 (Rostami-
Hodjegan et al. 
1999) 
 In vivo Tracking de-induction after 
rifampicin dosage, measuring 
6β-hydroxycortisol as 
substrate; interpreted by Yang 
et al. 
15 72 0.0096 (Tran et al. 1999; 
Yang et al. 2008) 
 In vitro Tracking apoprotein loss over 
time in cultured liver slices 
4 79 0.0088 (Renwick et al 
2000) 
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Table 1.4 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CYP 
Enzyme 
 
Source Method n Half-life 
(h) 
kdeg 
(h-1) 
Reference 
3A4 In vivo Tracking autoinduction 
profile from carbamazepine 
with midazolam as probe 
7 70 0.0099 (Magnusson et al 
2007) 
 In vivo De-induction profile 
following St John’s Wort 
induction 
12 46 (20-116) 0.017 (Imai et al. 
2008) 
 In vivo De-induction profile 
following carbamazepine 
induction 
15 86 0.0081 (Punyawudho et 
al. 2009) 
 In vivo De-induction profile 
following rifampicin 
induction 
11 86 0.008 (Reitman et al. 
2011) 
 In vitro De-induction profile in 
HepatoPac following 
rifampicin induction 
3 49 (43-56) 0.014 (Dixit et al 
2015) 
 
 In vitro siRNA knockdown followed 
by metabolite detection 
5 29 (22-39) 0.024 (Ramsden et al. 
2015) 
 In vitro SILAC labelling in 
HepatoPac 
4 30 (27-32) 0.023 (Takahashi et al. 
2017) 
3A5 In vitro Tracking apoprotein loss over 
time in cultured liver slices 
3 36 (15-70) 0.019 (Renwick et al 
2000) 
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1.6 . Mechanisms of CYP protein degradation 
 
Protein abundance in a cellular system is a balance between the rate of 
synthesis and degradation. The ability of the cell to remove and replenish proteins in a 
dynamic state of constant turnover is paramount to maintaining essential cellular 
functions and all protein turnovers are regulated in a specific way. Rates of protein 
synthesis are readily measurable by time-course experiments utilising radioisotopes 
and protein quantification, but kdeg is often more difficult to determine especially in 
vivo (Millward et al. 1981; Pratt et al. 2002). This is due to the complex interplay 
between different protein degradation mechanisms and paucity in understanding the 
signalling mechanisms initiating specific protein degradation. The two main 
mechanisms of protein degradation are: lysosomal and ubiquitin-proteasomal 
degradation (UPD), and both pathways participate in the degradation of CYP 
enzymes. ER-associated degradation (ERAD) refers collectively to the mechanisms 
(including both lysosomal and UPD) involved in the proteolysis of ER-bound proteins 
(such as the CYP proteins), and thus responsible for maintaining physiological levels 
of CYP.  
 Much of what is known about ERAD is derived from studies with 
Sacchromyces cerevisae (yeast) and in rat hepatocytes, but there is a high degree of 
evolutionary conservation in protein degradation found in mammals and yeast. ERAD 
has been classed into three distinct pathways: ERAD-L for proteolysis of ER-lumenal 
proteins, ERAD-M for polytopic ER-membrane bound proteins and ERAD-C for 
monotopic ER-membrane bound proteins with cytosolic domains. CYP proteins fall 
under the ERAD-C category (Kim et al. 2016). 
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1.6.1 ERAD/ALD 
Discovered in the 1950s, the lysosome was the first identified system of 
protein degradation. It is a vesicular organelle that occurs in the cytosol of eukaryotic 
cells and contains a multitude of proteases that catalyse proteolysis of intra- and extra-
cellular proteins, as well as cellular organelles. The degradation process is dynamic 
involving many stages of lysosomal maturation together with the digestion of both 
exogenous and endogenous proteins and particles, through different pathways. 
Exogenous proteins enter the lysosome through receptor-mediated endocytosis and 
pinocytosis (engulfment of extracellular fluids) and particles enter by phagocytosis; 
all three processes are collectively known as heterophagy. Endogenous proteins and 
cellular organelles are targeted by microautophagy and macroautophagy, respectively 
(Ciechanover 2005; Eskelinen & Saftig 2009). Of these lysosomal pathways, only 
macroautophagy has been linked to cellular degradation of ER-bound proteins such as 
CYP450s (Liao et al. 2010).  
The macroautophagy of CYP proteins is also referred as autophagic lysosomal 
degradation (ALD) or ERAD/ALD. The specific mechanisms and cellular participants 
of ERAD/ALD are still mostly unknown. However, macroautophagy generally 
involves the collaborative functions of over 35 ATG (autophagy-related genes) 
products that form multiprotein complexes to deliver relevant protein cargo for 
lysosomal degradation. This process is initiated by the formation of a phagophore, 
which is an isolation membrane that selectively engulfs a portion of the cytosol with 
intact organelles, such as the ER, to form an intracellular double-membrane vesicle 
called an autophagosome. The autophagosome that contains the protein cargo then 
fuses with the primary lysosomes to generate an autolysosome wherein lysosomal 
protease enzymes digest the contents and the end products are recycled or consumed 
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as an energy source (Correia 2003; Correia et al. 2014a; Kim et al. 2016; Bento et al. 
2016).  
Studies with rat liver have reported that long-lived proteins, such as ER-bound 
CYPs, undergo ALD in a selective process. Such as in the example of native rat 
CYP2E1, which undergoes biphasic degradation with a rapid phase (t1/2 = 7 h) and a 
slower phase (t1/2 = 37 h) (Correia 2003). ALD is responsible for at least some part of 
the slow phase of CYP2E1 degradation, as demonstrated by the accumulation of the 
enzyme when lysosomal degradation was inhibited by leupeptin (Ronis et al. 1991). 
Rat CYPs 2B1 and 2C11 are predominantly degraded by the ALD pathway (Masaki 
et al. 1987; Ronis & Ingelman-Sundberg 1989; Ronis et al. 1991; Murray et al. 2002).  
 
1.6.2 ERAD/UPD 
Non-lysosomal protein degradation occurs through calcium-dependent 
proteases and proteolytic systems found in the cytosol and in organelles, including the 
nucleus, ER and mitochondria. The most prominent of these is the adenosine 
triphosphate (ATP)/ ubiquitin (Ub)-dependent 26S proteasomal system. The cytosolic 
Ub/26S system is responsible for many cellular homeostatic processes including 
removal of erroneous proteins, processing of transcriptional protein precursors, 
intracellular protein trafficking and generation of peptides for antigen presentation, 
whereas in the nucleus it is involved in cell cycle regulation and cellular 
differentiation (Correia 2003). The cytosolic Ub-depdent 26S proteasomal system has 
been shown to participate in ER-protein degradation and is the predominant 
component of the CYP ERAD-C pathway (Ruggiano et al. 2014).  
The majority of intracellular proteins undergo UPD and the system involves 
concerted actions of enzymes that link chains of Ub (a highly conserved 76-residue 
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protein) onto proteins to mark them for degradation. The pathway entails an ATP-
dependent enzymatic conjugation of Ub to a proteolytic substrate followed by 
breakdown into peptides by the 26S proteasome complex. Three classes of enzymes 
catalyse the Ub-substrate coupling: the first is the Ub-activating enzyme (E1) that 
generates the Ub-thiolester ternary complex (a highly reactive form of Ub) in the 
presence of ATP, the second is the Ub-conjugating enzyme (E2) that shuttles the Ub-
thiolester directly between the E1 enzyme and target protein and the third is the Ub-
protein ligase (E3) enzyme. There are over 1000 types of mammalian E3 enzymes 
and they are critical for the specific recognition of target substrates in a highly 
regulated manner (Nakayama & Nakayama 2006). E3s catalyse the E2-mediated 
coupling of Ub-thiolester to target proteins via the formation of an isopeptide bond. 
The polyubiquitinated substrate is then targeted into the ATP-dependent multi-
catalytic proteasome (26S) complex for degradation into small peptides (Ciechanover 
1998; Correia 2003; Lecker 2006). 
The 26S proteasome, which forms a key component of the ATP/Ub-dependent 
proteolysis system, is composed of a 20S catalytic core and a 19S regulatory complex. 
The 20S core is barrel-shaped and consists of four rings (two outer α rings and two 
inner β rings) containing seven distinct subunits that assemble to form stacks with a 
hollow cavity in which proteolysis takes place. The 19S regulatory complex caps the 
20S catalytic core and regulates proteolysis by restricting barrel opening to only allow 
unfolded linear proteins to enter, thus preventing regular globular cellular proteins 
from erroneous proteasomal breakdown. The 19S complex is composed of 18 
subunits with a ring of 6 homologous ATPases at its base, including Rpn (non-
ATPase) subunits for polyubiquination recognition and deubiquitination, and Rpt 
AAA (ATPases associated with different cellular activities) ATPase subunits for 
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protein unfolding (Bedford et al. 2010). Altogether, the 19S regulatory complex 
carries out important functions such as: unfolding and translocation of proteins into 
the 20S core, polyubiquitin recognition for initiation of proteolysis and the de-
ubiquitination and regeneration of Ub to be reused for degradation of other proteins 
(Lecker 2006; Kim et al. 2016).  
CYP proteins are model examples of ERAD-C substrates due to their 
monotopic ER-topology and a cytosolic domain that is prone to oxidative/structural 
lesions by reactive oxygen species (ROS), due to their oxidative functions. 
Elucidation of rat hepatic CYP 3A and 2E1 ERAD has provided insights into CYP-
specific degradation pathways. Such ERAD involves post-translational 
phosphorylation of the CYPs by cytosolic kinases such as protein kinase A (PKA) and 
C (PKC), followed by polyubiquitination by E1, E2 and E3 enzymes and 26S 
proteasomal degradation in the previously discussed manner. Specific but not limited 
to CYPs, proteins are extracted out of the ER into the cytosol by the p97/VCP 
(Valosin-containing protein) AAA-ATPase, an abundant cytosolic chaperone and/or 
the Rpt4 AAA-ATPase subunit of the 19S regulatory complex prior to proteasomal 
degradation (Acharya et al. 2011; Kim et al. 2016).  
The specific participants of the E1, E2, E3 polyubiquinating pathways of 
human CYP proteins have been difficult to determine. Studies of yeast ERAD-C 
pathways have uncovered the Ubc6p/Ubc7p/Doa10p complex. Ubc6p and Ubc7p are 
ER-associated E2 enzymes that complexes with the Doa10p E3 ligase enzyme. 
Mammalian cells have a greater repertoire of E2/E3 complexes and the components 
found to be involved in ERAD include Hrd1, gp78/AMFR (autocrine motility factor 
receptor), TEB4/MARCH VI, RNF5/RMA1, RNF170 and CHIP (C-terminus of 
Hsc70-interacting protein). More than one E2/E3 Ub-ligase complex can target the 
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same proteins as substrates and may act synergistically, such as in the case of gp78 
and CHIP in CYP3A4 ubiquitination (further discussed in Chapter 6).  ERAD/UPD 
has also been implicated in the rapid phase of CYP2E1 degradation as well as in the 
biphasic degradation of CYP 2C9 and 2D6 (Kim et al. 2016).  
CYP proteins have distinct half-lives suggesting different mechanisms of 
signalling for degradation. However, human CYPs seem to be preferentially degraded 
by the ERAD/UPD over the ERAD/ALD pathway. The haem and protein moieties of 
individual isoforms also turn over at different rates, with haem turnover being 
relatively more rapid and constant than that of the protein (Correia 2003). CYP 
protein turnover is also highly variable between different isoforms and the molecular 
mechanisms for this heterogeneity are yet to be clarified.  
 
1.6.3 Targeting of CYP proteins for degradation 
The mechanisms that trigger normal CYP turnover are still relatively 
unknown, especially the determinants that trigger the ERAD/ALD pathway. 
Degradation of other intracellular proteins requires specific post-translational 
modifications such as: Ub-conjugation, GSH-protein disulphide formation, 
phosphorylation and glycosylation. They may also undergo unmasking of intrinsic 
molecular/structural signals (also referred as ‘degrons’), such as N-terminal residues, 
PEST/PAGE sequences, KFERQ motifs and C-terminal residues to initiate 
proteolysis. Understanding the processes that commit other intracellular proteins for 
proteolysis have provided clues for deriving determinants involved in CYP-specific 
degradation (Ravid & Hochstrasser 2008).  
Haem modification by oxidative uncoupling or drug inactivation triggers rapid 
CYP degradation (Almira Correia et al. 2011). Haem modification disrupts normal 
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CYP conformation and renders it an aberrant protein target for disposal by the 
ERAD/UPD system. The rapid phase of CYP2E1 degradation is thought to result 
from structural damage inflicted by ROS that is generated during its futile oxidative 
cycling in the absence of a substrate or with a poorly fitting substrate that allows ROS 
leakage from the active site. CYP2E1 undergoes biphasic degradation, but substrate 
binding (with ethanol or acetone) can stabilise the protein by diverting it from 
ERAD/UPD to the slower ERAD/ALD pathway which prolongs its t1/2 (Correia 2003; 
Kim et al. 2016). Studies involving the genetic knock-out of redox partner CPR in 
mice liver resulted in increased hepatic CYP content, thus supporting that oxidative 
cycling plays a major role in regulation of CYP abundance (Henderson et al. 2003). 
Although oxidative turnover proves to be a compelling determinant of CYP turnover, 
other requirements must exist as yeast cells have minimal CPR content and oxidative 
functions, yet ER-bound proteins do not necessarily switch to ALD as the 
predominant pathway.  
Intrinsic structural features or ‘degrons’ and/or post-translational 
modifications are involved in CYP recognition and designation into ALD or UPD 
pathway. Degrons are short linear amino acid sequences (usually containing S/T-
residues that undergo phosphorylation; termed phosphodegrons), structural motifs (C- 
or N-terminal residues) and/or cytosol-facing amino acids that engage the degradation 
machinery for molecular recognition and initiation of degradation. Specific 
ubiquitinated Lys (K) residues, along with PKA- and PKC- phosphorylated Ser and 
Thr residues associating with a nearby negatively charged Asp-Glu-Ser-Thr (DEST) 
cluster found on the CYP3A4 protein, form the ‘phosphodegron’ and serves as a 
molecular switch to enhance the gp78/CHIP (E2/E3-complex) recognition and 
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subsequent 26S proteasomal degradation (Correia et al. 2014b; Wang et al. 2015; 
Wang et al. 2011).  
ALD targeting generally involves 3 mechanisms that are assumed to be 
relevant for CYP ERAD/ALD: (i) LC3-interacting region motifs (LIRs; LC3 referring 
to microtubule-associated protein 1 light chain 3); (ii) monoubiquitination or Lys63-
linked polyubiquitination; and (iii) cargo receptors/adapters such as 
p62/sequestosome-1 (SQSTM1) and/or NBR1 (neighbour of BRCA1 gene1) that 
contains the LIR motif to target mono- or Lys63-ubiquitinated substrates to selective 
autophagy. The LIR is a linear 8-amino acid sequence that facilitates the docking of 
substrate to LC3 and subsequent targeting of the substrate to the phagophore. ALD 
substrates are tagged via mono- or polyubiquitination at the Lys63 position for the first 
Ub and Gly76 for the subsequent Ub. This K63-linked ubiquitination is involved in 
p62/MBR-1 recruitment and specific targeting to ALD and is considered a hallmark 
of ALD pathway. P62/SQSTM1 and NBR1 are autophagic cargo receptors that enable 
selective phagosomal engulfment of the protein cargo via docking of the LIR motif. 
These cargo receptors are most likely to be involved in CYP ALD due to their 
propensity to target Lys63-ubiquitinated substrates (Kim et al. 2016). CYP 2C9 and 
2D6 in transfected HepG2 cells have found to undergo degradation by both 
ERAD/ALD and ERAD/UPD pathways and K63-linked ubiquitination and LIR motifs 
were found in both CYPs, which supports them to be hallmarks of ALD (Wang et al. 
2012; Kim et al. 2016).  
The finding that CYPs undergo different pathways of degradation attests to 
not only to the mechanistic diversity of ER protein degradation but also the 
complexity.  Substrate ligands can stabilise certain CYPs and induce or prolong 
expression by blocking post-translational modifications such as haem modification, 
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oxidation or phosphorylation that would normally trigger degradation of the protein. 
Some substrate interactions can inhibit rapid UPD and divert the CYP to the ALD 
pathway that prolongs its life span, such as in the case of CYP2E1. It is evident that 
ERAD of CYP proteins play a significant role in regulating the basal hepatic 
microsomal content and thus may impact on substrate PK and interactions.  
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Utility of single pharmacological protein 
synthesis inhibitor agents for measuring protein 
degradation rate constants; an analysis in 
hepatic primary cells and tumour cell lines 
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2.1  Introduction 
The ability of the cell to remove and replenish proteins in a dynamic state of 
constant turnover is paramount to maintaining essential cellular functions. 
Mammalian protein half-lives range from minutes to years depending on the specific 
functions of the protein in question and protein turnover is tightly regulated through 
multiple molecular mechanisms. Collagen has an estimated t1/2 of 117 years whereas 
regulatory proteins such as nuclear receptors are mostly estimated in the region of <5 
hours (Alarid 2006; Toyama & Hetzer 2013). Characterisation of the degradation rate 
(kdeg) for specific proteins is required for better understanding of cell signalling 
processes involved in both normal and dysfunctional diseased cell states, thus studies 
of protein turnover are used in many different areas of cellular and molecular biology. 
In the context of PK studies for drug development, CYPs and other DME protein kdeg 
are important for the prediction of time-dependent DDIs, as discussed in Chapter 1. 
Protein degradation is commonly quantified as t1/2, the time taken for protein 
concentration to decrease by half (Zhou 2004; Belle et al. 2006; Zhang et al. 2007). 
This variable is interchangeable with kdeg by the following equations assuming first-
order decay kinetics (Belle et al. 2006), where N is the protein intensity at time t, N0 is 
the protein intensity at time T, k is the decay rate constant (and –k represents kdeg) and 
t1/2 is the half-life: 
     N! = N!e!!"     (15) 
 ln N! −  ln N! = −kt ⇒  t!! =  !"(!)!   (16) 
    −k = ln N! − ln N! ÷ t    (17) 
Historically, protein degradation has been studied using methods that either 
measure overall protein degradation or focus on a few specific proteins. Advances in 
high-throughput tagging methods have allowed measurement of degradation rates of 
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large numbers of defined proteins but there are caveats associated with these 
proteome-wide approaches; such as the potential of protein tagging disrupting regular 
degradation pathways (Yewdell et al. 2011). Methods for measuring protein 
degradation and subsequent derivation of kdeg, generally fall into two experimental 
designs: i) quantifying the amount of a specific protein before and after a cell 
perturbation then measuring the difference in protein abundance and time between the 
initial and new steady-state; or ii) quantifying changes in protein abundance in real-
time by time-course experiments (Alvarez-Castelao et al. 2012).  
The most common approach for measuring protein degradation is the pulse-
chase analysis and this method involves a ‘pulse’ stage of incubating cells with a 
radiolabelled amino acid, which allows the radiolabelled amino acids to be 
incorporated into newly synthesised proteins, followed by washing out of the excess 
unincorporated amino acids and then a ‘chase’ stage of incubation with unlabelled 
amino acids. The change in the proportion of labelled to unlabelled amino acid 
incorporation over time is used to calculate rate of protein degradation. Protein 
synthesis inhibitors, most commonly cycloheximide, are used in this method to 
eliminate reincorporation (Zhou 2004; Doherty et al. 2009). Another simple kinetic 
approach is based on inhibiting de novo protein synthesis with an initial cell treatment 
with pharmacological inhibitors or genetic interference, followed by the 
quantification of changes in protein content over time by immunoblotting (Alvarez-
Castelao et al. 2012; Dai et al. 2013), thereby tracking the degradation of untagged 
proteins. However, there are concerns with using protein synthesis inhibitor agents for 
measuring long-lived proteins because prolonged use of these pharmacological 
inhibitors are likely to introduce cytotoxicity that will disrupt the regular protein 
turnover process. Any loss in protein could be caused by cytotoxicity rather than the 
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protein degradation process itself, therefore a non-cytotoxic concentration will need to 
be determined prior to measuring the protein degradation rate. 
The more recent methods for measuring protein degradation are based on 
modifications to the traditional pulse-chase analysis with a focus on protein tagging to 
simultaneously measure the rates of a large number of proteins in a high throughput 
manner. For example, stable isotope labelling by amino acids (SILAC) in cell culture 
followed by mass-spectrometry (MS) (Mann 2006; Doherty et al. 2009; Fierro-Monti 
et al. 2013; Takahashi et al. 2017), isobaric tag for relative and absolute quantification 
(iTRAQ) (Jayapal et al. 2010) and global protein stability profiling (GPSP) utilising 
protein fusion constructs for reporter assays (Yewdell et al. 2011; Yen et al. 2008). 
The caveats of using fusion constructs to tag proteins is that any modifications to 
regular protein conformation may influence protein folding and any misfolding of 
proteins is likely to affect regular degradation pathways (Alvarez-Castelao et al. 2012; 
Yewdell et al. 2011).  
The focus of this chapter was on the more traditional methods of measuring 
protein degradation by initial treatment with protein synthesis inhibitor agents 
followed by quantification of protein disappearance by immunoblot detection. CYP 
protein t1/2 are thought to be in the medium-lived rrange of 10-140 hours (Yang et al. 
2008), thus it was hypothesized that using pharmacological inhibition to stop protein 
synthesis followed by tracking of CYP protein disappearance over a few days was a 
feasible method of deriving CYP kdeg. Due to the cytotoxic concerns with using 
protein synthesis inhibiting agents, a suitable agent that provided maximum protein 
synthesis inhibition with minimum cytotoxicity must be defined prior to being used in 
a subsequent time-course immunoblot approach to derive CYP protein kdeg.  
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Table 2.1 shows some commonly used protein synthesis inhibitor agents in 
biology research as recommended in Current Protocols in Cell Biology by N. H. Cole 
(2001) and some examples of the use of these compounds in various in vitro studies to 
measure messenger RNA (mRNA) or protein degradation. The four protein synthesis 
inhibitors used in this chapter were selected based on their different mechanisms of 
action along the protein synthesis process, as shown in Figure 2.1, and previous use in 
biomedical research.  
Actinomycin D (Sobell 1985) intercalates deoxyribonucleic acid (DNA) 
forming a stable complex with deoxyguanosine residues, thus blocking movement of 
RNA polymerase and subsequently transcription. Cycloheximide binds the 60S 
ribosomal subunit blocking the translocational step in amino acid elongation, thus 
inhibiting protein synthesis (Schneider-Poetsch et al. 2010). Emetine inhibits protein 
synthesis by binding onto the 40S subunit of ribosomes and inhibiting translocation of 
proteins (Akinboye 2011). Puromycin acts as an analogue of the 3′-terminal end of 
aminoacyl-tRNA that results in premature amino acid chain termination during 
translation of proteins (Azzam & Algranati 1973). The selected inhibitors 
actinomycin D, cycloheximide, emetine and puromycin were assessed to determine 
their suitability for protein degradation studies. 
Leucine incorporation assays and standard 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays were conducted to determine the level of 
protein synthesis inhibition and cytotoxicity respectively, across a range of drug 
concentrations in a human hepatic immortalised cell line, HepG2, and primary rat 
hepatocytes (PRH). Physiologically-relevant hepatic CYP kdeg values should ideally 
be derived from primary human hepatocytes as these cells are considered to be the 
‘gold standard’ representative of the in vivo human liver (LeCluyse 2001), however 
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the use of these cell systems are costly. Therefore, HepG2 and PRH were initially 
selected for the optimisation of protein synthesis inhibitor concentrations with the aim 
of transferring the optimised concentrations for use in primary human hepatocytes for 
a cost-saving optimisation approach.  
The aim of this chapter was to define a single concentration of an inhibitor 
agent that displayed maximum protein synthesis inhibition with minimal cytotoxicity, 
to stop de novo protein synthesis, for subsequent use in measuring CYP protein t1/2. 
The selected inhibitor agents were assessed for cytotoxicity by standard MTT assays 
and their potential to inhibit protein synthesis by leucine incorporation assay, in 
HepG2 and PRH cells.  
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Table 2.1 Protein synthesis inhibitor compounds used in cell biology research, collated from Cole (2001) 
Compound Mechanism of Action Concentration used in vitro to assess mRNA or protein degradation  
 
a-Amanitin Acts as a potent and specific inhibitor of mRNA 
synthesis by binding preferentially to RNA 
polymerase II. At high concentrations also inhibits 
RNA polymerase III. 
Van Nguyen et al. 1996: 5.4-108.8 µM in NIH 3T3 cells for up to 24 h; Tsao et 
al. 2012: 21.8 µM in COS cells for 14 h; Lugowski et al. 2017: 50 µM in HEK-
293 cells for up to 24 h 
Actinomycin D Inhibits transcription by complexing with 
deoxyguanosine residues on DNA and blocking 
the movement of RNA polymerase.  
Koeller et al. 1991: 4.0 µM in fibroblasts for up to 3 h; Van Nguyen et al. 1996: 
15.9 µM in NIH 3T3 cells for up to 24 h; Lee & Wayne 1998: 39.8 µM in bag 
cell neurons up to 32 h; Takei et al. 2000: 6.0 µM for 6 h; Leclerc et al. 2002: 
0.5-5 µM in CEM and Nalm6 cells for up to 24 h; Lugowski et al. 2017: 4.0 µM 
in HEK-293 cells for up to 24 h 
Anisomycin Inhibits protein synthesis by blocking the peptidyl 
transferase step during translation.  
Marroquin et al. 2004: 37.7 µM in murine leukemia cells for up to 96 h 
Cycloheximide The exact mechanism of action remains to be 
elucidated but it has been found to inhibit 
translation elongation through binding to 60S 
ribosomal subunit.  
Chang et al. 1981: 0.9 mM in CHO cells for 12 h; Welch & Wang 1992: 88.9 µM 
in NIH 3T3 cells for up to 60 h; Van Nguyen et al. 1996: 35.5 µM in NIH 3T3 
cells for 5 h; Fayadat et al. 2000: 100 µM in CHO cells for up to 24 h; Jeong et 
al. 2005: 355.4 µM in HepG2 cells for 4 h; Belle et al. 2006: 124.4 µM in yeast 
cells for 45 min; Chen & Madura 2008: 1.8 µM in yeast cells for up to 120 h; 
Bouligand et al. 2010: 71.1 µM in fibroblast cells for 2 h; Tsao et al. 2012: 71.1 
µM in COS cells for 14 h; Puskarjov et al. 2012: 100 µM in hippocampal slices 
for 4 h; Majumber et al. 2012: 248.8 µM in hippocampal neurons for up to 8 h 
Emetine Irreversibly blocks protein synthesis by inhibiting 
movement of ribosomes along mRNA by binding 
to 40S ribosomal subunit.  
Chang et al. 1981: 5 µM in CHO cells for 10 h; Fayadat et al. 2000: 100 µM in 
CHO cells for up to 24 h; Gelman et al. 2002: 75 µM in CHO cells for 4 h; 
Bouligand et al. 2010: 208.1 µM in fibroblasts for 6 h; Puskarjov et al. 2012: 100 
µM in hippocampal slices for 4 h; Weitzel et al. 2004: 100 µM in sea urchin egg 
cells for 30 min 
Hygromycin Inhibits protein synthesis at the translocation step 
on 70S ribosomes and causes misreading of 
mRNA.  
Tan & Walker 2010: 94.8 µM in HEK293 cells for 24 h; Chen & Madura 2008: 
0.2 mM in yeast cells for up to 120 h 
Puromycin Inhibits protein synthesis by causing premature 
release of nascent polypeptide chains by its 
addition to the growing chain end; structural 
analog of 3’-terminal end of the aminoacyl-tRNA.  
Chang et al. 1981: 0.2 mM in CHO cells for 12 h; Liao et al. 1998: 10 µM in 
HepG2 cells for 10 min; Lacsina et al. 2012: 20.0 µM in 293-Kb cells for 50 min 
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Figure 2.1 Mechanisms of action of selected protein synthesis inhibitor agents: actinomycin D, puromycin, emetine 
and cycloheximide. 
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2.2 Materials and methods  
 
2.2.1 Materials 
Dulbecco’s modified eagle medium (DMEM), foetal bovine serum (FBS), trypsin-
EDTA solution, Hank’s balanced salt solution (HBSS), thiazolyl blue tetrazolium 
(TBT), sterile water (W4502) and protein synthesis inhibitors; actinomycin D 
(A4262), emetine dihydrochloride hydrate (E2375) and puromycin dihydrochloride 
(P7255), were purchased from Sigma-Aldrich (Dorset, UK). HepG2 cells were 
purchased from American Tissue Culture Collections (ATCC, Virginia, USA). 
Cryopreserved primary rat hepatocytes, William’s E media, plating cocktail, 
maintenance cocktail, Geltrex® matrix and collagen I coated plates were purchased 
from Invitrogen Ltd (Paisley, UK). Cycloheximide (ab120093) was purchased from 
Abcam (Cambridge, UK). L-Leucine [4,5-3H] (MT-672E) was obtained from 
Moravek (California, USA).  
 
2.2.2 Cell line culture  
HepG2 cells were maintained in DMEM medium supplemented with 10% FBS 
solution. Cells were seeded in T175 culture flasks and grown in a 37°C 5% CO2 
humidified incubator. The media was changed every 48 hours and cells were sub-
cultured by the standard trypsin and centrifugation method when they reached 
approximately 80-90% confluence. The cells were discarded beyond passage 20.  
 
2.2.3 PRH culture  
Primary rat hepatocytes (PRH) were purchased from Invitrogen (Paisley, UK), 
isolated from male Sprague-Dawley rats at 9 weeks old (Lot. RS745). Cryopreserved 
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PRH were thawed in a 37°C water bath for approximately 2 mins until contents were 
around 90% thawed. Once thawed, the hepatocytes were added to 50 ml of pre-
warmed plating media (William’s E media without phenol red supplemented with 5% 
FBS, 1 µM dexamethasone, 1% solution of penicillin/streptomycin, 4 µg/ml Bovine 
insulin, 2 mM GlutaMAX™ and 15mM HEPES; CHRM® supplement A) and 
centrifuged for 3 min at 55 x g at 18oC and the supernatant fraction discarded. The 
hepatocytes were then resuspended in plating media at approximately 1 x 106 cells 
per ml density and counted.  
 
2.2.4 Cell counting and viability 
The cell numbers and viability of HepG2 and PRH were calculated using the 
Chemometec NucleoCounter® NC-100TM (Chemometec, Denmark). 150 µl of cell 
suspension was added to a fresh Eppendorf tube for total dead cells count, 50 µl of 
reagent A and B were added to 50 µl of cell suspension in a separate Eppendorf tube 
for total cell count. A cell viability of > 80% was required for experiments. Cell 
viability was calculated using the following equation: 
Cell viability % = 100 − ( Dead cells count Total cells count Reagent A + B  x 3 (dilution factor)) 
 
2.2.5 PRH plating and maintenance 
PRH cells were seeded in 96-well collagen-I coated plates and were incubated in 
plating media for 5 h at 37°C with 5% CO2 and 95% humidity to allow for cell 
adherence to culture plate. After 5 hour incubation, plating media was discarded and 
replaced with 0.022 mg/ml of Geltrex® Matrix in maintenance media (William’s E 
media supplemented with 0.1 µM dexamethasone, 0.5% penicillin/streptomycin 6.25 
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µg/ml human recombinant insulin, 6.25 µg/ml human transferrin, 6.25 ng/ml selenous 
acid, 1.25 mg/ml BSA, 5.35 µg/ml linoleic acid, 2nM GlutaMAX™ and 15mM 
HEPES). Protein concentration for each Geltrex® Matrix lot vary and the amount of 
Geltrex® required for each experiment was calculated by: 
Geltrex amount (ml) =  Incubation medium mL x 0.35(mg mL )
Geltrex protein concentration (mg mL )
 
Geltrex® Matrix was added to maintenance media on ice. After incubation overnight, 
the media containing Geltrex® was removed and replaced with regular maintenance 
media with varying drug concentrations and controls. Maintenance media with 
treatment conditions were replaced every 24 hours.  
 
2.2.6 Measuring cytotoxicity by standard MTT Assays  
Standard MTT assays were performed on HepG2 and PRH cells to determine cell 
viability. 2 x 104 cells per well of HepG2 were seeded into 96-well plates in DMEM 
with 10% FBS and left overnight in a 37°C humidified incubator to allow cells to 
adhere to the plate. PRH were seeded in collagen-I coated 96-well plates at a density 
of 2 x 104 cells per well. Old media was removed and replaced with 10 
concentrations between 0-300 µM diluted at third-log concentrations, of protein 
synthesis inhibitor drugs in fresh maintenance media and incubated for 72 hours, and 
the media containing treatment conditions were replaced every 24 hours. Vehicle 
controls and a control with no drug was included. The vehicle controls were 1% 
sterile water for emetine, puromycin and cycloheximide, or 1% dimethyl sulfoxide 
(DMSO) for actinomycin D, in cell maintenance media. Vehicle control wells 
required >90% cell viability for the solvent to be deemed suitable for drug 
dissolution. 20µl of 5mg/ml TBT in HBSS was added to each well and incubated for 
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2 hours. 100µl lysis buffer (50%v/v dimethylformamide and 20%v/v sodium dodecyl 
sulphate) was added to each well and the plate was incubated overnight at 37°C. The 
absorbance at 570nm, which correlated to cell viability, was determined by Tecan 
GENios micoplate reader (Germany).  
 
2.2.7 Measuring protein synthesis inhibition by [3H]-leucine incorporation  
HepG2 cells were seeded at 2 x 105 cells per well on 96-well plate in DMEM 
supplemented with 10% FBS and the plates were incubated overnight at 37°C to 
allow cells to adhere. PRH cells were seeded in collagen-I coated 24-well plates at a 
density of 2 x 105 cells per well. Old media was removed and replaced with 0-100µM 
of protein synthesis inhibitor drugs dissolved in DMEM with 10% FBS for HepG2 
cells or maintenance media for PRH and incubated for 72 hours in a 37°C humidified 
incubator. In the last 2 hours of incubation, cells were pulsed with 2µCi of [3H]-
leucine without removing the inhibitor. After 2 hours, the media containing [3H]-
leucine was removed by aspiration and the cells were washed twice with HBSS before 
removal from well by trypsinisation for 5 min at 37°C with 5% CO2 and 95% 
humidity. HepG2 cells were then harvested onto a filtermat using a TomTec cell 
harvester. The filtermat was sealed in a sample bag with melt-on scint and the level of 
protein synthesis was determined by the amount of [3H]-leucine incorporation 
measured using a MicroBeta detector (Perkin-Elmer, Cambridge, UK). PRH cells 
were transferred to scintillation vials following trypsinisation. 4 ml of scintillation 
fluid was added to each sample and radioactivity was determined using 
QuantaSmartTM software on Tri-Carb scintillation counter (Perkin-Elmer, 
Cambridge, UK).  
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2.2.8 Protein synthesis inhibitor drug analysis  
The protein synthesis inhibitors actinomycin D, cycloheximide, emetine and 
puromycin were tested individually in HepG2 and PRH cells. Actinomycin D was 
incubated at 0-10µM and 0-0.039µM and puromycin at 0-20µM and 0-5µM for 
leucine incorporation assays and MTT cytotoxicity assays, respectively. 
Cycloheximide was incubated at 0-300µM and emetine at 0-30µM for both leucine 
incorporation and MTT assays. These concentration ranges were determined after 
initial optimization in HepG2 cells utilizing a wide range of concentrations for each 
inhibitor to detect a sigmoidal concentration-response.  
 
2.2.9 IC50 and CC50 calculations  
The CC50 (concentration causing 50% cytotoxicity) and IC50 (concentration causing 
50% protein synthesis inhibition) for each inhibitor drug were calculated by non-
linear regression of drug concentration versus % protein synthesis inhibition (as 
determined by level of [3H]-leucine incorporation) and % cell viability (as determined 
by MTT assays) concentration-response graphs, respectively, using Graphpad Prism 6 
software. IC50 and CC50 values could only be determined when a sigmoidal 
concentration-response curve was observed. Where non-sigmoidal responses were 
seen, experiments were repeated with a wider concentration range until a sigmoidal 
relationship could be observed by eye. A mean value ± standard deviation (SD) was 
taken over at least four replicates in at least three independent experiments. 
 
2.2.10 Linear regression of HepG2 and PRH data  
Linear regression was carried out with Graphpad Prism 6 software for HepG2 and 
PRH derived CC50 and IC50 for each of the protein synthesis inhibitor drugs to 
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determine the correlation between HepG2 and PRH derived values and suitability of 
these cell types for measuring kdeg.  
 
 
2.3  Results  
2.3.1 Optimisation of concentration ranges for protein synthesis inhibitor drugs in 
MTT assays for accurate CC50 measurement 
A clear sigmoidal concentration-response relationship is required for accurate 
CC50 calculation by the Graphpad Prism 6 software. HepG2 cells were initially 
incubated with third-log dilutions of drug concentration over the range of 0-100 µM 
for all four protein synthesis inhibitors. Cell viability was calculated as a percentage 
of control, where no drug was added, and this was assumed to be to 100% viability. 
Figures 2.1 A and C depicting actinomycin D and emetine, respectively, did not 
display a sigmoidal concentration-response when the drug concentration range was at 
0-100 µM. Although puromycin did display a sigmoidal curve over this concentration 
range, accurate CC50 could not be determined as there was a sharp decrease in 
viability between two concentrations (Figure 2.1 C). A more gradual drop in cell 
viability is needed to better quantify CC50.  
Further optimisations with narrowing drug concentration ranges deemed 0-
0.039 µM for actinomycin D, 0-100 µM for cycloheximide, 0-30µM for emetine and 
0-5µM for puromycin to be the ideal concentration ranges to display a sigmoidal 
concentration-response with standard MTT assays. 
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Figure 2.1 HepG2 cell viability, determined by standard MTT assays, as a response to a 
range of protein synthesis inhibitor concentrations. Optimisation of concentration-response 
assays conducted in HepG2 cell lines. A. actinomycin D. B. cycloheximide C. emetine and D. 
puromycin. Data are expressed as the mean of 8 technical replicates ± SD in at least 1 
independent experiment. 
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2.3.2 Optimisation of concentration ranges for protein synthesis inhibitor drugs in 
[3H]-leucine incorporation assays for accurate IC50 measurement 
The Graphpad Prism 6 software was also used for calculation of IC50 and a 
clear sigmoidal concentration-response relationship was also required for accurate 
measurement. HepG2 cells were incubated with third-log dilutions of drug 
concentration over the range of 0-100 µM for all four protein synthesis inhibitor 
agents. The level of protein synthesis inhibition was calculated as a percentage of 
control, where no drug was added inhibition was assumed to be 0%. Figure 2.2.A 
shows that actinomycin D did not exhibit a sigmoidal concentration-response and 
further repeats were needed with a more narrow concentration range for emetine and 
puromycin, and a wider concentration range for cycloheximide. The outlier observed 
for 1 μM puromycin (Figure 2.2 D) futher attests to the variability in protein synthesis 
inhibition observed between 0.1 – 3 μM and therefore more concentrations within this 
range should be included to better define the concentration-response. A more gradual 
change in protein synthesis inhibition, than that shown in figure 2.2 were needed to 
accurately measure IC50. 
Further optimisations deemed 0-10 µM for actinomycin D, 0-300 µM for 
cycloheximide, 0-30 µM for emetine and 0-20µM for puromycin to be the ideal 
concentration range to display a sigmoidal concentration-response in protein synthesis 
inhibition as measured by [3H]-leucine incorporation assays. 
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Figure 2.2 Level of protein synthesis inhibition, determined by [3H]-leucine incorporation 
assay, as a response to incubations with a range of protein synthesis inhibitor 
concentrations. Optimisation of concentration-response assays conducted in HepG2 cell lines. A. 
Actinomycin D. B. Cycloheximide. C. Emetine and D. Puromycin. Data are expressed as the 
mean of 8 technical replicates ± SD in at least 1 independent experiment. 
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2.3.3 CC50 of protein synthesis inhibitor drugs determined by standard MTT assays 
in HepG2 and PRH cell types 
HepG2 and PRH were incubated with the optimised protein synthesis inhibitor 
drug concentrations as discussed in 2.3.1. The mean ± SD CC50 for the four inhibitors 
actinomycin D, cycloheximide, emetine and puromycin were found at 0.0062 ± 
0.0073, 0.57 ± 0.51, 0.081 ± 0.0090 and 1.3 ± 0.064 µM, respectively in HepG2 cells 
and 0.00098 ± 0.0018, 0.68 ± 1.3, 0.18 ± 0.70 and 1.6 ± 1.0 µM, respectively in PRH 
(Table 2.2). The CC50 concentrations were calculated from concentration-response 
graphs shown in figure 2.3. HepG2 cells were sensitive to puromycin concentrations 
as shown in the sharp decrease in cell viability between 1 and 2.5 µM (Figure 2.3.D).  
 
2.3.4 IC50 of protein synthesis inhibitor drugs determined by [3H]-leucine 
incorporation assays in HepG2 and PRH cell types 
HepG2 and PRH were incubated with the optimised protein synthesis inhibitor 
drug concentrations as discussed in 2.3.2. The mean ± SD IC50 for the four inhibitors 
actinomycin D, cycloheximide, emetine and puromycin were calculated at 0.039 ± 
0.0074, 6.6 ± 2.5, 2.2 ± 1.4 and 1.6 ± 1.2 µM, respectively, in HepG2 and 0.0017 ± 
0.0018, 0.29 ± 0.090, 0.62 ± 0.92 and 2.0 ± 2.0 µM, respectively in PRH (Table 2.2). 
The IC50 concentrations were calculated from concentration-response graphs shown in 
figure 2.4. PRH appears to be sensitive to emetine concentrations as shown in the 
high variability and sharp increase in protein synthesis inhibition between 0.078 and 
1.25 µM (Figure 2.4.C). 
The CC50 concentrations were lower compared to corresponding IC50 values 
for all four inhibitor drugs except cycloheximide in PRH; this indicates that the 
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inhibitors were more effective in generating cell death than protein synthesis 
inhibition and thus unsuitable for further protein degradation studies. 
 
   
Figure 2.3 CC50 of the four individual protein synthesis inhibitors in HepG2 and PRH. 
(A-D) Cell viability across different concentrations of inhibitors was measured by MTT 
assays and shown as percentage of control. Dotted line shows PRH and solid line for HepG2 
cells. Concentration-response curves were produced by Prism software and CC50 values were 
calculated from linear regression models. Data are shown as mean ± S.D from 4 independent 
experiments (n=4) carried out in 8 replicates for HepG2 and n=3 in quadruplicates in PRH. 
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Figure 2.4 IC50 of the four individual protein synthesis inhibitors in HepG2 and PRH. 
(A-D) Protein synthesis inhibition across different concentrations of inhibitors was 
measured by [3H]-Leucine incorporation assay and shown as percentage of inhibition of 
control. Dotted line shows PRH and solid line for HepG2 cells. Concentration-response 
curves were produced by Prism software and IC50 values were calculated from linear 
regression models. Data are shown as mean ± S.D from 4 independent experiments (n=4) 
carried out in 8 replicates for HepG2 and n=3 in quadruplicates in PRH. 
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2.3.5 Linear regression analysis of CC50 and IC50 between HepG2 and PRH cell 
types 
The CC50 and IC50 values for HepG2 and PRH for each of the four selected 
protein synthesis inhibitors were derived from concentration-response curves shown 
in figures 2.3 and 2.4. These calculated values, displayed in Table 2.2, were 
incorporated into linear regression analyses to determine the correlation and 
predictability of HepG2 and PRH cell types for CC50 and IC50.  
Figure 2.5 show a linear relationship of CC50 between HepG2 and PRH cells 
for all four protein synthesis inhibitor agents at R2=0.996. The inset graph in Figure 
2.6 shows a reasonable linear correlation for actinomycin D, emetine and puromycin 
at R2=0.655 when cycloheximide was omitted. The inset graph in Figure 2.7 also 
shows a strong linear relationship of IC50:CC50 at R2=0.997 when cycloheximide was 
omitted. Thus, cycloheximide fit in the linear relationship for cytotoxicity but not for 
protein synthesis inhibition. HepG2 and PRH produced CC50 values that were in good 
correlation for all four inhibitor drugs. The difference for cycloheximide in IC50 
estimations could be due to differential mechanisms of protein synthesis inhibition 
between the HepG2 and PRH cell types. 
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Table 2.2 CC50, IC50 and CC50:IC50 values derived from concentration-response 
curves for each protein synthesis inhibitor agent in HepG2 and PRH cells. 
 
Drug 
CC50 (µM) IC50 (µM) Ratio IC50:CC50 
HepG2 PRH HepG2 PRH HepG2 PRH 
       
Actinomycin D 0.0062 0.00098 0.039 0.0017 6.2 1.8 
Cycloheximide 0.57 0.68 6.6 0.29 11.6 0.42 
Emetine 0.081 0.18 1.4 0.62 18.0 3.5 
Puromycin 1.3 1.6 1.6 2.0 1.3 1.2 
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Figure 2.5 Linear regression analysis of CC50 between HepG2 and PRH cell types. 
Linear regression of the mean CC50 values of the four protein synthesis inhibitor drugs 
derived from HepG2 and PRH concentration-response cytotoxicity curves.   
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Figure 2.6 Linear regression analysis of IC50 between HepG2 and PRH cell types. 
Linear regression of the mean IC50 values of the protein synthesis inhibitor drugs derived 
from HepG2 and PRH concentration-response protein synthesis inhibition curves. 
Cycloheximide is omitted in the inset graph. 
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Figure 2.7 Linear regression analysis of IC50:CC50 concentration ratio between HepG2 
and PRH cell types. Linear regression of the IC50:CC50 ratio of HepG2 and PRH cells. 
Cycloheximide is omitted in the inset graph. 
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2.4 Discussion 
The use of protein synthesis inhibitors is the most common method for measuring 
protein degradation rates and has been documented by many sources over 4 decades 
(Goldberg & Dice 1974; Curfman et al. 1980; Princiotta et al. 2003; Zhou 2004; Belle 
et al. 2006; Delgado-Vega et al. 2012; Chistyakov et al. 2014). As discussed 
previously in Chapter 1, ineffective inhibition of de novo protein synthesis will distort 
the accuracy of the measured rate of protein degradation. Protein synthesis inhibitor 
agents universally stop protein synthesis by inhibiting fundamental gene transcription 
and translation processes, thus prolonged inhibition will inevitably affect proteins that 
are essential for cell survival. Despite their cytotoxic risks, protein synthesis inhibitors 
are worth exploring for their potential to use in short-term degradation rate studies as 
they provide the most simple, economical and readily available approach to inhibit de 
novo protein synthesis. The aim of this chapter was to define a single inhibitor at a 
concentration that provided maximum protein synthesis inhibition with minimal 
cytotoxicity, which could then be used in subsequent kinetic experiments to 
accurately estimate CYP protein degradation rates. 
Protein synthesis inhibitors have been commonly used in previous studies of 
protein degradation, yet there has been little consideration for their cytotoxic effects 
and none have reported optimisations for a specific concentration to use. It is evident 
from Table 2.1 that historically, a range of different protein synthesis inhibitor 
compounds were used over a range of concentrations and incubation times have been 
used for the purpose of measuring mRNA or protein stability in different cell systems. 
Cycloheximide is the most commonly used of all inhibitor agents for this purpose and 
some previous studies have used this inhibitor with cell cultures at millimolar 
concentrations (Chang et al. 1981; Pan & Haines 1999; Princiotta et al. 2003; Jeong et 
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al. 2005; Majumder et al. 2012), which was much higher than the non-toxic 
concentration range found here. Moreover, Welch & Wang (1992) cultured NIH 3T3 
cells with 88.9 µM for 60 h and Chen & Madura (2008) cultured yeast cells in 1.8 µM 
for 120 h; both of which are higher than the non-toxic concentrations reported here 
for cycloheximide over a long incubation period. However, it must be noted that 
different cellular systems may well have different tolerance of inhibitor agent-induced 
cytotoxicity and thus, concentrations ought to be optimised for each given cellular 
system. 
In this chapter, the CC50 and IC50 for four protein synthesis inhibitor agents were 
measured in two cell types to define their potential to inhibit protein synthesis without 
cytotoxicity. In all cases, except for cycloheximide in PRH (as reflected in IC50:CC50 
< 1), the CC50 concentrations for the individual inhibitors were lower than the 
corresponding IC50 in both cell types, suggesting that protein synthesis inhibition 
could not be studied in the absence of an effect on other cellular functions. On closer 
inspection with cycloheximide in PRH, the concentration that provided 20% 
cytotoxicity or 80% viability (CC20) was 0.11 µM and this was lower than the IC50 at 
0.29 µM. This means that at 80% cell viability, which was considered the maximum 
level of acceptable toxicity, cycloheximide produced less than 50% protein synthesis 
inhibition and therefore insufficient for protein degradation studies. Clearly, a 
different approach to single protein synthesis inhibitors was needed to increase the 
level of target protein synthesis inhibition and reduce cytotoxicity.  
Earlier studies with actinomycin D and puromycin reported toxicity in HeLa cells 
at concentrations within the range investigated here. Studies by Sawicki & Godman 
(1971) showed that at 0.08 µM actinomycin D was sufficient to cause cell toxicity in 
HeLa cells and the data in this chapter is in agreement with these findings. Dudani et 
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al. (1988) reported 79.6% protein synthesis inhibition at 0.9 mM and cytotoxicity was 
detected at 0.9 µM after incubation of HeLa cells with puromycin; the data presented 
herein agreed with these findings and suggests that puromycin is cytotoxic at 
concentrations lower than those required for protein synthesis inhibition.  
Conversely, Low et al. (2009) conducted cytotoxicity assays Huh-7 cells that were 
treated with emetine and reported over 90% cell viability at 10 µM; this concentration 
is much higher than the cytotoxic range derived here. Although the reason for this 
disparity is not apparent, cytotoxicity of these inhibitors may vary between different 
cell types and for this reason two hepatic cell types were analysed in this Chapter.  
The single drug analyses were carried out in HepG2 and PRH with reasonable 
agreement in protein synthesis inhibition and cytotoxicity between these cell types for 
actinomycin D, emetine and puromycin; as demonstrated by the linear relationship 
displayed in Figures 2.5 – 2.7. A strong linear correlation (R2=0.996) was observed in 
the CC50 values derived from both cell types and also in the IC50:CC50 (R2=0.997) 
when cycloheximide was omitted, and a reasonable correlation (R2=0.655) in IC50 
when cycloheximide was omitted. The correlations between two cell types confirm 
the reliability of findings that the inhibitors were more efficacious in bringing about 
cytotoxicity than protein synthesis inhibition. Cycloheximide did not fit in the 
correlation for IC50; this could perhaps be explained by differential mechanisms of 
protein synthesis inhibition in different species as HepG2 cell lines are of human 
origin. However, elucidation of this hypothesis is beyond the scope of this thesis.  
Optimisation of protein synthesis inhibitor concentrations was initially carried out 
in HepG2 and PRH cells with the intention of transferring the optimised conditions to 
measure CYP kdeg in primary human hepatocytes. One advantage of using HepG2 (a 
hepatic immortalised cell line) and PRH are that they are relatively inexpensive 
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compared with primary human hepatocytes. HepG2 cells express similar mRNA 
transcripts as primary human hepatocytes and are recommended for studying DME 
regulation pathways (Westerink & Schoonen 2007). Unlike HepG2 cells, PRH 
express the full panel of phase I and II DMEs and are therefore considered a better 
representative model for the in vivo liver. However, there are reported differences 
between liver-specific metabolic functions across species (Vilei et al. 2001) and 
differential expression of CYP enzymes occur in sandwich culture between human 
and rat (Kern et al. 1997), therefore CYP kdeg derived from hepatocytes of human 
origin ought to provide a better representative for the human in vivo condition. 
In summary, single protein synthesis inhibitor drugs are unsuitable for measuring 
protein degradation rates due to their propensity to cause cell death. Any loss of signal 
in subsequent protein kinetic analyses will be distorted by the loss of signal caused by 
cell death. The incubation time with the protein synthesis inhibitor drugs was for 72 
hours in the current study and as such, measurement of degradation for proteins with 
medium or long (over 72 hours) half-lives, as in the case of CYP enzymes, are likely 
to be particularly problematic. A different approach avoiding the use of single protein 
synthesis inhibitor drugs, eliciting increased target protein synthesis inhibition with 
less cytotoxicity is needed for measurement of CYP kdeg. The purpose of chapter 3 
was therefore to assess whether a combination of inhibitors would be more 
appropriate.  
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CHAPTER 3 
 
Utility of multiple protein synthesis inhibitor 
combinations for measuring CYP protein 
degradation rate constant 
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3.1 Introduction 
It was concluded in Chapter 2 that individual protein synthesis inhibitor drugs, 
which are commonly used in processes to measure protein degradation, are likely to 
be unsuitable for measuring CYP degradation due to confounding cytotoxic effects 
when used in vitro. However, pharmacological interference remains the most simple 
and cost effective method of stopping protein synthesis and an assessment of inhibitor 
combinations was therefore worthy of analysis. 
Combination drug therapies can increase efficacy, decrease toxicity and 
reduce resistance compared to monotherapy. Combination regimens are routinely 
used in the treatment of many diseases such as HIV, cancer and hypertension 
(Foucquier & Guedj 2015). This is possible due to the principles of PD interactions 
(Jia et al. 2009) and drug synergism in which each agent within the combination 
contributes to the desirable effect and so lower doses of each agent can be 
administered to achieve optimal efficacy, while reducing risks of toxicity. One 
clinical example of a synergistic dose-reduction effect is in the use of capecitabine 
and docetaxel in combination for treatment of advanced metastatic breast cancer 
(Verma et al. 2005). It was found that 1250 mg/m2 capecitabine combined with 75 
mg/m2 docetaxel significantly improved survival compared with 100 mg/m2 docetaxel 
alone (O’Shaughnessy et al. 2002). The use of combinations of antiretrovirals have 
been crucial in the treatment of HIV and one example, amongst many, of a clinically 
significant synergistic effect is in the administration of ritonavir and squinavir in 
combination. Ritonavir inhibits saquinavir metabolism therefore increases therapeutic 
effects compared to administering saquinavir alone (Merry et al. 1997). 
There are several different methodologies used to assess synergism of drug 
combinations and the advantages and limitations between these approaches are widely 
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debated amongst biologists and mathematicians (Chou 2010). The most commonly 
used methods for assessing synergism in drug combinations fall into two main 
designs: effect-based and dose-effect-based approaches (Foucquier & Guedj 2015). 
Effect-based approaches assess drug synergy by comparing the overall effect 
of a drug combination to the effects produced by the drugs individually. Dose-effect-
based strategies aim to assess what amount, or the relative contribution, of each drug 
produces a specified quantifiable effect and such approaches rely on the principles of 
Loewe Additivity (Loewe 1926). The basis for predicting the effects of a drug 
combination is based on the concept of dose equivalence; this is the determination of 
the doses of each drug alone that give the same effect. When the ratio of equally 
effective dose is the same for the drugs in combination at every concentration, then 
drug additivity is inferred and the combination effect can be predicted. In this case, a 
constant relative potency occurs between the drug pairs and can be described by the 
following equation, where two drugs A and B are administered at doses a and b, 
respectively (Tallarida 2010): 
!! +  !! = 1  (33) 
Isobolographic analysis is the most common dose-effect-based method of 
combination drug analysis based on the principles of Loewe Additivity (Loewe 1926). 
An isobologram is a graph that is constructed on a coordinate system with individual 
drug doses on the x and y-axis and a linear line of additivity that is used to 
differentiate synergy (superadditive) and antagonism (subadditive) from additive 
interactions (Tallarida 2006). The graph is produced from two drugs that produce a 
similar measurable effect and a dose-effect profile is produced for each drug 
individually. The efficacy and potency is derived from the individual concentration-
effect curves for each of the drugs and allows a determination of the expected 
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combination effect. The expected effect is termed the ‘additive effect’ and a 
difference from additivity infers synergy or antagonism (Tallarida 2011). Synergy and 
antagonism represents greater or lesser effects for drugs in combination than the 
simple additive effect expected, respectively (Tallarida 2010). Additivity implies no 
interaction between the drug combinations, where each drug contributes to the effect 
according to its own potency. Figure 3.1 shows theoretical isobolograms indicating 
these interactions; if the curve lies below the line of additivity then a lower 
concentration is needed to reach a specified effect and synergy is assumed. 
Conversely, if it lies above then a higher dose is required and antagonism is infered.  
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Figure 3.1 Theoretical isobolograms showing synergy (A) and antagonism (B). 
FIC denotes fractional inhibitory concentration of drug A or drug B (See equations 
3.1-3.3). The solid black line represents the line of additivity.  
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Synergy for a desired effect and antagonism of an undesired effect is the ideal 
scenario when assessing drug combinations. Drug combination effects are often not 
predictable in a concentration-dependent manner as constituent concentrations of each 
drug within the combination may present different effects. Accordingly, different 
concentration ratios of the drugs in combination are assessed to determine an optimal 
combination at specific concentrations for synergising a desirable effect (Tallarida 
2010). 
MTT assays were the only form of cell viability analysis employed in Chapter 
2 to determine cytotoxicity. Viable cells within culture convert MTT into a purple 
coloured formazan product with optimal absorbance at 570 nm. When cells die, they 
lose the ability to convert MTT into formazan therefore the intensity of colour 
formation, as determined by absorbance value, serves as a surrogate estimate for cell 
viability (Riss et al. 2004). The exact mechanism of MTT reduction to formazan 
product remains poorly understood but it is likely that reduced nicotinamide adenine 
dinucleotide (NADH) and NADPH electron transfer in the mitochondria are involved; 
thus it is widely accepted that MTT assays are a measure of mitochondrial function 
(Berridge & Tan 1993). Several chemical compounds, especially reducing 
compounds, are known to interfere with MTT assays and can produce signals by 
increasing absorbance values in the absence of viable cells. Consequently there are 
limitations to using MTT assays to alone to determine cell viability. This limitation 
was addressed in this chapter through the use of multiple cell viability assays, which 
determine cell viability through different mechanisms and using different indicators 
as measure of viability. As cell death can be caused by multiple mechanisms, such as 
those leading to apoptosis or necrosis, using a single method of determining cell 
viability may not be a true measure of cell death. The GSH-Glo™ glutathione assay 
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measures oxidative stress and the CellTiter-Glo® luminescent assay measures ATP 
production; both assays detect early indicators of cytotoxicity. Converesly, trypan 
blue exclusion tests for membrane integrity and can be considered a measure of the 
later stages in the cascades of cell death. The comparison of cell viability estimated 
from MTT assays to other established cytotoxicity assays will confirm the robustness 
of the data reported in Chapter 2.  
The aim of this chapter was to investigate the potential for using multiple 
protein synthesis inhibitor drug combinations for measuring CYP protein degradation 
rates. The principles of concentration-effect-based combination drug analysis were 
employed to study the in vitro effects and find possible synergy in protein synthesis 
inhibition and antagonism in cytotoxicity in two-drug combinations of the four 
previously chosen protein synthesis inhibitors: actinomycic D, cycloheximide, 
emetine and puromycin, detailed in 2.1, for use in subsequent degradation rate 
studies. Three and four-drug combinations were also investigated at sub-cytotoxic 
concentrations for level of protein synthesis inhibition and cytotoxicity. A range of 
different cytotoxicity assays including GSH-Glo™ glutathione, CellTiter-Glo® 
luminescent and Trypan blue exclusion assays were also performed on the three and 
four-drug combinations to assess the robustness of using MTT assays as a measure of 
cell viability. 
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3.2 Materials and methods  
3.2.1 Materials 
Dulbecco’s modified eagle medium (DMEM), foetal bovine serum (FBS), trypsin-
EDTA solution, Hank’s balanced salt solution (HBSS), dimethyl sulfoxide (DMSO), 
sterile water (W4502), thiazolyl blue tetrazolium (TBT) and protein synthesis 
inhibitors; actinomycin D (A4262), emetine dihydrochloride hydrate (E2375) and 
puromycin dihydrochloride (P7255), were purchased from Sigma-Aldrich (Dorset, 
UK). HepG2 cells were purchased from American Tissue Culture Collections (ATCC, 
Virginia, USA). Cycloheximide (ab120093) was purchased from Abcam (Cambridge, 
UK). L-Leucine [4,5-3H] (MT-672E) was obtained from Moravek (California, USA). 
CellTiter-Glo® luminescent cell viability assay and GSH-Glo™ glutathione assay 
were purchased from Promega (Southampton, UK).  
 
3.2.2 Cell culture and plating 
HepG2 cell line was maintained and plated as described in 2.2.2 and 2.2.4, 
respectively. After overnight incubation to allow for cell adherence, old media was 
removed and cells were dosed with desired drug combinations. Cells were incubated 
for 72 h at 37 °C with 5% CO2 and 95% humidity with drug-containing media and 
this media was replaced every 24 h.  
 
3.2.3 Two-drug combination fixed-ratio isobologram analysis 
The effects of two-drug combinations on HepG2 cells were assessed using a modified 
fixed-ratio isobologram method, published by Fivelman et al., that detects synergy, 
additivity or antagonism between a pair of drugs (Fivelman et al. 2004). Stock 
solutions of the drugs were prepared at 10 mM in sterile water or DMSO then diluted 
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in cell line maintenance media (DMEM with 10% FBS) to achieve desired 
concentration with the dissolution vehicle at <1% of final concentration. The IC50 and 
CC50 of the individual drugs were derived from concentration-response assays 
described in 2.2.9. The four protein synthesis inhibitor drugs (actinomycin D, 
cycloheximide, emetine and puromycin) formed six different two-drug combinations 
and for these combinations dilutions were made to allow the IC50 or CC50 to fall at 
about the fourth three-fold serial dilution. The dilutions of each of the two drugs in 
each combination were prepared in 7 fixed ratios 6:0, 5:1, 4:2, 3:3, 2:4, 1:5 and 0:6. 
These mixtures were then serially diluted three-fold in quadruplicates to generate a 
range of eight concentrations for each condition. Cell viability and protein synthesis 
inhibition assays were conducted as described in 2.2.6 and 2.2.7 to generate a 
concentration-response curve to calculate the CC50 and IC50, respectively, for drug A 
and B in each mixture. The fractional inhibitory concentrations (FICs) were 
calculated using equations 3.1, 3.2 and 3.3 (Gorka et al. 2013):  FIC! = !"!" !" !!!" !" !"#$ ! !" !"#$%&'(%"&!"!" !" !!!" !" !"#$ ! !"#$%    [3.1] FIC! = !"!" !" !!!" !" !"#$ ! !" !"#$%&'(%"&!"!" !" !!!" !" !"#$ ! !"#$%   [3.2] FIC!"#$% = FIC! + FIC!    [3.3] 
Isobologram curves were generated by plotting FICA versus FICB. FICindex = 1 was 
taken as indicative of an additive effect between drug A and B, FICindex <1 indicative 
of synergy and FICindex >1 indicative of antagonism. There were four replicates per 
condition and the assays were repeated four times. 
 
3.2.4 Measuring protein synthesis inhibition in two-drug combinations by [3H]-
leucine incorporation 
HepG2 cells were seeded at 2 x 105 cells per well on 96-well plates. Cells were then 
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dosed with drug-containing media in concentrations described in 3.2.3. [3H]-leucine 
incorporation assays were conducted after 72 h incubation as described in 2.2.7 on all 
six two-drug combinations at each fixed-ratio to generate an IC50 for each drug in 
each mixture. Only combinations that displayed additivity or synergy in the level of 
protein synthesis inhibition were proceeded for analysis of cytotoxicity to determine 
useful two-drug combinations for protein degradation studies.   
 
3.2.5 Measuring cytotoxicity of two-drug combinations by standard MTT assay 
HepG2 cells were seeded at 2 x 104 cells per well on 96-well plates.  Cells were then 
dosed with drug-containing media in concentrations described in 3.2.3. After 72 h 
incubation, the levels of cytotoxicity of the two-drug fixed-ratio combinations 
explained in 3.2.3 were determined by standard MTT assays as described in 2.2.6 to 
generate a CC50 for each drug in each mixture. Vehicle controls and a control with no 
drug were included. Only combinations that displayed additive or synergistic protein 
synthesis inhibition were included. 
 
3.2.6 Calculation of CC10 concentrations for three and four-drug combination 
analysis 
Three-drug combinations: actinomycin D, cycloheximide and emetine; actinomycin 
D, puromycin and emetine; actinomycin D, puromycin and cycloheximide; and 
puromycin, cycloheximide and emetine, and four-drug combination: actinomycin D, 
puromycin, cycloheximide and emetine were assessed at sub-cytotoxic concentrations 
of each drug (CC10; concentration of inhibitor providing 10% cytotoxicity or 90% 
viability). The CC10 value was determined from the concentration-response curves 
derived from single drug incubation experiments in HepG2 cells shown in Figure 2.3. 
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The EC50 (concentration that gives 50% maximum response) and hill slope (H) 
derived from GraphPad Prism 6 software were inputted to the GraphPad calculator 
which calculated the CC10 value by the following equation: 
EC! = ( F100− F)!/! x EC!" 
Where F represents the desired response percentage. The CC10 concentrations are 
shown in Table 3.1.  
 
Table 3.1 The CC50, hill slope and CC10 values derived in HepG2 cells in 
response to protein synthesis inhibitors 
Drug CC50 (µM) Hill Slope CC10 (nM) 
    
Actinomycin D 0.0062 -0.61 0.17 
Cycloheximide 0.57 -0.69 2.4 
Emetine 0.081 -0.89 7.0 
Puromycin 1.3 -13 107 
 
 
3.2.7 Measuring protein synthesis inhibition in three and four-drug combinations by 
[3H]-leucine incorporation 
HepG2 cells were seeded at 2 x 105 cells per well on 96-well plates. Cells were then 
dosed with three or four-drug combinations made up at CC10 for each drug by dilution 
in HepG2 maintenance media to achieve final concentrations shown in Table 3.1. 
Cells were incubated for 72 h with drug-containing media replaced every 24 h. For 
each of these combinations the level of protein synthesis inhibition was assessed by 
[3H]-leucine incorporation as described in 2.2.7.  
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3.2.8 Measuring cytotoxicity of three and four-drug combinations 
Cytotoxicity of the three and four-drug combinations on HepG2 cells were 
determined by several different toxicity assays. Further toxicity assays, in addition to 
MTT (CellTiter-Glo®, GSH-Glo™ glutathione and trypan blue exclusion) were 
performed on three and four-drug combinations to confirm the robustness of MTT 
assays as a measure of cell viability.   
3.2.8.1 Standard MTT assay 
HepG2 cells were seeded at 2 x 104 cells per well onto 96-well plates. After initial 
incubation to allow for adherence, cells were incubated with the three and four-drug 
combinations described above for 72 h. Standard MTT assays were performed after 
72 h using methods described in 2.2.6.  
3.2.8.2 CellTiter-Glo® luminescent cell viability assay 
HepG2 cells were seeded at 2 x 104 cells per well onto 96-well plates. CellTiter-Glo® 
luminescent cell viability assay were performed following 72 h incubation with three 
and four-drug combinations. A vehicle control and a control containing media only 
with no cells were included to obtain background luminescence. Plated cells and 
CellTiter-Glo® reagents were equilibrated at room temperature (RT) for 30 min. 
Equal volumes of CellTiter-Glo® substrate was added to buffer to create CellTiter-
Glo® reagent. An equal volume to cell culture medium, 100 µl, of CellTiter-Glo® 
reagent was added to each well then mixed for 2 min on an orbital shaker. The plate 
was incubated for 10 min at RT to stabilise luminescent signal and then read by Tecan 
GENios micoplate reader (Germany). The luminescence corresponds to the amount of 
ATP present, which indicates the presence of metabolically active viable cells. All 
readouts were normalised against background fluorescence and cell viability was 
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determined as a percentage of control where no drug was added and viability assumed 
at 100%. 
3.2.8.3 GSH-Glo™ glutathione assay 
HepG2 cells were seeded at 1 x 104 cells per well on 96-well plates. After overnight 
incubation, cells were incubated with the three and four-drug combinations for 72 h. 
Vehicle controls and a control with no drug were included for background 
luminescence. All media was removed at 72 h and 100 µl GSH-Glo™ reagent (made 
up of Luciferin-NT substrate and GSH diluted 1:100 in GSH-Glo™ reaction buffer) 
was added to each well and then mixed for 2 min on an orbital shaker. The plate was 
incubated for 30 min at RT. 100 µl reconstituted luciferin detection reagent was added 
to each well before plates were mixed for further 2 min on an orbital shaker.  The 
plate was incubated for 15 min at RT before luminescence was read by Tecan GENios 
micoplate reader (Germany). All readouts were normalised against background 
fluorescence and cell viability was determined as a percentage of control where no 
drug was added and viability assumed at 100%. GSH-Glo™ glutathione assays 
measures the conversion of a luciferin derivative into luciferin in the presence of 
glutathione and glutathione S-transferase (GST) as an indication of oxidative stress, a 
surrogate measure of cell death.  
3.2.8.4 Trypan blue exclusion 
HepG2 cells were seeded at 5 x 104 cells per well, left overnight and for adherence 
before incubation with the three and four-drug combinations for 72 h. Following 
incubation, the cells were washed twice with HBSS solution then either trypsinised 
for 5 min or incubated with cell dissociation buffer at 37°C with 5% CO2 and 95% 
humidity for cell removal, before being transferred in suspension to Eppendorf tubes. 
10µl of cell suspension was added to 10µl of trypan blue solution and placed on a 
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Countess™ slide. Cell viability was calculated using a Countess™ automated cell 
counter (LifeTechnologies, UK) that contained internal algorithms to determine cell 
viability. 
 
3.2.9 Data Analysis 
The IC50 and CC50 values in HepG2 cells derived from the single inhibitor analyses 
(Table 2.2) were used for two-drug combination fixed-ratio isobologram analyses. 
Concentration-response curves were created individually for each drug (A and B) in 
the two-drug combination at each of the 7 fixed ratios to generate IC50 and CC50 
values to calculate FIC values for isobolograms. All concentration-response curves 
were generated in GraphPad Prism 6 software as described in 2.2.9.  
Statistical analyses of the three and four-drug combinations were completed 
using SPSS software, whereby a Shapiro-Wilk test was used to test for normality 
followed by unpaired T-test for normal populations and Mann-Whitney tests used for 
non-normal populations. P<0.05 was taken as significant. 
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3.3  Results  
3.3.1 Antagonistic two-drug protein synthesis inhibitor combinations 
The fixed-ratio isobologram method was employed to assess additivity, 
synergy or antagonism in both protein synthesis inhibition and cytotoxicity between 
drug pairs. Figure 3.2 shows a typical concentration-response curve produced by the 
fixed-ratio method to generate IC50 and CC50 values for each individual drug within 
the drug pairs at each fixed-ratio concentrations. The IC50 and CC50 values of the 
drugs alone and in combination were used to calculate the FICindex, which is plotted in 
an isobolographic analysis (Figures 3.3, 3.4 and 3.5). 
All six combinations of drug pairs for the four inhibitors were analysed for 
protein synthesis inhibition. Three of the six two-drug combinations: cycloheximide 
and emetine; cycloheximide and puromycin; emetine and puromycin, showed 
antagonism for protein synthesis inhibition at all ratios (Figure 3.3). This meant the 
drugs showed decreased efficacy in inhibiting protein synthesis in combination than 
with the inhibitors alone, therefore these drug pairs were deemed unsuitable for 
protein degradation studies. As such, isobolograms to assess cytotoxicity were not 
carried out for these combinations.  
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Figure 3.2 Typical concentration-response curves produced by the fixed-ratio method. 
Cycloheximide and emetine drug pair is shown for analysis of protein synthesis inhibition in 
HepG2 cells. A. Cycloheximide concentration-response. Ratios Drug A : Drug B represent 
cycloheximide : emetine. B. Emetine concentration-response. Ratios Drug A : Drug B represent 
emetine : cycloheximide. Individual IC50 values are derived for the individual drugs in each fixed-
dose ratio to calculate corresponding FIC values for isobolographic analysis. N = 4. 
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Figure 3.3 Isobolograms showing antagonistic interactions for protein synthesis inhibition in 
HepG2 cells.   A. cycloheximide and emetine B. cycloheximide and puromycin and C. emetine and 
puromycin. Dotted line represents the line of additivity. Red line corresponds to drug pair 
interactions for protein synthesis inhibition. FICA and FICB correspond to the fractional inhibitory 
concentrations of the first and second drugs in each drug pair listed.  
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3.3.2 Additive two-drug protein synthesis inhibitor combination 
As seen in Figure 3.4, actinomycin D and emetine showed additivity (no 
interaction) between the drugs for protein synthesis inhibition and was investigated 
for interactions in cytotoxicity. The drug pair showed synergy at all ratios for 
cytotoxicity, indicating that actinomycin D and emetine in combination did not 
improve efficacy in protein synthesis inhibition but increased cytotoxic effects 
compared to the drugs alone. As such, this combination was also deemed unsuitable 
for measuring CYP protein degradation rates.  
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Figure 3.4 Isobolograms showing protein synthesis inhibition and cytotoxicity 
interactions for actinomycin D and emetine in HepG2 cells. Dotted line represents the 
line of additivity. Red line corresponds interactions for protein synthesis inhibition. Blue 
line corresponds to interactions for cytotoxicity. FICA and FICB correspond to the fractional 
inhibitory concentrations of the first and second drug in each drug pair listed in the ratio.  
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3.3.3 Synergistic two-drug protein synthesis inhibitor combinations 
Two of the six combinations: actinomycin D and cycloheximide, and actinomycin 
D and puromycin, showed desirable synergy for protein synthesis inhibition at most 
ratios, therefore these combinations were investigated for interactions in cytotoxicity. 
However, upon analysis of cytotoxicity both of these combination also displayed 
strong synergy for cytotoxicity as shown in Figure 3.5. This suggests that although in 
combination the drugs showed increased efficacy for protein synthesis inhibition, they 
also demonstrated strong undesirable synergy for producing cytotoxicity.  
Interestingly, at ratios of 5:1 and 4:2 for actinomycin D : cycloheximide and 
actinomycin D : puromycin, these combinations were synergistic for protein synthesis 
inhibition and antagonistic for cytotoxicity as seen in Figure 3.5. The IC50 and CC50 
values at these ratios were investigated and shown in Table 3.2. However, despite the 
synergy for protein synthesis inhibition and antagonism for cytotoxicity at these 
ratios, the CC50 values for these drug pairs in combination were still lower than the 
IC50 values and thus cytotoxicity was observed at lower concentrations than those 
required to inhibit protein synthesis. The CC50 concentrations for actinomycin D in 
combination with cycloheximide at 5:1 and 4:2 ratios were 0.012 and 0.014 µM and 
the corresponding IC50 concentrations were 0.028 and 0.035 µM, respectively. The 
CC50 values for cycloheximide in combination with actinomycin D at 5:1 and 4:2 
ratios were 0.026 and 0.012 µM and the corresponding IC50 concentrations were 2.5 
and 1.3 µM, respectively. For actinomycin D and puromycin, the CC50 concentrations 
for actinomycin D at 5:1 and 4:2 ratios were 0.0098 and 0.0081 µM and the 
corresponding IC50 concentrations were 0.016 and 0.021 µM respectively. As for 
puromycin the CC50 values at 5:1 and 4:2 ratios were 0.060 and 0.020 µM and the 
corresponding IC50 concentrations were 0.69 and 0.36 µM, respectively, as shown in 
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Table 3.2. Even for two-drug combinations at ratios that showed desirable synergy in 
protein synthesis inhibition and antagonism for cytotoxicity, such combinations were 
still more potent in bringing about cytotoxicity. Therefore all two-drug combinations 
of the four protein synthesis inhibitor drugs assessed were unsuitable for subsequent 
analysis of protein degradation.  
 
Table 3.2 IC50 and CC50 of protein synthesis inhibitor drug combinations at 
ratios that showed synergy for protein synthesis inhibition and antagonism for 
cytotoxicity 
 
Drug 
Combination (A 
and B) 
Ratio Protein synthesis inhibition 
(µM) 
Cytotoxicity (µM) 
FIC50 of 
drug A 
FIC50 of 
drug B 
FCC50 of drug 
A 
FCC50 of drug 
B 
Actinomycin D and 
cycloheximide 
4:2 0.028 2.5 0.012 0.026 
5:1 0.035 1.3 0.014 0.012 
Actinomycin D and 
puromycin 
4:2 0.016 0.69 0.0098 0.060 
5:1 0.021 0.36 0.0081 0.020 
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Figure 3.5 Isobolograms showing protein synthesis inhibition and cytotoxicity 
interactions in HepG2 cells. A. actinomycin D and cycloheximide. B. actinomycin D and 
puromycin. Dotted line represents the line of additivity Red line corresponds interactions for 
protein synthesis inhibition. Blue line corresponds to interactions for cytotoxicity. FICA and 
FICB correspond to the fractional inhibitory concentrations of the first and second drug in 
each drug pair listed in the ratio. Arrows indicate drug pair ratios that showed synergism for 
protein synthesis inhibition or antagonism for cytotoxicity. 
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3.3.4 Three and four-drug combination analysis for protein synthesis inhibition 
Three and four-drug combinations at sub-toxic concentrations (CC10 of each 
when incubated alone) were assessed to investigate whether protein synthesis 
inhibition could be achieved at concentrations lower or equal to those causing 
cytotoxicity. The CC10 (90% cell viability concentration) were calculated for each 
drug to be 0.17, 24, 7.0 and 110 nM for actinomycin D, cycloheximide, emetine and 
puromycin in HepG2 cells, respectively (Table 3.1). Figure 3.6 shows that three and 
four-drug combinations exhibited < 50% leucine incorporation and therefore 
insufficient levels of protein synthesis inhibition was achieved in all combinations for 
subsequent use in protein degradation studies. 
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Figure 3.6 Level of [3H]-Leucine incorporation for three and four inhibitor 
combinations at sub-cytotoxic concentrations (CC10) in HepG2 cells. APCE 
corresponds to actinomycin D, puromycin, cycloheximide and emetine, respectively. 
***P<0.001 significance was calculated compared to control group. Data are shown as 
mean ± S.D from n=3 experiments carried out in triplicates. 
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3.3.5 Three and four-drug combination analysis for cytotoxicity 
HepG2 cell viability in response to incubation with three and four-drug 
combinations at CC10 of each inhibitor was assessed with several different toxicity 
assays. Figure 3.7 shows that over 50% cell death occurred across all drug 
combinations except for puromycin, cycloheximide and emetine (PCE). However, 
this combination was also ineffective at inhibiting protein synthesis, as shown in 
Figure 3.6, where level of leucine incorporation was higher than control.  
There was good agreement between the different toxicity assays in relation to 
the level of cytotoxicity measured as a response to the three and four-drug 
combinations, with the exception of GSH-Glo™, which consistently measured a 
higher viability across all combinations. Overall, three and four-drug combinations of 
the selected protein synthesis inhibitors were deemed to be unsuitable for further 
protein degradation studies even at low concentrations due to high cytotoxicity levels 
and low protein synthesis inhibition potential. 
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Figure 3.7 Cytotoxicity for three and four inhibitor combinations at sub-cytotoxic 
concentrations (CC10). Three and four inhibitor combinations were prepared at CC10 
concentrations. A range of cytotoxicity assays including standard MTT, GSH, ATP and 
trypan blue exclusion assays were conducted on HepG2 cells. APCE corresponds to 
actinomycin D, puromycin, cycloheximide and emetine, respectively. ***P<0.001 
significance was calculated compared to corresponding control. Data are shown as mean ± 
S.D from n=3 experiments carried out in triplicates. 
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3.4 Discussion 
Pharmacological interference through protein synthesis inhibitor drugs is the most 
common and inexpensive method of achieving protein synthesis inhibition for 
subsequent use in methods for measuring rates of protein degradation (Alvarez-
Castelao et al., 2012). In Chapter 2, four protein synthesis inhibitor drugs were 
deemed individually unsuitable for assessing protein degradation due to overt 
cytotoxicity. However, it is known that drug combinations that exhibit similar effects 
can sometimes produce synergy and any inhibitor combination that was able to 
produce improved protein synthesis inhibition and reduced cytotoxicity was worth 
investigating. The aim of this chapter was to assess the utility of multiple inhibitor 
drugs at all possible combinations from the four selected protein synthesis inhibitor 
drugs used in Chapter 2. Ideally, a drug combination that provided synergy for protein 
synthesis inhibition and antagonism for cytotoxicity would be the most suitable for 
subsequent use in quantifying CYP protein degradation rate. However, even through 
rigorous investigation of all possible combinations, no inhibitor combination was able 
to generate sufficient protein synthesis inhibition in the absence of cytotoxicity. This 
study supports the previously reported concerns over pharmacological inhibitors 
being too disruptive to normal cellular function to measure natural rates of protein 
turnover (Yewdell et al. 2011; Eden et al. 2011). 
Protein synthesis inhibitor drugs bring about inhibition of universal protein 
synthesis by inhibiting fundamental protein transcription and translation machinery; it 
is therefore unsurprising that such drugs are cytotoxic as proteins vital for cell 
survival will also be affected in prolonged inhibition. MTT assays were the only 
method used to derive CC50 across the four individual protein synthesis inhibitor 
drugs in Chapter 2. Since MTT assays specifically assess the formazan production 
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pathway as a measure of cellular mitochondrial damage (Berridge & Tan 1993), other 
forms of cytotoxicity assays including CellTiter-Glo®, GSH-Glo™ and trypan blue 
exclusion, which assess other mechanisms of cytotoxicity, were carried out to validate 
the findings. The CellTiter-Glo® luminescent cell viability assay is a form of ATP-
assay, where ATP present in viable cells convert luciferin substrate into luciferase that 
emits light photons. The intensity of light photons emitted, measured as a luminescent 
signal, is an indicator of cell viability as only viable cells are able to produce ATP 
(Posimo et al. 2014; Riss et al. 2004). The GSH-Glo™ glutathione assay is another 
commercially available assay based on the detection of glutathione (GSH) levels as a 
measure of oxidative stress, potentially leading to cell death. Luciferin derivative is 
converted to luciferin in the presence of GSH and GST and the luciferin is then 
converted to luciferase in the presence of ATP and O2 and light is generated. The 
luminescent signal detected is directly proportional to the amount of GSH present and 
this is an indicator of cytotoxicity (Promega). The Trypan Blue exclusion test of cell 
viability measures viable cells through principles of dye exclusion. Live cells with 
intact cell membranes do not take up Trypan Blue dye whereas dead cells with 
permeable membrane stain blue. By calculating the proportion of dead stained cells in 
a total cell count, the amount of viable cells in a sample can be calculated (Strober 
2001). Each of the cytotoxicity assays measure a specific indicator of cytotoxicity 
however, the assays alone may not definitively show cell death therefore a range of 
toxicity assays were utilised for the same concentrations in the same cell type to 
confirm the robustness of the assays individually as a measure of cell death.   
Good agreement across cytotoxicity assays in response to most three and four-
drug combinations were observed, with the exception of puromycin, cycloheximide 
and emetine in which higher cellular toxicity was detected in MTT than other assays. 
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The GSH-Glo™ assay generally derived higher cell viability across the different drug 
combinations; this is perhaps due to GSH being a measure of oxidative stress, which 
is a surrogate indicator of cell death and GSH may not be fully depleted even as cells 
die via a different mechanism. It should be noted that GSH-Glo™ assays alone could 
not be used to predict the CC50 because they were in disagreement with the other 
assays that clearly demonstrated cytotoxicity. Interestingly, all three and four-drug 
combinations involving actinomycin D showed significant cytotoxicity across all 
viability assays which is consistent with the synergy in cytotoxicity observed in all 
two-drug combinations involving this drug. Therefore, actinomycin D was clearly the 
most cytotoxic of the four drugs in HepG2 cells.  In this study, cell viability was 
determined through several different cytotoxicity assays that utilise different 
mechanisms and indicators of cell death. The reasonably good agreement across 
assays confirmed that MTT was a robust method of measuring of cell viability in 
chapter 2.  
No two-drug combinations, even at ratios that appeared to be synergistic for 
protein synthesis inhibition and antagonistic for cytotoxicity, were suitable for use in 
protein degradation analysis. This highlights a need for caution when interpreting data 
from isbolograms because on closer inspection of such seemingly suitable 
combinations the CC50 at these ratios were still less than corresponding IC50, which 
means that the combinations were still more potent in generating toxicity than protein 
synthesis inhibition. It is important to compare the source data rather than drawing 
conclusions based upon the interaction. The requirements and limitations of using 
isobolograms for assessing drug combinations have been discussed in detail by 
several sources (Tallarida 2006; Li et al. 2011; Chou 2010; Foucquier & Guedj 2015; 
Zhou et al. 2016; Matthews et al. 2017). Isobolograms do not provide the exact extent 
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of synergy nor statistical differentiation and their effective use is limited by 
inconsistencies in mathematical definitions of additive, syngergistic and antagonistic 
interactions.  
For all drug combinations, the data suggest that inhibiting mechanisms of protein 
synthesis by pharmacological interference (even with lower concentration 
combinations) is not a physiologically appropriate method of measuring kdeg because 
all protein systems, including those essential for cell survival are likely to be affected. 
Furthermore, several studies have shown that cycloheximide causes disruption to 
protein degradation machinery affecting both lysosomal (Thoene et al. 1985) and 
UPD (Hanna et al. 2003; Dai et al. 2013) protein degradation pathways. Other protein 
synthesis inhibitors including emetine and puromycin have also been reported to 
impact on lysosomal degradation (Thoene et al 1985). Guzelian and Barwick 
suggested that cycloheximide directly inhibits CYP degradation machinery in PRH 
(Guzelian & Barwick 1979). In support of this, Tokunaga et al. found that 
cycloheximide and puromycin suppressed ERAD (discussed in Chapter 1) in baby 
hamster kidney cells (Tokunaga et al. 2003). ERAD is a recognised pathway of CYP 
protein degradation therefore these inhibitors are particularly unsuitable for use in 
measuring CYP kdeg as they will likely affect normal CYP turnover.  
Consistent with Chapter 2, 72 h was selected to be the incubation time point due 
to the likelihood of CYP t1/2 fitting within this time course (Yang et al 2008) and 
indeed other studies have conducted cell incubations with cycloheximide beyond 72 h 
(Chen & Madura 2008). Clearly, 72 h incubation with protein synthesis inhibitors was 
too long as demonstrated by the overt cytotoxicity detected for all combinations. 
However, it may be possible to use synergistic combinations for protein synthesis 
inhibitors on a shorter time frame for measuring degradation of proteins with a shorter 
 121 
t1/2 but further optimisation would be needed to define a cut-off point. A potential 
limitation of this study is that protein binding was not assessed. However, it should be 
recognised that protein binding would be expected to impact both cytotoxicity and 
protein synthesis inhibition by impacting free-drug concentration. In taking protein 
binding into account, lower concentrations for potency would be anticipated but the 
ratio would not be expected to be different. 
There have been recent reports of protein synthesis inhibitors actively inducing a 
range of protein mRNA production that also impact accuracies for calculating protein 
degradation rates downstream (Chen & Feigelson 1979; Hattori & Gross 1995; 
Schuetz et al. 1995; Stordeur et al. 1995). Furthermore, Joiakim et al. (2004) reported 
superinduction of CYP1A1 mRNA in MCF10A cell line cultures in response to 
multiple protein synthesis inhibitors including cycloheximide, anisomycin and 
puromycin; further supporting the notion that these inhibitor drugs are unsuitable 
especially for use in measuring CYP degradation. Taken collectively with the data 
presented in this chapter, the use of protein synthesis inhibitors for CYP enzyme kdeg 
estimation is not recommended. As such, further work with these inhibitors was not 
conducted. 
 Despite the wide-ranging importance of protein degradation, there has been no 
single recognised method for its measurement. However, the use of protein synthesis 
inhibitors, whether alone or in combination, should be avoided particularly for 
medium and long t1/2 proteins. Protein synthesis inhibitor drugs not only impact on 
essential cell survival proteins but are also known to induce mRNA of several 
different genes and affect protein degradation machinery, which would in turn 
dramatically impact any protein degradation rate derived downstream. The more 
recent methods of measuring rates of degradation focus on high-throughput 
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approaches aiming to quantify many different proteins in parallel; these involve 
metabolic labelling of proteins of interest followed by MS analysis (Doherty & 
Beynon 2006; Yewdell et al. 2011). Newly developed quantitative proteomic methods 
provide an important alternative to chemical inhibition, but reproducibility across 
different experiments and the impact of protein labelling on endogenous protein 
degradation warrants full investigation.  
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Using mRNA suppression to estimate CYP3A4 
degradation rate constant in primary human 
hepatocytes 
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4.1 Introduction 
CYP enzymes are important DMEs indicated in many clinically-relevant 
DDIs. Any alterations to their activity through induction, inactivation or inhibition 
can manifest as changes in PK profiles of the victim substrate drug(s) (Tanaka 1998; 
Chu et al. 2009). DDIs can cause an increase or decrease of exposure and thus a 
change in therapeutic effect and/or increased potential for adverse effects. Approaches 
to assessing DDI potential for a new drug candidate have traditionally been conducted 
in vitro using animal and human samples, which require the translation to the human 
in vivo situation. Where preclinical studies indicate DDI liability, DDI studies have 
also been carried out in vivo in humans by measuring PK profiles in clinical trials, but 
these studies invoke huge costs and require ethical approval (Kuhlmann & Mück 
2001). Increasingly, regulators have advocated the use of in silico approaches to DDI 
prediction as an alternative or alongside clinical studies (Yeo et al. 2013; Zhao et al. 
2012; Leong et al. 2012). Such methods include PBPK modelling which integrates 
physiological system-specific parameters with drug-specific parameters derived from 
in vitro and in vivo experiments. Once the model has been adequately verified and 
deemed ‘fit-for-purpose’, the impact of intrinsic and extrinsic sources of variability in 
PK can be predicted, including DDIs (Einolf 2007; Rostami-Hodjegan 2012).  
At the kinetic level, CYP protein abundance at steady-state comprises of a 
continuous turnover of proteins that balance de novo synthesis at zero-order and 
degradation at first-order (Belle et al. 2006). However, many endogenous factors such 
as drugs, hormones and foods can induce or inhibit CYP expression (Zanger & 
Schwab 2013), thus disrupting the steady-state abundance and accordingly, the time 
required to return to steady-state is partially dependent on its rate of degradation 
(Yang et al 2008). As previously mentioned, the enzyme P450 degradation rate 
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constant, kdeg, is an important system parameter that gives rise to the timescale of 
interactions, which is required for predicting time-dependent DDIs such as those 
arising from MBI and induction of enzymes (Yang et al 2008).   
Owing to the challenges with methodology and sample size there is a lack of 
consensus on CYP turnover half-lives, which places a significant limitation on the 
accurate prediction of changes in drug concentration-time profiles associated with 
interactions involving enzyme MBI and/or induction (Almond et al. 2009). 
Consequently, there is a paucity of reported kdeg values for many of the CYP enzymes 
that are involved in clinically relevant DDIs. As such, inaccurate kdeg continues to be 
a source of error in metabolic time-dependent DDIs and several sources have 
documented the importance of accurate kdeg values in facilitating accurate predictions 
of DDI magnitudes (Houston & Galetin 2010; Lutz et al. 2013; Almond et al. 2009).  
The measurement of kdeg values should ideally be achieved by specific 
labelling of enzymes in humans in vivo, but this direct method has proven to be 
understandably difficult and surrogate kdeg values derived from in vitro approaches 
are needed. As discussed previously in Chapter 1, CYP3A4 is involved in the 
metabolism of around 50% of all marketed drugs and due to this wide specificity; the 
enzyme has been most widely implicated in DDIs. Examples of inhibitors, inducer 
and substrates of CYP3A4 are given in Table 1.1 and classic examples drug that cause 
clinically-significant CYP3A4 TDIs include diltiazem, verapamil, erythromycin and 
troleandomycin (Grimm et al. 2009; Chen et al. 2011). As such, CYP3A4 has been 
the most extensively studied of all CYP enzymes with the reported half-life values 
ranging from 10 to 140 hours (Yang et al. 2008). These half-life values were derived 
by a plethora of different in vivo and in vitro methods.  
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The three main in vitro approaches include: (i) measuring CYP apoprotein 
expression loss in liver models without treatment over time (Maurel 1996; Renwick et 
al. 2000), (ii) induction of CYP enzymes followed by tracking of de-induction and 
recovery profiles (Maurel 1996; Dixit et al. 2016) and (iii) Pulse-chase analysis after 
de-induction (Pichard et al. 1992). Many in vitro studies have shown that CYP 
apoprotein and enzyme levels decline differentially over time in culture (Guillouzo et 
al. 1985; Paine 1990; Morel et al. 1990) thus, enzyme degradation rates can be 
derived from tracking the loss of expression assuming that the changes are caused 
solely by endogenous enzyme degradation mechanisms. However, this method is 
limited by the assumption that there is no de novo enzyme synthesis and that the 
decline in cell viability does not contribute to the enzyme expression loss observed.  
In the second aforementioned approach, enzyme turnover is estimated from 
measuring the increased level of activity instigated by incubation of liver with 
multiple doses of a known inducer compound to reach a maximally induced new 
steady-state, then removing the inducer and measuring the time taken to return to the 
basal non-induced enzyme level using probe substrates. The main caveats to this 
approach include, again, the assumption that there is no de novo CYP protein 
synthesis and the interindividual variability in the inducibility of CYP enzymes 
between donor livers.  
The pulse-chase method is frequently used to predict turnover and half-life of 
various proteins (Belle et al. 2006; Montgomery et al. 2003; Boisvert et al. 2012) and 
typically the protein of interest is labelled with a radioactive amino acid precursor 
during pre-incubation followed by a chase period where an excess of non-radioactive 
amino acid is added to the culture to prevent further incorporation of radiolabelled 
precursor amino acid. Cells are then harvested and the radioactivity determined over 
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several time points to measure rate of protein disappearance to determine half-life 
(Zhou 2004; Jansens & Braakman 2003). This technique is limited by the potential of 
isotope labelling distorting normal CYP degradation mechanisms thereby producing 
an inaccurate degradation rate constant value.  
Another simple kinetic approach circumventing the problem of radiolabelling 
the protein of interest, involves inhibiting de novo protein synthesis by treatment with 
pharmacological inhibitors, followed by the quantification of changes in protein 
content over time by immunoblotting (Alvarez-Castelao et al., 2012; Dai et al., 2013). 
However as deduced in Chapters 2 and 3, the use of pharmacological inhibitors 
should be avoided due to their cytotoxic effects precluding the propensity for protein 
synthesis inhibition (Chan et al. 2017). More recently, based on the principle of 
inhibiting de novo protein synthesis, Ramsden et al. (2015) utilised RNA interference 
(RNAi) and interleukin-6 (IL-6) to specifically knockdown CYP3A4 gene expression 
in vitro in the HepatoPac model, followed by tracking its degradation and recovery 
profile to estimate kdeg.  
siRNAs are short 20-30 nt (nucleotide) sequences of non-coding RNA that 
regulate the genome mainly through inhibitory effects by silencing the translation of 
the regulated parts of the genome via the RNAi pathway (Carthew & Sontheimer 
2009). The mechanism of siRNA gene silencing is depicted in Figure 4.1. In 
eukaryotic cells the RNase-III-type enzyme Dicer cleaves long double-stranded 
siRNA into short 21-26 nt siRNA duplexes. Components of the RNAi machinery then 
recognise the siRNA duplex and incorporate a single strand of siRNA into the RNA-
induced silencing complex (RISC). The argonaute 2 protein within RISC unwinds the 
siRNA and cleaves off the passenger or sense strand. The activated RISC complex 
containing the antisense siRNA strand binds and cleaves mRNA at the site that 
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contains the complementary sequences to the single antisense strand, therefore 
inhibiting subsequent gene translation (Dorsett & Tuschl 2004; Whitehead et al. 
2009). The activated RISC complex continues to destroy more mRNA targets, further 
propagating the gene-silencing response. siRNA occurs endogenously within cells as 
a mechanism of genetic regulation but it can also be synthetically produced and 
introduced experimentally via transfection vectors, circumventing the Dicer process 
(Whitehead et al 2009). Increasingly, siRNA has been exploited in vitro, enabling the 
knockdown of genes to analyse specific gene functions. RNAi has also been used as a 
therapeutic approach in the treatment of diseases including cancer and autoimmune 
disorders (Aagaard & Rossi 2007; Wittrup & Lieberman 2015). For DME kdeg 
investigations, it was hypothesised that by introducing target gene-specific siRNA, 
the translation of target protein is specifically silenced without impacting on regular 
cellular survival and protein degradation mechanisms. This circumvents the 
previously encountered problems of cytotoxicity and de novo protein synthesis during 
analysis of degradation rates.  
Based on the findings from Ramsden et al. (2015), the aim of this Chapter was 
to investigate the utility of CYP3A4-specific siRNA, as an alternative in vitro 
approach to protein synthesis inhibitors, for suppressing synthesis of CYP3A4 mRNA 
and protein. CYP3A4 kdeg was derived by tracking activity and protein expression 
loss over time in cryopreserved primary human hepatocytes.  
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Figure 4.1 Mechanism of siRNA gene silencing. Adapted from Dorsett et al 
(2004).  
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4.2 Materials and methods 
4.2.1  Materials 
Plateable cryopreserved primary human hepatocytes (HMCPIS Lot. Hu1591, Hu1824 
and Hu8241), CHRM® media, William’s E media, thawing and plating supplements 
(CM3000), maintenance supplements (CM4000), 24-well collagen I coated plates and 
opti-MEM® I media were purchased from Invitrogen Ltd (Paisley, UK). TaqMan® 
reverse transcription reagents, TaqMan® gene expression assays for CYP3A4 
(Hs00604506_m1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 
Hs02758991_g1) and hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1; 
Hs02800695_m1), TaqMan® gene expression master mix, PrestoBlue® cell viability 
reagent, CYP3A4 (P2377) and control (P2315) BACULOSOMES® plus reagent, 
Lipofectamine® RNAiMAX reagent, NuPAGE® Western blot materials and 
TRIzol® reagent were purchased from ThermoFisher Scientific Inc. (Loughborough, 
UK). ON-TARGETplus human CYP3A4 SMARTpool, GAPD control pool and non-
targeting pool siRNA were purchased from GE Healthcare Dharmacon™ (UK). 
Western blot primary and secondary antibodies: anti-CYP3A4 (ab3572), anti-beta 
actin (ab6276), anti-GAPDH (ab181602), goat polyclonal anti-mouse IgG1 (ab97240) 
and goat polyclonal to rabbit IgG (ab97080) were purchased from Abcam 
(Cambridge, UK). Luminata™ Forte Western HRP substrate was bought from 
Millipore (Watford, UK). TWEEN®20, Bradford Reagent, urea solution, CelLytic™ 
M, protease inhibitor cocktail, 1’-hydroxymidazolam, RNase-free water and other 
Western blot buffer ingredients were purchased from Sigma-Aldrich (Dorset, UK). 
Midazolam hydrochloride was purchased from Tocris (Bristol, UK).   
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4.2.2 Cryopreserved primary human hepatocyte culture 
4.2.2.1 Cell thawing 
Cryopreserved primary human hepatocytes were thawed in a 37 °C water bath for 
approximately 2 min until contents were around 90% thawed. Once thawed, the 
hepatocytes were added to 50 ml of pre-warmed plating media (William’s E media 
without phenol red supplemented with 5% FBS, 1 µM dexamethasone, 1% solution of 
penicillin/streptomycin, 4 µg/ml Bovine insulin, 2 mM GlutaMAX™ and 15mM 
HEPES; CHRM® supplement A) and centrifuged for 10 min at 100 x g at 18oC and 
the supernatant fraction discarded. The hepatocytes were then resuspended at 
approximately 1 x 106 cells per ml density in plating media, which was prepared as 
Williams E media without phenol red supplemented with 1μM dexamethasone, 1% 
solution of penicillin-streptomycin, 4 μg/ml insulin, 5% FBS, 2 mM GlutaMAX™ 
and 15 mM HEPES (CM3000, supplement A). The donor demographics are given in 
Table 4.1. 
4.2.2.2 Cell counting and plating 
The cell viability and count were determined as described in 2.2.4. Primary human 
hepatocytes were seeded at 500 μl per well on 24-well collagen-I coated plates at a 
density of 3 x 105 viable cells/well for CYP3A4 metabolism activity and protein 
expression analyses. Cells were incubated with plating media for 5 hours at 37°C with 
5% CO2 and 95% humidity to allow cell adherence prior to siRNA transfection. After 
5 hours of incubation, the plating media was replaced with maintenance media 
(William’s E media supplemented with 0.1 µM dexamethasone, 0.5% 
penicillin/streptomycin 6.25 µg/ml human recombinant insulin, 6.25 µg/ml human 
transferrin, 6.25 ng/ml selenous acid, 1.25 mg/ml BSA, 5.35 µg/ml linoleic acid, 2nM 
GlutaMAX™ and 15 mM HEPES) for untreated control or dosed with varying siRNA 
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conditions in optiMEM® I reduced serum media. Following siRNA transfection, 
maintenance media was replaced every 24 hours. The use of Geltrex™ matrix overlay 
is generally recommended for primary hepatocytes to maintain phenotype during 
culture. However, after private correspondence with authors of the publication by 
Vozza-Brown et al. they advised against the use of Geltrex™ as it was found that the 
matrix interfered with siRNA delivery, consequently Geltrex™ was not used in 
conjunction with siRNA experiments. 
 
Table 4.1 Donor demographics of the cryopreserved primary human hepatocytes  
 
 
4.2.3 Small-interfering RNA (siRNA) treatment 
CYP3A4 siRNA experiments were conducted by modification of the knockdown 
protocol published by Vozza-brown et al. (2005). 5X siRNA buffer (300 mM KCl, 30 
mM HEPES-pH 7.5, 1.0 mM MgCl2) was prepared and diluted to 1X concentration 
with RNAse-free water. siRNA was stored at 10 µM stock concentration in 1X 
siRNA buffer at -20°C until use.  
After 5 hours incubation with hepatocyte plating media, cells were washed 
and treated with Dharmacon ON-TARGETplus human CYP3A4 SMARTpool 
Demographics Donor 1 Donor 2 Donor 3 
Donor ID Hu1591 Hu1824 Hu8241 
Age 29 66 60 
Gender Male Female Male 
Ethnicity Caucasian Caucasian Caucasian 
Characteristics Rare alcohol user. 
No tobacco or drug 
use reported 
Tobacco use. No 
alcohol or drug use 
Tobacco and 
alcohol user. No 
drug use 
Cause of death Not reported Not reported Cardiac related 
Cell viability 91% 93% 94% 
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siRNA. Positive ON-TARGETplus GAPD human control pool and negative control 
ON-TARGETplus non-targeting pool were also included. The sequences of the 
siRNA used are shown in Table 4.2. 1.25 μl of transfection reagent Lipofectamine 
RNAiMAX™ was complexed with ON-TARGETplus siRNA in reduced serum opti-
MEM® I media for 30 minutes prior to addition to cell culture. Hepatocytes were 
exposed to the siRNA overnight for 15 hours before the cells were washed and media 
replaced with standard hepatocyte maintenance media. Cells were subsequently 
incubated at 37°C with 5% CO2 and 95% humidity for a range of time post CYP3A4 
siRNA treatment. CYP3A4 metabolic activity, mRNA and protein expression were 
assessed at specific time points. Time 0 hours was taken at 5 hours incubation with 
plating media, prior to siRNA transfection and maintenance media replacement. 
 
Table 4.2 siRNA sequences.  
siRNA Sequence 
  
ON-TARGETplus human 
CYP3A4 SMARTpool 
5’-CAUCCCAAUUCUUGAAGUA-3’ 
5’-GUGGAAAACUCAAGGAGAU-3’ 
5’-GAACUGAAGCUCUUAUUAU-3’ 
5’-CCAACUGUCUCGAUGCAAU-3’ 
 
 
ON-TARGETplus human 
GAPD control pool 
 
5’-GUCAACGGAUUUGGUCGUA-3’ 
5’-CAACGGAUUUGGUCGUAUU-3’ 
5’-GACCUCAACUACAUGGUUU-3’ 
5’-UGGUUUACAUGUUCCAAUA-3’ 
 
 
ON-TARGETplus Non-targeting 
pool 
 
5’-UGGUUUACAUGUCGACUAA-3’ 
5’-UGGUUUACAUGUUGUGUGA-3’ 
5’-UGGUUUACAUGUUUUCUGA-3’ 
5’-UGGUUUACAUGUUUUCCUA-3’ 
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4.2.4 Cytotoxicity determined by PrestoBlue™ cell viability reagent 
PrestoBlue™ reagent is a resazurin-based cell viability assay that is able to monitor 
live cells not requiring lysis at the final stage of analysis and therefore, appropriate for 
detecting cytotoxicity caused by siRNA and transfection reagent in primary human 
hepatocytes following knockdown. Due to the expense of primary human 
hepatocytes, PrestoBlue™ assay optimisation was initially conducted in HepG2 cells 
because they displayed concentration-dependent toxicity in Chapter 2 in response to 
actinomycin D.  
4.2.4.1. Optimisation of PrestoBlue™ assay in HepG2 cells 
HepG2 cell line was maintained and plated as described in 2.2.2 and 2.2.4, 
respectively. Cells were seeded at 3x105 per well on 24-well culture plates and 
incubated with 0.0001-10 µM actinomycin D dissolved in cell line maintenance 
media. Drug dissolution vehicle and cells with no drug treatment were included as 
controls. The assay was carried out in triplicates. HepG2 cells were incubated with 
varying concentrations of actinomycin D at 37°C with 5% CO2 and 95% humidity for 
72 hours, with media replaced every 24 hours. At the end of incubation, 50 µl of 10X 
PrestoBlue™ reagent was directly added to each well and fluorescence was read at 10 
min intervals for 80 min with excitation at 560 nm and 590 nm emission on a 
CLARIOstar® microplate reader (BMG LABTECH, Aylesbury, UK). Final readings 
were taken at a time point before signal saturation and normalised against background 
fluorescence.  
4.2.4.2. Determination of siRNA and transfection reagent inflicted 
cytotoxicity 
Following siRNA treatment and cell incubation to a designated time point, 50 µl of 
10X PrestoBlue™ reagent was directly added to each well. Media only with no cells, 
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cells incubated with transfection reagent and cells with no treatment were included as 
controls. Fluorescence was read with excitation at 560 nm and 590 nm emission at 10 
min intervals for 60 min on a CLARIOstar® microplate reader (BMG LABTECH, 
Aylesbury, UK). Final readings were taken at a time point before signal saturation and 
normalised against background fluorescence. The media containing PrestoBlue™ 
reagent was washed off the cells 3 times with HBSS prior to proceeding with further 
experimental procedures. 
 
4.2.5 CYP3A4 mRNA knockdown quantification 
The magnitude of siRNA knockdown was determined by quantifying gene expression 
by reverse-transcription polymerase chain reaction (RT-PCR) following a designated 
time of incubation. 
4.2.5.1 Total mRNA isolation 
After siRNA treatment and incubation, total RNA isolation was carried out using the 
standard TRIzol® reagent extraction protocol by Ambion/Life Technologies. Media 
was discarded and hepatocytes were treated with 1 ml TRIzol® reagent and 
homogenised for 5 min at RT. The cell lysates were transferred to 1.5 ml centrifuge 
tubes and samples were vortexed with chloroform at 0.2 ml per 1 ml of TRIzol® and 
incubated for 2 min at 30°C before centrifugation at 13,200 x g for 15 min at 4°C. 
The aqueous phase of the samples were transferred into new centrifuge tubes. 0.5 ml 
per 1ml TRIzol® of 100% isopropanol was added and incubated for 10 min at RT 
before centrifugation at 12,000 x g for 10 min at 4°C. The supernatant fraction was 
then removed leaving the mRNA pellet that was washed with 1 ml of 75% ethanol per 
1 ml of TRIzol® used. The samples were vortexed with 75% ethanol then centrifuged 
at 7500 x g for 5 min at 4°C. The supernatant fraction was then discarded and mRNA 
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pellet left to dry. The mRNA pellet was resuspended in 30 µl RNase-free water and 
incubated on a heat block at 60°C for 15 min. The isolated mRNA was stored at -
80°C until analysis. Total mRNA was quantified by NanoDrop™ 1000 
spectrophotometer with an average purity (A260/280) of >1.80. 
4.2.5.2 cDNA synthesis 
Complementary DNA (cDNA) synthesis was performed using Taqman® reverse 
transcription kit. 2 µg of total mRNA was reverse transcribed with 3 µl 10X 
Taqman® RT buffer, 1.75 mM MgCl2, 0.5 mM dNTP mix, 1.0 U/µl RNase inhibitor, 
2.5 U/µl MultiScribe™, 2.5 µM random hexamers and reaction mixes were made up 
to 50 µl per sample with RNase-free water. cDNA amplification was performed in a 
GeneAmp® PCR 9700 thermocycler (Applied Biosystems, UK) with cycling 
conditions of 25°C for 10 min, 37°C for 30 min and 95°C for 5 min. The cDNA 
samples were kept at 4°C overnight for analysis the following day. Total cDNA was 
quantified by NanoDrop™ 1000 spectrophotometer with an average purity (A260/280) 
of >1.80, then diluted to produce a working stock of 5 ng/µl. 
4.2.5.3 Gene amplification by RT-PCR 
Real-time PCR (qPCR) were developed for quantification relative to HPRT1, 
housekeeping gene; assays were conducted according to Taqman® gene expression 
protocol. All samples were completed in quadruplicate. A 25 µl reaction mix 
consisting of 1.25 µl of 20X Taqman® custom gene CYP3A4 (assay ID, 
Hs00604506_m1), GAPDH (Hs02758991_g1) or HPRT1 (Hs02800695_m1) assay, 
40 ng cDNA in 8 µl, 3.25 µl RNase free water and 12.5 µl of 2X Taqman® Master 
Mix were dispensed into a 96-well plate. Negative controls where RNase-free water 
was added in place of cDNA was included. The plates were then covered with 
Microseal® adhesive PCR plate sealing film and centrifuged briefly up to 2000 rpm 
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to mix the reaction contents to eliminate air bubbles from the solution mix. PCR 
conditions were run at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 
60°C for 1 min.  
4.2.5.4 Calculating relative expression 
Relative CYP3A4 and GAPDH mRNA expression against housekeeping gene HPRT1 
were performed in an Opticon2™ Fluorescence Detector (MJ Research, UK). The 
cycle threshold [C(t)] was set to ignore any aberrant fluorescence to ensure that only 
gene amplification was measured. Data was normalised to the primary hepatocyte 
vehicle control or untreated control sample collected at time 0 (T0) and relative 
expression was derived using two methods: the comparative C(t) method given by the 
following equation, 𝐶! =  2!∆∆!(!) 
 or the Pfaffl method (Pfaffl 2001), given by the following equation: 
Relative expression ratio =  (E!"#$%!)∆!"!"#$%!(!"#$%"&!!"#$%&)(E!!")∆!"!"#(!"#$%"&!!"#$%&)  
Where Etarget is the qPCR efficiency from target gene; Eref is qPCR efficiency of 
reference gene; ΔCPtarget is the deviation of control-sample of target gene to test 
sample and ΔCPref is the deviation of control-sample of reference gene to test sample.  
 
4.2.6 CYP3A4 protein quantification 
4.2.6.1 Protein extraction 
Two different established methods of protein extraction were carried out to determine 
a suitable method for maximum extraction of proteins. 
(i) Modified TRIzol® protein extraction method 
The efficiency of protein extraction by TRIzol® reagent using the method published 
by Ambion/LifeTechnologies is known to be limited by problems of protein 
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resolubilisation (Hummon et al. 2007). Therefore, a modified version with improved 
resolubilisation was conducted as detailed in a publication by Simões et al. (2013). 
 Following phase separation and removal of the aqueous phase containing 
mRNA as detailed in 4.2.5.1, protein separation and isolation were conducted as 
follows: 300 µl of 100% ethanol was added to tube containing the interphase and 
phenol-chloroform phase. The tube was mixed by inversion then incubated for 2-3 
min at RT before centrifugation at 2000 x g for 5 min at 4°C to pellet the DNA. The 
phenol-ethanol supernatant layer containing protein was transferred into a new 
centrifuge tube. 1.5 ml of 100% isopropanol was then added and samples incubated 
for 10 min RT. The samples were then centrifuged at 12,000 x g for 15 min at 4°C to 
pellet the protein. The supernatant was discarded and washed 3 times with 2 ml 0.3 M 
guanidine hydrochloride in 95% ethanol with 20 min incubation at RT between 
washes. The samples were then centrifuged at 7,500 x g for 5 min at 4°C. 2 ml of 
100% ethanol was then added, vortexed and left to incubate for 20 min RT. Samples 
were centrifuged at 7,500 x g for 5 min at 4°C and ethanol wash supernatant 
discarded. 1.5 ml of 1:1 solution of 8 M urea (in Tris-Hcl 1 M, pH 8.0) and 1% 
sodium dodecyl sulphate (SDS) was added to the cell pellet and vortexed to resuspend 
pellet in solution. The solution was then sonicated for 5 cycles of 15 s and placed on 
ice for 30 s to solubilise the protein. The mixture was then centrifuged at 3,200 x g for 
10 min at 4°C to sediment any insoluble material. The supernatant containing the 
dissolved protein was transferred to a new centrifuge tube and stored at -80°C until 
analysis.  
(ii) CelLytic™ M protein extraction method 
CelLytic™ M protein extraction was conducted according to manufacturer’s 
recommendations. A separate sample from which mRNA was extracted by TRIzol® 
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reagent was included for CelLytic™ M protein extraction. After siRNA treatment and 
cell incubation, media was discarded from culture dish and cells were washed four 
times with HBSS before removal from well by trypsinisation for 5 min at 37°C with 
5% CO2 and 95% humidity. 1 ml of cell maintenance media was added to neutralise 
the trypsin-EDTA solution and the cells in solution were transferred to 1.5 ml 
centrifuge tubes. The samples were centrifuged at 4,500 x g for 5 min at 4°C to pellet 
cells. The supernatant was discarded and cells were resuspended in 1 ml HBSS before 
further centrifugation at 2,000 x g for 5 min at 4°C to wash cells. The supernatant was 
then discarded. 125 µl of CelLytic™ M lysis solution and 12.5 µl protease inhibitor 
cocktail (which was stored on ice during use) was added to cell pellet and mixed 
vigorously to lyse cells. The samples were then incubated on an oscillating table for 
15 min before centrifugation at 13,900 x g for 15 min at 4°C. The supernatant 
containing protein samples were collected and stored at -80°C until analysis. 
4.2.6.2 Quantification of extracted protein by Bradford assay 
Protein concentrations of the isolated samples were determined by the Bradford 
reagent assay according to protocol provided by Sigma-Aldrich. Bovine serum 
albumin (BSA) standards were prepared at 8 concentrations at two-fold dilutions in 
the range of 0-1.5 mg/ml in CelLytic™ M buffer with 10% protease inhibitor 
cocktail. Protein standards were made to 20 µl per well on a 96-flat well plate with 
buffer. Protein samples were added at 1, 2.5 or 5 µl in 20 µl per well CelLytic™ M 
buffer with 10% protease inhibitor cocktail. Conditions were performed in duplicates. 
250 µl of 1X Bradford Reagent was added to each well at RT, mixed for 30 s on 
orbital shaker then incubated in darkness for 30 min. The absorbance of the samples 
were measured at 595 nm on a CLARIOstar® microplate reader (BMG LABTECH, 
Aylesbury, UK). Protein concentrations of the samples were determined by 
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comparing the net A560 values against the standard curve and only plates with 
standard curve where R2≥0.99 were included. 
4.2.6.3 Protein quantification by Western blotting 
20 µg of total protein, as determined by Bradford assay, and 0.5 µl CYP3A4 
BACULOSOMES® plus reagent (positive control) was added to 5 µl of 4X 
NuPAGE® LDS sample buffer, 2 µl of NuPAGE® reducing agent and made up to 21 
µl volume using deoinised water. Samples were heated at 100°C for 5 min. 20 µl of 
sample and 3 µl of Kaleidoscope™ prestained protein standard (Bio-Rad, UK) were 
loaded onto a NuPAGE® 4-12% Bis-Tris Gel with 200 µl NuPAGE® antioxidant and 
electrophoresed for 1 hour 30 min at 150 V. Following electrophoresis, the proteins 
were blotted onto a Amersham Protran 0.45 nitrocellulose membrane using a 
Criterion™ blotter method (Bio-Rad, UK) run at 30 V for 60 min.  
After protein transfer, the membrane was blocked in 5% non-fat dried milk 
(NFDM) or BSA in 0.01% Tween-tris buffered saline (T-TBS) for 2 hours RT, 
washed with 0.01% T-TBS solution 3 times for 5 min, followed by incubation with 
primary antibody (anti-cytochrome P450 3A4, ab3572) at 1/2000 dilution in 2% 
NFDM or BSA in 0.01% T-TBS overnight at 4°C. The following day, the membrane 
was washed 3 times with 0.01% T-TBS for 5 min then incubated with secondary 
antibody (goat polyclonal secondary antibody to rabbit IgG, ab97080) at 1/5000 in 
2% NFDM or BSA in 0.01% T-TBS for 2 hours at 4°C. For detection of loading 
control β-actin, the membrane was blocked with 10% NFDM or BSA in 0.01% T-
TBS overnight at 4°C. The following day, membranes were washed 3 times with 
0.01% T-TBS for 5 min before incubation with primary antibody (anti-β-actin 
antibody, ab6276) at 1/5000 in 2% NFDM or BSA in 0.01% T-TBS for 2 hours at 
4°C. After primary antibody incubation, membrane was washed 3 times with 0.01% 
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T-TBS for 5 min before incubation with secondary antibody (goat polyclonal 
secondary antibody to mouse IgG1, ab97240) at 1/2000 in 2% NFDM or BSA in 
0.01% T-TBS for 1 hour at 4°C. For GAPDH loading control, membranes were 
initially blocked with 10% BSA in 0.01% T-TBS overnight before GAPDH was 
probed for using primary antibody (anti-GAPDH, ab181602) at 1/10,000 for 2 hours 
at 4oC and secondary antibody (ab97080) at 1/10,000 dilution incubated for 1 hour RT 
in 2% BSA in 0.01% T-TBS. Following incubation with secondary antibodies, 
membranes were washed 3 times in 0.01% T-TBS for 5 min followed by 2 times 20 
min wash in 0.01% T-TBS. 
Between the detection of each protein, the membrane was stripped and re-
probed. After enhanced chemiluminescence (ECL) detection, membranes were 
washed for 5 min in 0.01% T-TBS, then 2 times 20 min with acidic glycine stripping 
buffer, followed by 2 times 10 min 1X Tris-buffer saline (TBS) solution and 2 times 
10 min 0.01% T-TBS. The membranes were then blocked and probed for a new 
protein as indicated above. 
Protein bands were visualised by ECL detection. Following the final wash, the 
membrane was blotted dry and incubated with 3 ml Luminata™ Forte Western 
Horseradish Peroxidase (HRP) substrate solution for 5 min. Excess substrate was 
drained and membrane placed under plastic wrap. Detection was carried out in the 
dark room where an X-ray film was placed on the blot and the film was exposed 
between 10-600 s for CYP3A4, β-actin and GAPDH protein band detection. The X-
ray film was then placed in a developing solution for approximately 30 s for the 
image to appear before immersing in fixing solution for 30 s followed by water for 30 
s. Quantification of protein bands were achieved using GS-800™ calibrated 
densitometer (Bio-Rad, Hercules, CA) and ImageJ software (NIH). Relative protein 
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quantification was determined by normalising CYP3A4 band against β-actin or 
GAPDH loading control band density. 
 
4.2.7 Assessment of CYP3A4 activity by probe substrate turnover  
Midazolam (MDZ) and 1’hydroxymidazolan were dissolved in high performance 
liquid chromatography (HPLC) grade 100% methanol to form a stock solution at 1 
mM that was stored at -20°C until use. The probe substrate selected for CYP3A4 
activity was 3.4 μM MDZ (the concentration was chosen based on recommendations 
from personal communications with Dr Beth Williamson) and the probe substrate 
compound was prepared in hepatocyte maintenance media in <0.5% methanol. In the 
final hour of incubation in control and siRNA-treated samples, cells were spiked with 
MDZ to a final concentration of 3.4 μM and incubated for 60 min at 37°C with 5% 
CO2 and 95% humidity. CYP3A4 activity was measured as 1’-hydroxymidazolam 
metabolite formation following incubation with MDZ at 0, 48, 72 and 96 hours after 
CYP3A4 siRNA transfection. After 60 min incubation with MDZ, the media was 
removed and immediately stored at -80°C to terminate further activity until analysis. 
1’-hydroxymidazolam metabolite was extracted from cell maintenance media matrix 
and analysed by high performance liquid chromatography-ultraviolet (HPLC-UV). 
4.2.7.1 Drug extraction from media matrix 
Extraction of 1’-hydroxymidazolam metabolite involved addition of acetone (5:1 v/v) 
to 400 μl of media sample. The samples were then mixed on a turntable for 30 min at 
RT followed by centrifugation at 13,000 x g for 30 min at 4°C. The metabolite-
containing supernatant fraction was then removed and transferred to a glass tube. The 
samples were dried overnight in a Savant SpeedVac rotary evaporator (Thermo 
 145 
Scientific, UK). The resulting dried compounds were reconstituted in 150 μL mobile 
phase A with 20% acetonitrile (ACN) v/v.  
4.2.7.2 Metabolite quantification by HPLC-UV 
MDZ and 1’-hydroxymidazolam were chromatographically separated and quantified 
by HPLC with ultraviolet detection (HPLC-UV). 100 μL of reconstituted sample was 
injected into a Dionex HPLC system (Thermo, UK). Two mobile phases were used 
for the chromatographic run and the run was conducted using a using a multi-step 
gradient with a reverse-phase Fortis® column (3 μM, C18, 100 x 4.6 mm; Fortis® 
Technologies Ltd., Neston, UK). The conditions were as follows: 
 
Mobile phase A 80% 25 mM KH2PO4 in ddH2O, 20% 
ACN, pH 3.14 
Mobile phase B 100% ACN 
Wash 50% H2O, 50% MeOH 
Internal wash reservoir 100% H2O 
Flow rate 1 ml.min-1 
Injection volume 100 µl 
Run time 9.18 min 
Retention time of 1’-
hydroxymidazolam 
4.88 min 
Detection wavelength 235 nm 
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The gradient mobile phase run conditions are as follows: 
Time (min) Mobile phase A (%) Mobile phase B (%) 
0.0 80 20 
1.0 80 20 
1.1 60 40 
6.0 55 45 
6.1 20 80 
8.0 20 80 
8.1 80 20 
9.0 80 20 
 
Calibration curves were prepared with 10 concentrations including blank media with 
no drug and a range of 1’-hydroxymidazolam concentrations between 0.04-20 μM. A 
linear calibration curve with R2≥0.999 was required for quantification.  Precision and 
accuracy were determined using 3 sets of quality controls (QCs; including low, 0.5 
μM; medium, 3 μM and high, 10 μM) in each run, on 3 consecutive days. Accuracy 
was defined as the percentage deviation from the nominal concentration and precision 
determined by SD at each QC concentration. Average recovery of 1’-
hydroxymidazolam was determined by comparing peak area of the drug extracted 
from 3 QCs against samples directly injected with no extraction procedure taken to be 
100%. The recovery for 1’-hydroxymidazolam was calculated at >90% in all 
replicates. 
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4.2.8 CYP3A4 kdeg and t1/2 calculations and statistical analyses  
Kdeg and half-life were calculated using GraphPad Prism 6 software (GraphPad 
Software, CA). Linear regression was used and the percentage of metabolite, 
fluorescence unit or normalised protein expression, relative to untreated control at 
each time point post siRNA treatment, was transformed by taking the natural 
logarithm (Ln). Half-life values for CYP3A4, representative of kdeg, were derived from 
the slope (k) of linear regression using the following equation as described in 2.1: 
t!! =  ln(2)k  
Data was plotted with Ln percentage on the y-axis and incubation time (h) on the x-
axis and kdeg taken from the slope (k). All statistical analyses were carried out using 
GraphPad Prism 6 software. 
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4.3 Results 
4.3.1 Optimisation of PrestoBlue™ reagent for cell viability analysis 
 The PrestoBlue™ cell viability reagent detected concentration-dependent 
cytotoxicity in response to incubation with varying actinomycin D concentrations in 
HepG2 cells, as shown in Figure 4.2. and the CC50 was 0.0009 µM. This is consistent 
with the findings in Chapter 2 and therefore confirms the utility of PrestoBlue™ 
reagent for detecting live cell cytotoxicity. PrestoBlue™ reagent was subsequently 
used to determine cytotoxicity for the optimisation of siRNA experiments.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. HepG2 cytotoxicity in response to actinomycin D dose. HepG2 cells were 
incubated with varying concentrations of actinomycin D for 72 hours to confirm utility 
of PrestoBlue™ assay for determination of cytotoxicity. Fluorescence reading shown 
was taken at 10 min incubation with PrestoBlue™ reagent. Data shown as mean ±SD 
of 3 replicates from N=1 experiment. 
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4.3.2 Optimisation of mRNA knockdown time-course and siRNA dosage 
 Primary human hepatocytes were initially treated with 50 or 100 nM 
concentrations of siRNA and incubated for 24, 48 and 72 h to determine the 
achievable level of mRNA knockdown after a single siRNA dose. Figure 4.3 shows 
that over 50% CYP3A4 knockdown was achieved at 48 h with both 50 and 100 nM 
siRNA. GAPDH mRNA expression was also successfully reduced by GAPD-
targeting siRNA. CYP3A4 expression in non-targeting control (NTC) samples 
remained high as expected. No statistically significant mRNA knockdown was 
achieved in untreated, optiMEM and NTC control conditions compared with the 
corresponding vehicle control and therefore confirms the validity and specificity of 
CYP3A4 siRNA for target gene knockdown experiments. 
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Figure 4.3 Relative mRNA knockdown following siRNA treatment and 24-72 h 
incubation in primary human hepatocytes (Hu1591). CYP3A4 and NTC siRNA 
treatment corresponds with CYP3A4 mRNA and GAPDH siRNA treatment corresponds 
to GAPDH mRNA expression relative to HPRT1 housekeeping gene. Data analysed by 
comparative C(t) method and expressed as mean ±SD as percentage of vehicle control 
of each time point of 4 replicates from N=1 experiment. Unpaired t-test were performed 
between each treatment condition against the corresponding vehcle control where, 
*P<0.05, **P<0.01 and ***P<0.001.  
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As CYP3A4 mRNA was still detectable after 72 h incubation, hepatocytes were 
cultured up to 96 h with 10, 50 and 100 nM siRNA dosage to determine the time-
course of knockdown. Cell viability was determined at 72 and 96 h to ensure that 
siRNA was not causing cytotoxicity to mask any mRNA knockdown effects. As such, 
siRNA and vehicle control (RNAiMAX™ transfection reagent) treatments, as shown 
in Figure 4.4, caused no significant cytotoxicity as viability remained above 75% of 
untreated control in all treatment conditions. 
Figure 4.4 Primary human hepatocyte (Hu1591) cell viability after siRNA 
treatment and culture over 72 and 96 h. Cell viability was determined by 
PrestoBlue™ live cell assay. Fluorescence readings were taken at designated 
incubation time points after 10 min incubation with PrestoBlue™ reagent. Cell 
viability was calculated as the fluorescence measured as a percentage of the untreated 
sample at each time point from N=1 experiment. 
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Figure 4.5 Relative mRNA knockdown following siRNA treatment and 72 and 96 h 
incubation, data analysed by two methods. A. Comparative CT method. B. Pfaffl method. 
CYP3A4 and non-targeting control (NTC) siRNA treatment corresponds with CYP3A4 mRNA and 
GAPDH siRNA treatment corresponds to GAPDH mRNA expression relative to HPRT1 
housekeeping gene. Data expressed as mean  ±SD as percentage of vehicle control from 4 replicates 
from N=1 indepdendent experiment. Where, *P<0.05, **P<0.01 and ***P<0.001.  
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Figure 4.5 shows the CYP3A4 and GAPDH mRNA knockdown over the incubation 
of 72 and 96 h after a single dose of siRNA. The data was analysed by 2 different 
methods. Over 50% knockdown (compared to vehicle control) was achieved for 
CYP3A4 mRNA in CYP3A4 siRNA treated samples up to 96 h. This confirms the 
use of a single siRNA dose for prolonged knockdown. Similar levels of knockdown 
were achieved with 50 and 100 nM siRNA concentrations, which were slightly more 
than with 10 nM CYP3A4 siRNA. The data was analysed using two different 
methods as a comparison. The Pfaffl method of gene expression analysis takes into 
account the efficiency of qPCR reactions. Both comparative C(t) and Pfaffl methods 
produced a similar trend for the same data. However, Figure 4.5 shows that the range 
of SD was smaller for Pfaffl analysis. Therefore, the Pfaffl method will be used for all 
subsequent gene expression analyses. 
 In order to optimise the dosage of siRNA for knockdown experiments, mRNA 
expression was analysed at the 48 h time-point as shown in Figure 4.6 Around 70% 
reduction in CYP3A4 mRNA expression was detected after 50 and 100 nM CYP3A4 
siRNA treatment, whereas knockdown was not achieved with 10 nM siRNA. 
Interestingly, GAPDH did not show a dose-dependent level of knockdown as lower 
mRNA expression was detected at 50 nM than 100 nM of GAPDH siRNA in both 
Figures 4.5 and 4.6. This confirms the need for dose optimisation in siRNA 
experiments.  
ON-TARGETplus siRNA complexed with 1.25 µl RNAiMAX® transfection 
reagent appeared to be non-toxic for primary human hepatocytes. A 50 nM dose of 
siRNA and time-course of 48, 72 and 96 h incubation were selected for subsequent 
siRNA experiments to derive CYP3A4 kdeg.  
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Figure 4.6 Relative mRNA expressions after 48 h incubation with varying siRNA 
concentrations and treatment conditions. CYP3A4 and NTC siRNA treatment 
corresponds with CYP3A4 mRNA and GAPDH siRNA treatment corresponds to GAPDH 
mRNA expression relative to HPRT1 housekeeping gene. Data analysed by comparative 
C(t) method and expressed as mean ±SD as percentage of vehicle control from 4 technical 
replicates in N=4 independent experiments in primary human hepatocytes (Hu1591). 
Unpaired t-test was performed between each treatment condition with vehicle control 
where *P<0.05. 
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4.3.3 Development of Western blotting conditions 
Non-specific protein bands often appear on Western blots that make 
identification of target protein difficult, therefore a positive control is recommended 
(Mahmood & Yang 2012). Varying volumes of CYP3A4 and control (which is 
transfected with WT baculovirus) BACULOSOME® plus reagent were blotted for 
CYP3A4 protein expression to validate the use and concentration of this reagent for a 
positive control. Figure 4.7 shows a strong protein band detected at above 50 kDa for 
CYP3A4 BACULOSOME® samples, this band was likely to be for CYP3A4 protein 
that was expected at 57 kDa. Although a band was seen at 0.5 and 1 µl of the control 
reagent, these bands were likely due to the overspill of the adjacent CYP3A4 
BACULOSOME® sample as no strong bands were detected with neighbouring wells 
with increasing volumes of control. Clearly, a volume of 0.5 µl or less of CYP3A4 
BACULOSOME® reagent was needed for subsequent experiments as the streaky blot 
suggested that too much protein was present. The contrast between CYP3A4 protein 
detection in CYP3A4 and control reagents validate the use of CYP3A4 
BACULOSOME® plus reagent as a positive control. 
 
 
Figure 4.7 Detection of CYP3A4 protein expression in varying quantities of 
CYP3A4 and Control BACULOSOME® plus reagent.  
1 0.5 2 5 10 1 0.5 2 5 10 
CYP3A4 (µl) Control (µl) 
50 kDa 
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Cellular protein was extracted by CelLytic™ M lysis and TRIzol® reagents to 
compare their uses. Successful TRIzol® protein extraction would reduce the need for 
a separate culture well for mRNA and protein analysis, however several sources have 
reported problems of solubility of the extracted protein pellet using this method 
(Hummon et al 2007). Figure 4.8 shows that under the same siRNA treatment 
conditions and incubation times, protein was not detected beyond 72 h incubation 
with protein extracted with TRIzol®. Therefore, a separate culture well utilising 
CelLytic™ M lysis reagent was required and will be used for all subsequent protein 
extraction from primary human hepatocytes.  
 
 
 
 
 
 
Figure 4.8 Comparison of CelLytic™ M and TRIzol® protein extraction 
methods in siRNA-treated primary human hepatocytes (Hu1591). Primary 
human hepatocytes were treated with 50 nM CYP3A4 and NTC siRNA for 48-120 
h prior to protein extraction by CelLytic™ M or TRIzol® reagents. CYP3A4 
protein detection was carried out by Western blotting as detailed in 4.2.6. 
CelLytic™ M 
TRIzol® 
Bac 48 72 96 120 72 96 120 
CYP3A4 siRNA (h) NTC siRNA (h) 
50 kDa 
50 kDa 
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All protein bands were normalised to a housekeeping gene as a loading control 
for determination of relative protein expression. GAPDH and β-actin are common 
choices for Western blotting loading controls in mammalian cell types. Figure 4.9 
shows that GAPDH expression was more consistent across all treatment conditions 
and time compared to β-actin, furthermore previous publications have demonstrated 
variability of housekeeping protein expression amongst different tissue types (Kim et 
al. 2014). All CYP3A4 protein bands were therefore normalised to GAPDH 
expression to determine relative expression and protein abundance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAPDH 
β-actin 
0 48  72  96  48  72  96  48  72  96  
50nM CYP3A4 (h)  50nM NTC (h) 50nM Untreated (h) 
Figure 4.9 Comparison of GAPDH and β-actin expression in siRNA treated and 
untreated primary human hepatocytes.  Cryopreserved primary human hepatocytes 
were treated with 50 nM CYP3A4 or NTC siRNA, or left untreated and incubated for 
48-96 h. After incubation period, protein was isolated by CelLytic™ M lysis buffer and 
protein detection was carried out by Western blotting utilising both GAPDH and β-actin 
as comparison with expression quantified by ImageJ software as detailed in 4.2.6. 
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4.3.4 Optimisation of HPLC-UV conditions for 1’-hydroxymidazolam 
detection 
The standards extracted from primary hepatocyte maintenance media showed 
good linearity over the concentration range of 0.04 to 20 µM (R2≥0.999) for 1’-
hydroxymidazolam. As the MDZ parent drug was detected simultaneously with 1’-
hydrozymidazolam metabolite to determine level of CYP3A4 activity in hepatocyte 
cultures, a clear separation between the two drug peaks was required. Figure 4.10 
shows a representative chromatogram in the co-detection of MDZ and metabolite and 
the calibration curve for 1’-hydroxymidazolam.  
 
 
A 
B 
Figure 4.10 A. Representative chromatogram for the co-detection of MDZ and 1’-
hydroxymidazolam. B. Representative calibration curve of extracted standards of 1’-
hydroxymidazolam over the concentration range of 0.04 to 20 µM.  
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Precision and accuracy of the 1’-hydroxymidazolam detection assay were 
assessed and the percentages are shown in Table 4.3 for each individual run. The 
percentage error of accuracy and precision was below 15% for all 3 repeats at all 3 
QC concentrations. Interestingly, 1’hydroxymidazolam eluted before the parent MDZ 
compound, which is unexpected for reverse-phase chromatography. However, the 
chemical components of the mobile phases and their pH may alter the retention of the 
compounds. 
 
 
Table 4.3 shows the accuracy and precision of 3 repetitions of the assay. Accuracy 
and precision were assessed in triplicate at 3 levels low (0.5 µM), medium (3 µM) and 
high (10 µM) in 3 independent experiments. 
 
 
 Low QC  
(0.5 µM) 
Medium QC  
(3 µM) 
High QC  
(10 µM) 
Assay 1 
Amount detected  (µM) 0.55 2.94 10.56 
Variance of accuracy (%) 11.0 -2.02 5.59 
Variance of precision (%) 13.0 5.08 2.62 
Assay 2 
Amount detected (µM) 0.56 3.12 10.41 
Variance of accuracy (%) 12.7 4.07 4.06 
Variance of precision (%) 2.99 2.81 2.84 
Assay 3 
Amount detected (µM) 0.44 3.06 9.85 
Variance of accuracy (%) -12.44 2.07 -1.50 
Variance of precision (%) 2.47 1.69 1.47 
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4.3.5 Magnitude of CYP3A4 mRNA knockdown 
Following incubation of primary human hepatocytes with CYP3A4 SMARTpool 
siRNA (50 nM) for 0-96 h, 60 (± 9.4) %, 70 (± 6.7) % and 66 (± 6.7) % CYP3A4 
mRNA knockdown was achieved after 48, 72 and 96 hours of incubation, as shown in 
Figure 4.11. The 24 hour incubation time point was not included because previous 
optimisations, as shown in Figure 4.3, did not show significant CYP3A4 mRNA 
knockdown at this time point, therefore any subsequent detection of decrease in 
CYP3A4 protein or activity may not be due solely to degradation. Figure 4.11 ahows 
that siRNA specific for CYP3A4 elicited significant prolonged mRNA suppression 
following a single dose over the course of 96 hours.  
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Figure 4.11 Impact of siRNA on CYP3A4 mRNA expression. Primary human 
hepatocytes were dosed and incubated with 50nM CYP3A4 SMARTpool siRNA for 
15 h in reduced serum optiMEM™ I media. After siRNA incubation, media was 
replaced and cells were incubated for 48, 72 and 96 hours in 37
o
C 5% CO
2 
after initial 
dosing. CYP3A4 mRNA expression was determined by RT-PCR. The level of 
CYP3A4 expression is given as a percentage of untreated control at each time point 
and time 0 was taken after initial cell plating prior to siRNA treatment. Data represents 
mean ± SD from n=3 donors. Unpaired t-test was performed between each incubation 
time point and T0 where *P<0.05, **P<0.01 and ***P<0.001. 
 
0 48 72 96
0
20
40
60
80
100
120
Time (h)C
Y
P3
A
4 
m
R
N
A
 E
xp
re
ss
io
n 
(%
 o
f c
on
tr
ol
)
*
** **
 162 
4.3.6 Deriving CYP3A4 kdeg from protein expression after siRNA treatment 
The CYP3A4 protein degradation rate constant was derived with two 
methods: (1) from tracking differential CYP3A4 protein decline in untreated 
hepatocytes and (2) tracking protein decline after siRNA treatment. The relative 
CYP3A4 expression normalised to GAPDH was calculated (Figure 4.12) and the 
protein density at each time point compared to control (T0) was fit to a linear 
regression model and the slope is taken as rate of degradation (Figure 4.13). NTC was 
not included in the blot shown in Figure 4.12A because there were not enough wells 
on the electrophoresis gel to accommodate the NTC samples. The CYP3A4 protein 
kdeg values derived by the two methods are summarised in Table 4.4. Overall, kdeg 
derived from untreated hepatocytes resulted in a longer half-life than siRNA-treated. 
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A 
B 
Figure 4.12 Quantification of CYP3A4 protein by Western blotting. A. 
Representative Western blot of Hu1591. The CYP3A4 protein density was 
normalised to GAPDH. B. The CYP3A4 protein density ratio normalised to 
GAPDH shown for siRNA-treated hepatocytes and corresponding untreated 
control. Data represents mean ± SD of 1 replicate from N=3 donors. Unpaired t-
test was performed between the siRNA-treated and corresponding untreated 
hepatocytes at each time point. 
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Figure 4.13. Determination of the CYP3A4 degradation rate constant by 
protein analysis. CYP3A4 protein degradation over time was quantified by 
Western blot. CYP3A4 protein density was normalized to GAPDH and is 
expressed as a percentage of T0. A. CYP3A4 kdeg derived from untreated 
hepatocytes. B. CYP3A4 kdeg derived from siRNA-treated hepatocytes. The natural 
logarithm of the percent of T0 is given and the slope of the loss of enzyme protein 
expression is used to calculate the protein half-life, which is equal to the rate of 
degradation. Data represents 1 replicate from N=3 donors. 
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4.3.7 Deriving CYP3A4 kdeg from activity after siRNA treatment 
After exposure to CYP3A4 targeting siRNA for 48, 72 or 96 hours, 1’-
hydroxymidazolam metabolite formation was quantified to determine CYP3A4 
activity. Figure 4.14 shows that concentration of 1’-hydroxymidazolam detected was 
lower for CYP3A4 siRNA-treated hepatocytes compared with untreated and NTC-
treated. Interestingly, in untreated and NTC-treated conditions there appears to be an 
increase in activity between 72 and 96 h, however the rebound in activity is not as 
significant in siRNA treated condition implicating sustained mRNA suppression by 
siRNA. 
The percentage of activity at each time point compared to T0 was fit to linear 
regression models based on assumed first-order enzyme degradation kinetics as 
shown in Figure 4.15 to calculate kdeg. The CYP3A4 kdeg values were derived by 
tracking the decline of CYP3A4 activity in siRNA-treated samples and the average 
kdeg from the 3 donors were calculated to be 0.0202 (± 0.00026) h-1 and t1/2 of 34.2 (± 
0.49) h. Unlike protein samples, the kdeg was not able to be calculated from untreated 
samples as there were no decline in metabolite production observed over time (Figure 
4.15.A). 
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Figure 4.14 Determination of CYP3A4 activity by formation of probe substrate 
metabolite. Primary human hepatocytes were treated with CYP3A4 or non-targeting 
control (NTC) siRNA and incubated over 48, 72 and 96 h. Formation of 1’-
hydroxymidazolam after 60 min incubation with 3.4 µM MDZ was quanified with 
HPLC-UV. Data represents mean ± SD from n=3. Unpaired t-test was performed 
between each treatment condition with corresponding untreated control where *P<0.05. 
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Figure 4.15 Determination of the CYP3A4 degradation rate constant by activity 
analysis. CYP3A4 activity was determined by formation of 1’-hydroxymidazolam. 
CYP3A4 activity is expressed as a percentage of T0. A. CYP3A4 kdeg derived from 
untreated hepatocytes. B. CYP3A4 kdeg derived from siRNA-treated hepatocytes. 
The natural logarithm of the percent of T0 is given and the slope of the loss of 
enzyme activity is used to calculate the protein half-life, which is equal to the rate of 
degradation. Data represents 1 replicate from N=3 donors. 
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A summary of the kdeg and t1/2 values calculated from protein and activity 
methods are given in Table 4.4. Mean values were derived from one experimental 
replicate of hepatocytes from three donors.  
 
 
Table 4.4 Summary of the kdeg and t1/2 values derived from protein and activity 
methods of analysis using untreated and siRNA treated samples. 
Parameter Donor 1 Donor 2 Donor 3 
t1/2 (h)  derived from protein determined by 
Western blot in untreated samples 
76.4 61.3 35.5 
kdeg (h-1) derived from protein determined by 
Western blot in untreated samples 
0.0090 0.0113 0.0195 
Average t1/2 (h) 57.7 (± 20.7) 
Average kdeg (h-1) 0.0132 (± 0.0055) 
t1/2 (h)  derived from protein determined by 
Western blot in siRNA treated samples 
34.3 49.3 31.0 
kdeg (h-1) derived from protein determined by 
Western blot in siRNA treated samples 
0.0202 0.0141 0.0223 
Average t1/2 (h) 38.2 (± 9.8) 
Average kdeg (h-1) 0.0189 (± 0.0043) 
t1/2 (h)  derived from activity determined by probe 
substrate metabolite formation in siRNA treated 
samples 
34.8 33.9 34.0 
kdeg (h-1) derived from activity determined by probe 
substrate metabolite formation in siRNA treated 
samples 
0.0199 0.0204 0.0203 
Average t1/2 (h) 34.2 (± 0.49) 
Average kdeg (h-1) 0.0202 (± 0.00026) 
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4.4 Discussion 
Physiologically relevant kdeg values of DMEs are important for the accurate 
prediction of time-dependent DDIs in PBPK modelling. There are currently large 
disparities or missing values published for the enzymes most involved in clinically 
significant DDIs and no agreement on the best method of assessment (Yang et al. 
2008). Traditional approaches of measuring CYP enzyme degradation rates are 
limited by the de novo protein synthesis in the duration of degradation measurement. 
There is a general consensus that steady-state protein abundance is a dynamic balance 
between protein synthesis and degradation (Gottesman & Maurizi 1992), such that 
unaccounted levels of protein synthesis during the assessed time period will distort 
the degradation rate calculated in such approaches. Other common methods for 
measuring protein degradation rates utilise protein synthesis inhibitor drugs such as 
cycloheximide and actinomycin D which inhibits cellular protein synthesis 
mechanisms to stop universal protein production, followed by tracking the 
disappearance of specific target protein with pulse-chase analysis (Alvarez-Castelao 
et al. 2012; Yewdell et al. 2011; Zhou 2004). The concern with such an approach is 
that the chemical inhibitor drugs are cytotoxic and will disrupt normal cellular 
function including protein degradation pathways that will in turn distort degradation 
rates and this is demonstrated with findings in Chapters 2 and 3. Ramsden et al. 
(2015) used siRNA and IL-6 to specifically inhibit CYP3A4 protein synthesis without 
impacting on regular cellular mechanisms and a similar siRNA-silencing approach 
was used in this Chapter to specifically target CYP3A4 protein circumventing the 
concern of cytotoxicity. This study demonstrated that utilising gene-specific siRNA 
produced significant knockdown of CYP3A4 mRNA and protein with minimal 
cytotoxicity. CYP3A4 was knocked down at the functional protein level as shown in 
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Figure 4.14 where CYP activity was lower for siRNA-treated hepatocytes compared 
with untreated and NTC. 
A consensus value of hepatic CYP3A4 kdeg for use in PBPK models has been 
investigated (as summaried in Table 1.3) and subsequently evolved based upon new 
techniques and on prediction accuracy. For example, 0.0077 h-1 (corresponding to 
half-life of 90 hours) was derived from meta-analysis of all the published CYP3A 
values until 2008 (Yang et al. 2008). However, Wang et al. (2010) found better 
prediction accuracy for 54 DDIs involving CYP3A mechanism-based inhibition 
interactions using 0.03 h-1 as the kdeg value compared to 0.0077 h-1. Other subsequent 
studies also found superiority with 0.03 h-1 compared with 0.0077 h-1 (Friedman et al. 
2011; Yamashita et al. 2013). Rowland Yeo et al. (2011) reported that 0.0193 h-1 
produced decreased bias and increased precision in 29 time-dependent metabolic 
inhibition DDIs compared with 0.0077 h-1 and Mao et al. (2013) further validated this 
value and reported that a CYP3A4 half-life of between 25-35 hours (0.019 - 0.027 h-1 
kdeg) yielded the most accurate crizotinib drug interaction predictions. Subsequently, 
this value has been used in numerous published examples of DDI prediction (Peters et 
al. 2012; Ke et al. 2016; Xu et al. 2015).  
Interestingly, the CYP3A4 kdeg values of 0.019 h-1 (t1/2 of 36.4 hours) and 
0.020 h-1 (t1/2 of 34.3 hours) derived from siRNA-treated hepatocytes in loss of 
protein method and tracking activity decline, respectively, were in close agreement to 
the 25-35 hour t1/2 range reported by Mao et al. (2013) and was closer than the kdeg 
value derived by tracking protein disappearance in untreated hepatocytes (0.013 h-1; 
t1/2 of 53.3 hours) as shown in Table 4.4. This suggests that derivation of kdeg from 
siRNA-treated samples was the more robust method. Moreover, the kdeg values 
derived from both protein and activity in siRNA-treated hepatocytes were in close 
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agreement to each other. Understanding the potential of de novo protein synthesis 
distorting overall measurement of enzyme degradation during the analysis period, this 
is perhaps unsurprising. However, whether the difference between the values derived 
from protein and activity assays will impact on DDI predictions will require further 
modelling to confirm the best method.  
Extraction of RNA and proteins from a single sample is beneficial for accurate 
correlations between response in the transcriptome and proteome (Hummon et al. 
2007; Simões et al. 2013). However, the method of standard TRIzol® extraction of 
proteins was insufficient due to problems of protein resolubilisation and therefore two 
separate methods of protein isolation including a modified TRIzol® extraction 
protocol published by Simões et al. (2013) and a standard whole-cell protein 
extraction method utilising CelLytic™ M detergent solution according to 
manufacturer’s protocol, were tested. It was found that a separate sample extracted by 
CelLytic™ M lysis buffer yielded more protein which attests to the limitations of 
using Western blotting to derive rates of protein degradation. However, Takahashi et 
al. (2017) recently reported a CYP3A4 kdeg value of 0.026 h-1 derived from SILAC 
and specific protein quantifications with mass spectrometry. Therefore, deriving kdeg 
by quantification of proteins over activity is likely to be possible with sensitive 
protein quantification methods. Simple semi-quantitative protein detection by 
methods such as Western blotting may not be optimal due to insufficient sensitivity 
and variability in detection between experiments.  
It should be noted that there may be differential expression of CYP enzymes 
between cell types within an individual and this may impact upon kdeg. For example, 
the Simcyp default hepatic 3A4 kdeg is 0.0193 h-1 whilst the intestinal value is 0.030 h-
1. The faster rate of intestinal turnover of CYP3A4 is likely to be due to the turnover 
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of the enterocyte itself in which the enzyme resides, as the reported human intestinal 
epithelia complete turnover is estimated to be around 3.5 days (Darwich et al. 2012). 
Intestinal drug metabolism is known to contribute to exposure of orally administered 
drugs and several DDI prediction strategies incorporate the estimated contribution of 
gut metabolism (Almond et al. 2016; Xie et al. 2016). Other CYP enzymes detected in 
human small intestine include CYP 1A1, 1B1, 2C9, 2C19 2D6, 2E1, 2J2 and 3A5, 
with 3A4/5 accounting for 80% and 2C for around 18% abundance (Paine et al. 
2006). Since protein turnover rates can vary between tissue types as well as species 
(Waterlow 1984; Millward et al. 1981), the established method here should be 
verified in intestinal cells for the relevant CYP enzymes detected in the gut, especially 
when the expected protein turnover rate is less than that of the enterocyte. Intestinal 
kdeg values for that of CYPs 2C8 and 2C19, with estimated t1/2 of 23 and 26 h, 
respectively (Table 1.4), should be determined in the relevant cell systems for 
incorporation into time-dependent DDI prediction models. 
A potential limitation to the accuracy of the hepatic CYP3A4 kdeg derived here 
is that the study was conducted in only three hepatocyte donors. Hepatic CYP3A4 
expression is subject to genetic polymorphisms (Lamba et al. 2010) and it would 
therefore be of interest to capture inter-individual variability in kdeg through the study 
of as many donors as possible or through the use of pooled hepatocytes to generate an 
average kdeg value representative of a wider population. CYP3A4 is the most 
extensively studied in terms of kdeg and DDIs whereas values for other CYPs 
implicated in time-dependent interactions remain scarce (as shown in Table 1.4). The 
cost-effective in vitro method described in this Chapter can be applied to measure 
degradation rates for other less well-characterised CYPs. 
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CHAPTER 5 
 
Using mRNA suppression to estimate CYP2B6 
degradation rate constant in primary human 
hepatocytes 
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5.1 Introduction 
As discussed in Chapter 4, the kdeg of DMEs is a known source of error in the 
prediction of time-dependent DDIs in PBPK modelling. Previous attempts at 
quantifying this kinetic parameter have focused primarily on CYP3A4 with highly 
variable estimates and little consensus as to which methods yield the most 
physiologically-relevant values (Yang et al 2008). Methods of quantifying protein 
degradation rates traditionally involve using radiolabelled isotopes for tagging the 
protein of interest or tracking protein loss over time by immunoblotting (Yewdell et al 
2011; Alvarex-Castelao et al 2012). The caveats of these approaches, as discussed in 
Chapter 4, are that the degradation rates derived do not account for de novo protein 
synthesis during the period of investigation, which would distort the overall level of 
protein abundance and impact upon the accuracy of the measured degradation rate.  
Other in vitro approaches that address this caveat incorporate the use of 
protein synthesis inhibitor drugs to pharmacologically inhibit universal protein 
synthesis in the given test cell system (Zhou et al 2004; Belle et al 2006). However, as 
demonstrated in Chapters 2 and 3, protein synthesis inhibitor drugs instigate protein 
inhibition by acting on fundamental protein synthesis machinery that are essential for 
cell survival, consequently they generate high levels of cytotoxicity even at low 
concentrations in most cell types. Furthermore, they can also affect protein 
degradation processes (Dai et al 2013) and are therefore unsuitable for measuring 
endogenous protein degradation rates. It was demonstrated in Chapter 4 that using 
CYP3A4-specific siRNA, de novo protein production was reduced without overt 
cytotoxicity and kdeg values were derived that were in good agreement with published 
values. The kdeg values derived from siRNA-treated hepatocytes also seemed to be 
more consistent with literature compared to kdeg derived from untreated hepatocytes. 
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To date, kdeg for CYP3A4 is the most extensively studied amongst all DMEs 
due to the well established importance of CYP3A4 in xenobiotic metabolism. Kdeg 
values for other CYP and non-CYP enzymes remain scarce, yet many other CYP 
isoforms, such as CYP2B6, CYP2C8, CYP2C9 and CYP2D6, are implicated in time-
dependent DDIs (Riley & Wilson 2015). There are currently large disparities or 
missing values published for the enzymes most involved in complex DDIs.  
There is currently a growing interest in CYP2B6 as this CYP isoform is 
inducible with highly variable expression levels between individuals, accounting for 
2-10% of overall CYP abundance and an estimated 8% contribution to metabolism of 
all clinically-used drugs (Wang & Tompkins 2008; Hedrich et al 2016). As the list of 
identified CYP2B6 substrates is growing (Table 1.2), so is the enzyme’s importance 
in propagating DDIs, especially in time-dependent induction interactions due to its 
highly inducible nature (Faucette et al. 2004). Clearly, an accurate kdeg value for 
CYP2B6 will be important for the predictions of DDIs propagated by this enzyme. 
The objectives of this Chapter were two-fold. The first was to induce CYP2B6 
expression in HepG2 and Caco-2 cell lines from which optimisations of CYP2B6 
protein and activity detection could be carried out. Previously, Martin et al. (2008) 
reported CYP2B6 induction in HepG2 and Caco-2 cell lines at both the mRNA and 
protein level. We hypothesised that increasing the expression of CYP2B6 in cancer 
cell lines would provide a sufficient level of activity from which the turnover of probe 
substrate to metabolite can be detected by HPLC-UV. Thus, the induced cell lines can 
be used as a cheaper system compared with primary human hepatocytes in which the 
HPLC-UV detetction of probe substrate metabolite can be optimised. The second 
objective for this Chapter was to determine the kdeg of the CYP2B6 enzyme by 
utilising the approach validated in Chapter 4 for measuring CYP3A4 kdeg. This 
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approach involved using siRNA for suppression of mRNA followed by the tracking 
of enzyme activity and protein loss over time in primary human hepatocytes.  An 
additional method of activity detection, using CYP2B6-Glo™ assay, was employed 
for studying CYP2B6 as the enzyme expression levels were expected to be low and 
therefore the HPLC-UV instrument may have insufficient sensitivity to detect the 
production of probe substrate metabolite. 
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5.2 Materials and methods 
5.2.1. Materials 
HepG2 and Caco-2 cell lines were obtained from ATCC (Virginia, USA). Plateable 
cryopreserved primary human hepatocytes (HMCPIS Lot. Hu1591, Hu1824 and 
Hu8241), CHRM® media, William’s E media, thawing and plating supplements 
(CM3000), maintenance supplements (CM4000), 24-well collagen I coated plates and 
opti-MEM® I media were purchased from Invitrogen Ltd (Paisley, UK). TaqMan® 
reverse transcription reagents, TaqMan® gene expression assays for CYP2B6 
(Hs04183483_g1) and GAPDH (Hs02758991_g1), TaqMan® gene expression master 
mix, CYP2B6 (P3028) and control (P2315) BACULOSOMES® plus reagent, 
Lipofectamine® RNAiMAX reagent, NuPAGE® Western blot materials and 
TRIzol® reagent were purchased from ThermoFisher Scientific Inc. (Loughborough, 
UK). ON-TARGETplus human CYP2B6 SMARTpool and non-targeting pool siRNA 
were purchased from GE Healthcare Dharmacon™ (UK). Western blot antibodies: 
anti-CYP2B6 (VMA00041) and goat polyclonal anti-mouse IgG (STAR207P) were 
purchased from Bio Rad (Oxford, UK), anti-CYP2B6 (ab198870 and ab140609), anti-
GAPDH (ab181602) and goat polyclonal to rabbit IgG (ab97080) were bought from 
Abcam (Cambridge, UK). Luminata™ Forte Western HRP substrate was obtained 
from Millipore (Watford, UK). DMEM, FBS, TWEEN®20, Bradford Reagent, 
CelLytic™ M, protease inhibitor cocktail, salicylamide, rifampicin (RIF), 
phenobarbital (PB), bupropion hydrochloride, (2S,3S)-hydroxybupropion, RNase-free 
water and other Western blot buffer ingredients were purchased from Sigma-Aldrich 
(Dorset, UK). P450-Glo™ CYP2B6 assay was from Promega (Southampton, UK). 
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5.2.2 CYP induction in tumour cell lines 
5.2.2.1 Caco-2 and HepG2 cell line culture  
HepG2 and Caco-2 cells were cultured as detailed in section 2.2.2. HepG2 cells were 
maintained in DMEM medium supplemented with 10% FBS solution and Caco-2 
cells were cultured in DMEM supplemented with 15% FBS. Cell lines were passaged 
or plated at 80% confluence and discarded beyond passage 20.  
5.2.2.2 Induction of CYP3A4 and CYP2B6 in HepG2 and Caco-2 cell lines 
HepG2 and Caco-2 cells were seeded at 3 x 105 cells per well in 24-well plates in 
DMEM medium supplemented with 10% or 15% FBS solution, respectively, and 
incubated overnight in a 37oC 5% CO2 humidified incubator overnight to allow cells 
to adhere to the plate bottom. The following day, cells were dosed with 2, 10 and 20 
μM RIF and 100, 500 and 1000 μM PB and incubated for 24, 48 and 72 hours to 
determine the time and level of maximum induction. A vehicle control containing 1% 
methanol, an untreated control and controls consisting of RNA extracted from a 
primary human hepatocyte sample at 0 and 24 h (positive control) after plating 
(described in 4.2.3) were also included. The control and drug-containing media were 
removed and replaced every 24 h. 
5.2.2.3. Magnitude of mRNA induction quantified by RT-PCR 
After 24, 48 and 72 h incubation, total RNA was isolated, using TRIzol® reagent, and 
quantified as described in section 4.2.5.1. cDNA was synthesised from the isolated 
RNA with Taqman® reverse transcription kit as detailed in 4.2.5.2. The magnitude of 
mRNA induction at each incubation time-point was determined by quantifying 
CYP3A4 and CYP2B6 mRNA expression relative to the housekeeping gene GAPDH 
by qPCR.  The protocols for CYP3A4 and CYP2B6 quantification are as detailed in 
4.2.5 and 5.2.5, respectively. Data was normalised to the primary hepatocyte control 
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sample collected at time 0 (T0) and relative expression was derived using the Pfaffl 
method (Pfaffl 2001) as explained in 4.2.5.4. 
5.2.2.4. Magnitude of induced CYP2B6 activity determined by P450-Glo™ 
assay and UV-HPLC analysis in Caco-2 cell line 
Caco-2 cells were induced as described in 5.2.2.2 with 10 µM RIF; the level of 
induced activity was determined by two methods: the CYP2B6 P450-Glo™ assay and 
via bupropion probe substrate metabolite formation by UV-HPLC. In the first 
aforementioned method, the CYP2B6 P450-Glo™ assay was conducted as described 
in 5.2.7. For probe substrate metabolite detection, the protocol was as follows: 2 hours 
prior to the designated incubation time-point, Caco-2 cells were dosed with 500 µM 
of bupropion and incubated for 2 h at 37oC, 5% CO2 in a humidified incubator. The 
bupropion probe concentration used was described previously (Levy et al. 2015; 
Zhang et al. 2016). Cell culture media containing probe and metabolite were removed 
and immediately stored at -80oC to stop any further reaction until analysis. (2S,3S)-
hydroxybupropion metabolite was extracted from the culture media as described in 
5.2.8.2 and quantified as detailed in 5.2.8.3. 
5.2.3 Cryopreserved primary human hepatocyte culture 
Cryopreserved primary human hepatocytes were thawed and plated as described in 
section 4.2.2. The donor demographics are given in Table 5.1; three hepatocyte 
donors were used and CYP2B6 kdeg were derived from 1 experiment from the three 
donors. Hepatocytes were seeded on 24-well collagen-I coated plates at a density of 3 
x 105 viable cells per well for CYP2B6 metabolism activity and protein expression 
analyses. Hepatocytes were seeded at 1 x 105 viable cells/well for mRNA and P450-
Glo™ CYP2B6 analyses. The media volume used was 500 μl per well. Cells were 
incubated with plating media for 5 hours at 37°C with 5% CO2 and 95% humidity to 
 182 
allow cell adherence prior to siRNA transfection. After 5 hours of incubation, the 
plating media was replaced with maintenance media for untreated control or dosed 
with varying siRNA conditions in optiMEM media. Following siRNA transfection, 
maintenance media was replaced every 24 hours for the duration of the experiment. 
 
Table 5.1 Donor demographics of the cryopreserved primary human hepatocytes  
 
 
5.2.4 Small-interfering RNA treatment 
Experiments using siRNA to suppress CYP2B6 expression were conducted following 
a modified knockdown protocol published by Vozza-brown et al. (2005). CYP2B6 
siRNA was prepared and stored at 10 µM stock concentration in 1X siRNA buffer (as 
described in 4.2.3) at -20°C until use.  
After 5 hours incubation with hepatocyte plating media, cells were washed 
with HBSS and then treated with Dharmacon ON-TARGETplus human CYP2B6 
SMARTpool siRNA. Negative control of ON-TARGETplus non-targeting pool and 
untreated and vehicle controls were also included. The sequences for the siRNA are 
given in Table 5.2. 1.25 μl of transfection reagent Lipofectamine RNAiMAX™ was 
complexed with siRNA in reduced serum opti-MEM® I media for 30 minutes prior to 
Demographics Donor 1 Donor 2 Donor 3 
Donor ID Hu1591 Hu1824 Hu8241 
Age 29 66 60 
Gender Male Female Male 
Ethnicity Caucasian Caucasian Caucasian 
Characteristics Rare alcohol user. 
No tobacco or drug 
use reported 
Tobacco use. No 
alcohol or drug use 
Tobacco and 
alcohol user. No 
drug use 
Cause of death Not reported Not reported Cardiac related 
Cell viability 91% 93% 94% 
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addition to the cells. Hepatocytes were exposed to the siRNA overnight for 15 hours 
before the cells were washed and replaced with standard hepatocyte maintenance 
media. Cells were subsequently incubated at 37°C with 5% CO2 and 95% humidity 
after CYP2B6 siRNA treatment. CYP2B6 metabolic activity, mRNA and protein 
expression were assessed at specific time points. Time 0 hours was taken at 5 hours 
incubation with plating media, prior to siRNA transfection and maintenance media 
replacement. 
 
Table 5.2 siRNA sequences.  
siRNA Sequence 
  
ON-TARGETplus human 
CYP2B6 SMARTpool 
5’-GGGGAUAUGGUGUGAUCUU -3’ 
5’-GGGAGAUUGAACAGGUGAU -3’ 
5’-UGCAGGAAAUCAAUGCUUA -3’ 
5’-AAACAUCUCUAAAGCCUGA -3’ 
 
 
ON-TARGETplus Non-targeting 
pool 
 
5’-UGGUUUACAUGUCGACUAA-3’ 
5’-UGGUUUACAUGUUGUGUGA-3’ 
5’-UGGUUUACAUGUUUUCUGA-3’ 
5’-UGGUUUACAUGUUUUCCUA-3’ 
 
 
 
5.2.5 CYP2B6 mRNA knockdown quantification 
Total RNA was isolated with TRIzol® reagent using the protocol described in 
4.2.5.1 and cDNA was synthesised from the isolated RNA as described in 4.2.5.2 with 
Taqman® reverse transcription kit.  
The magnitude of siRNA knockdown at each incubation time-point was 
determined by quantifying CYP2B6 mRNA expression relative to housekeeping gene 
GAPDH by qPCR.  The protocol is as follows: a 25 µl reaction mix consisting of 1.25 
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µl of 20X Taqman® custom gene CYP2B6 (assay ID, Hs04183483_g1) or GAPDH 
(Hs02758991_g1) assay, 40 ng cDNA in 8 µl, 3.25 µl RNase free water and 12.5 µl of 
2X Taqman® Master Mix were dispensed into a 96-well plate. All samples were 
completed in triplicate. Negative controls with RNase-free water added in place of 
cDNA were also included. The plates were then covered with Microseal® adhesive 
PCR plate sealing film and centrifuged briefly up to 2000 rpm to mix the reaction 
contents to eliminate air bubbles from the solution mix. PCR conditions were run at 
95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.  
Determination of the relative CYP2B6 mRNA expression against GAPDH was 
performed in an Opticon2™ Fluorescence Detector (MJ Research, UK). The cycle 
threshold [C(t)] was set to ignore any aberrant fluorescence to ensure that only gene 
amplification was measured. Data was normalised to the primary hepatocyte vehicle 
control or untreated control sample collected at time 0 (T0) and relative expression 
was derived using the Pfaffl method (Pfaffl 2001) as described in 4.2.5.4. 
 
5.2.6 CYP2B6 protein quantification 
5.2.6.1 Protein extraction and quantification 
Cellular protein was extracted using CelLytic™ M lysis buffer with extraction 
protocol as described in 4.2.6.1(ii). Quantification of the extracted protein was 
determined by Bradford assay as explained in 4.2.6.2.  
5.2.6.2. Protein detection by Western blotting 
20 µg of total protein, as determined by Bradford assay, and CYP2B6 
BACULOSOMES® plus reagent (positive control) was added to 5 µl of 4X 
NuPAGE® LDS sample buffer, 2 µl of NuPAGE® reducing agent and made up to 21 
µl volume using deoinised water. Samples were heated at 100°C for 5 min. 20 µl of 
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sample and 3 µl of Kaleidoscope™ prestained protein standard (Bio-Rad, UK) were 
loaded onto a NuPAGE® 4-12% Bis-Tris Gel with 200 µl NuPAGE® antioxidant and 
electrophoresed for 1 hour 30 min at 150 V. Following electrophoresis, the proteins 
were blotted onto a nitrocellulose membrane using a Criterion™ blotter method (Bio-
Rad, UK) run at 30 V for 60 min.  
After protein transfer, the membrane was blocked in 5% BSA in 0.01% 
Tween-tris buffered saline (T-TBS) for 2 hours RT, washed with 0.01% T-TBS 
solution 3 times for 5 min, followed by incubation with primary antibody anti-
cytochrome P450 2B6 (ab198870 at 1/500, ab140609 at 1/1000 or VMA00171 at 
1/1000 dilution) in 2% BSA in 0.01% T-TBS overnight at 4°C. The following day, 
the membrane was washed 3 times with 0.01% T-TBS for 5 min then incubated with 
secondary antibody (goat polyclonal to rabbit IgG [ab97080] at 1/2000 corresponding 
to ab198870 and ab140609 or goat polyclonal secondary antibody to mouse IgG, 
[STAR207P] at 1/5000 corresponding to VMA00171) in 2% BSA in 0.01% T-TBS 
for 2 hours at 4°C. For detection of loading control GAPDH, the membrane was 
blocked with 10% BSA in 0.01% T-TBS overnight at 4°C. The following day, 
membranes were washed 3 times with 0.01% T-TBS for 5 min before incubation with 
primary antibody (anti-GAPDH antibody, ab181602) at 1/10,000 in 2% BSA in 
0.01% T-TBS for 2 hours at 4°C. After primary antibody incubation, membrane was 
washed 3 times with 0.01% T-TBS for 5 min prior to incubation with secondary 
antibody (goat polyclonal to rabbit IgG, ab97080) at 1/10,000 in 2% BSA in 0.01% T-
TBS for 1 hour RT. Following incubation with secondary antibodies, membranes 
were washed 3 times in 0.01% T-TBS for 5 min followed by 2 times for 20 min. 
Between the detection of each protein, the membrane was stripped and re-
probed. After enhanced chemiluminescence (ECL) detection of CYP2B6 protein, 
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membranes were washed for 5 min in 0.01% T-TBS, then 2 times 20 min with acidic 
glycine stripping buffer, followed by 2 times 10 min 1X Tris-buffer saline (TBS) 
solution and 2 times 10 min 0.01% T-TBS. The membranes were then blocked and 
probed for the GAPDH control protein, as indicated above. 
Protein bands were visualised by ECL detection. Following the final wash, the 
membrane was blotted dry and incubated with 3 ml Luminata™ Forte Western 
Horseradish Peroxidase (HRP) substrate solution for 5 min. Excess substrate was 
drained and membrane placed under plastic wrap. Detection was carried out in the 
dark room where an X-ray film was placed on the blot and the film was exposed 
between 10-600 s for CYP2B6 and GAPDH protein band detection. The X-ray film 
was then placed in a developing solution for approximately 30 s for the image to 
appear before immersing in fixing solution for 30 s followed by water for 30 s. 
Quantification of protein bands were achieved using GS-800™ calibrated 
densitometer (Bio-Rad, Hercules, CA) and ImageJ software (NIH). Relative protein 
quantification was determined by normalising CYP3A4 band against GAPDH loading 
control band density. 
 
5.2.7 CYP2B6 activity assessment by P450™ Glo assay 
CYP2B6 are reported to be lowly expressed at around 2-10% of total hepatic CYP 
abundance (Wang & Tompkins 2008), thus in anticipation of insufficient probe 
metabolite formation detectable by UV-HPLC, CYP2B6-Glo™ assay was employed 
to act as comparison to probe substrate activity assays. 3 M salicylamide stock was 
prepared in DMSO, as and stored at -20oC until use. Salicylamide was added to 
inhibit phase II conjugation of the CYP2B6-metabolised product. 
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Primary human hepatocytes were seeded at 1 x 105 cells per well in 24-well 
collagen-coated plates and treated with siRNA. At 0, 12, 24, 36, 48 and 60 hours post 
siRNA dosing, CYP2B6 activity was determined using the P450™ Glo assay 
(Promega, UK). At these incubation time points, the culture medium was removed 
and cells were washed twice with 500 µl HBSS, then 3 µM of luciferin-2B6 (1 in 
1000 dilution) containing 3 mM salicylamide dissolved in HBSS was added to each 
well and incubated for 90 min at 37°C with 5% CO2 and 95% humidity, according to 
manufacturer’s instructions. Untreated, vehicle-treated and no cell controls were 
included. Luciferin detection reagent was equilibrated to RT and made up to 1:1 of 
reconstitution buffer and detection reagent supplied by the kit. 150 µl of the incubated 
media containing luciferin-2B6 and salicylamide was transferred to a new opaque 24-
well plate and 150 µl of the luciferin detection reagent was added to the media. The 
plate was then left to incubate for 20 min at RT in the dark prior to reading 
luminescence on a CLARIOstar® microplate reader (BMG LABTECH, Aylesbury, 
UK). The background luminescence (no cell control) value was subtracted from all 
treated and untreated conditions containing primary human hepatocytes. 
 
5.2.8 Assessment of CYP2B6 activity by probe substrate turnover 
5.2.8.1 Buproprion probe substrate dosing 
Bupropion hydrochloride and (2S,3S)-hydroxybupropion were dissolved in HPLC 
grade 100% methanol to form a stock solution at 100 mM that was stored at -20°C 
until use. The probe substrate for CYP2B6 activity was 500 μM bupropion prepared 
in hepatocyte maintenance media in <0.5% methanol. The bupropion probe 
concentration used was described previously (Levy et al. 2015; Zhang et al. 2016). In 
the final 2 hours of incubation in control and siRNA-treated samples, cells were 
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spiked with bupropion to a final concentration of 500 μM and incubated for 2 h at 
37°C with 5% CO2 and 95% humidity. CYP2B6 activity was measured as (2S,3S)-
hydroxybupropion metabolite formation following incubation with bupropion at 0, 12, 
24, 48 and 60 hours after siRNA transfection. After 2 h incubation with bupropion, 
the media was removed and immediately stored at -80°C until analysis, to terminate 
further metabolism.  
5.2.8.2 Metabolite extraction from media matrix 
Two approaches for hydroxybupropion extraction from hepatocyte culture media was 
carried out to determine a suitable method for maximum recovery; the first involved 
using a range of organic solvents and the second included a protocol modified from 
Loboz et al. (2005).  
In the first approach, 1 ml of organic solvent including methanol, ACN, ethyl 
acetate, acetone or heptane were added 5:1 v/v to 200 μl of metabolite-containing 
media sample. The samples were then mixed on a turntable for 30 min at RT followed 
by centrifugation at 13,000 x g for 30 min at 4°C. The metabolite-containing 
supernatant fraction was removed and transferred to a 5 ml round-bottom glass tube. 
The supernatant fraction was dried overnight with no heat in a Savant SpeedVac 
rotary evaporator (Thermo Scientific, UK). The resulting dried compounds were 
reconstituted in 150 μL mobile phase A with 20% acetonitrile v/v.  
The second approach involved adding 100 μl of 0.5 M carbonate buffer (pH 
10.8) with 1.5% isoamyl alcohol and 1 ml heptane to 400 μl of media sample. The 
samples were vortexed for 20 s, mixed on a turntable for 20 min and followed by 
centrifugation at 1,500 x g for 15 min. The organic supernatant layer was transferred 
to a new 1.5 ml Eppendorf tube containing 100 μl of 0.1 M HCl. The samples were 
then vortexed for 20 s, mixed on a turntable for 20 min and centrifuged at 1,500 x g, 
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as before. The organic supernatant layer was then discarded and the drug-containing 
aqueous layer was transferred to a 5 ml round-bottom glass tube and dried in a Savant 
SpeedVac rotary evaporator (Thermo Scientific, UK) overnight with no heat. The 
dried compounds were reconstituted in 150 μL mobile phase A (with 20% ACN v/v) 
and 100 μL was injected into a Dionex HPLC system (Thermo, UK).  
5.2.8.3 Metabolite quantification by UV-HPLC 
Bupropion and (2S,3S)-hydroxybupropion were chromatographically separated and 
quantified by HPLC-UV. 100 μL of reconstituted sample was injected into a Dionex 
HPLC system (Thermo, UK). Two mobile phases were used for the chromatographic 
run and the run was conducted using a using a multi-step gradient with a reverse-
phase Fortis® column (3 μM, C18, 100 x 4.6 mm; Fortis® Technologies Ltd., 
Neston, UK). The conditions were as follows: 
 
Mobile phase A 80% 10 mM KH2PO4 in ddH2O, 20% 
ACN, pH 5.5 
Mobile phase B 100% ACN 
Wash 50% H2O, 50% MeOH 
Internal wash reservoir 100% H2O 
Flow rate 1 ml.min-1 
Injection volume 100 µl 
Run time 8.1 min 
Retention time of (2S,3S)-
hydroxybupropion 
4.22 min 
Detection wavelength 214 nm 
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The gradient mobile phase run conditions are as follows: 
Time (min) Mobile phase A (%) Mobile phase B (%) 
0.0 80 20 
0.5 80 20 
5.0 40 60 
5.0 20 80 
7.0 20 80 
7.1 80 20 
8.1 80 20 
 
Calibration curves were prepared with 10 concentrations including blank 
media with no drug and a range of (2S,3S)-hydroxybupropion concentrations between 
0.02-20 μM. A linear calibration curve with R2≥0.999 was required for the assay run 
to be deemed acceptable.  Precision and accuracy were determined using 3 sets of 
quality controls (QCs; including low, 0.1 μM; medium, 0.5 μM and high, 3 μM) in 
each run, on 3 consecutive days. The average recovery of (2S,3S)-hydroxybupropion 
was determined by comparing peak area of the drug extracted from 3 QCs against 
samples directly injected with no extraction procedure taken to be 100%. The 
recovery for (2S,3S)-hydroxybupropion was calculated at >90% in all replicates for 
the extraction method using carbonate buffer and isoamyl alcohol (method 2). 
 
5.2.9 CYP2B6 kdeg and t1/2 calculations and statistical analyses 
CYP2B6 kdeg and t1/2 were calculated as detailed in 4.2.8. Statistical analyses were 
carried out using GraphPad Prism software. 
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5.3 Results 
5.3.1 Inducibility of CYP2B6 mRNA in HepG2 and Caco-2 cell lines 
CYP3A4 and CYP2B6 mRNA were not detected in HepG2 cells after 24, 48 
and 72 h incubation with RIF and PB despite detection of GAPDH across all 
conditions. CYP3A4 and CYP2B6 mRNA was detected across all time points in 
untreated samples of primary human hepatocytes. 
CYP3A4 mRNA was not detected in Caco-2 cells after incubation with RIF 
and PB over 72 h. Low levels of CYP2B6 mRNA expression was observed in Caco-2 
after 48 h incubation with RIF and PB at all concentrations as shown in Figure 5.1. 
Interestingly after 72 h of culture, CYP2B6 was detected at low levels in untreated 
and 1% MeOH treated Caco-2 cells.  
Figure 5.1 Relative induction of CYP2B6 mRNA in Caco-2 cell line after treatment with RIF 
and PB over 72 h. Data analysed by Pfaffl method and expressed as the mean fold expression 
relative to primary human hepatocyte (PHH) obtained at time 0. Positive control is untreated PHH 
collected at each incubation time-point. N=1 independent experiment with 3 technical replicates.  
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5.3.2 Optimisation of HPLC-UV conditions for (2S,3S)-hydroxybupropion detection 
Two extraction methods were employed to determine the maximum recovery 
of (2S,3S)-hydroxybupropion metabolite from Willam’s E primary human hepatocyte 
maintenance culture medium. A higher percentage of recovery was achieved with 
Method 2 (protocol adapted from Loboz et al 2005) compared with Method 1 even at 
lower concentrations, as shown in Table 5.3. Therefore, Method 2 was employed for 
all subsequent (2S,3S)-hydroxybupropion metabolite extraction for HPLC-UV 
detection for CYP2B6 activity analysis. Method 2 consistently gave over 100% 
recovery at all three concentrations, which suggests possible differences in compound 
stability between control standards and etracted samples. However the maximum 
variance from the 100% recovery value was observed at the low QC at 114.8%, which 
was within the acceptable limits of 15% variation to account for human error. 
 
Table 5.3. (2S,3S)-hydroxybupropion extraction efficiency from William’s E medium 
using two methods of extraction.  
Recovery (%) 
 
 
 
Method 1 
(N=1) 
Organic 
Solvent 
Low (0.5 µM) Medium (3 µM) High (10 µM) 
Acetone N/A 114.0 79.5 
Heptane 36.7 44.3 33.8 
Ethyl acetate 73.9 58.5 46.2 
Methanol N/A 108.1 97.7 
Acetonitrile N/A 119.8 96.0 
Recovery (%) 
 
 
Method 2 (N=3) 
 
Low (0.1 µM) Medium (0.5 µM) High (3 µM) 
 
114.8 (±12.7) 
 
108.8 (±1.6) 
 
104.9 (±3.1) 
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The standards extracted from primary hepatocyte maintenance media using 
Method 2 showed good linearity over the concentration range of 0.02 to 20 µM 
(R2≥0.999) for (2S,3S)-hydroxybupropion. As the bupropion parent drug was detected 
simultaneously with (2S,3S)-hydroxybupropion metabolite to determine level of 
CYP2B6 activity in hepatocyte cultures, a clear separation between the two drug 
peaks was required. Figure 5.3 shows a representative chromatogram in the co-
detection of buproprion and metabolite and a representative calibration curve for 
(2S,3S)-hydroxybupropion. 
 
 
 
Figure 5.3 A. Representative chromatogram for the co-detection of bupropion and 
(2S,3S)-hydroxybupropion. B. Representative calibration curve of extracted standards 
of (2S,3S)-hydroxybupropion over the concentration range of 0.02 to 20 µM.  
A 
B 
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Precision and accuracy of the (2S,3S)-hydroxybupropion detection assay were 
assessed and the percentage deviation are shown in Table 5.4 for each individual run. 
The percentage error of accuracy and precision was below 15% for all 3 repeats at all 
3 QC concentrations. 
 
 
Table 5.4 shows the accuracy and precision of 3 repetitions of the assay. Accuracy 
and precision were assessed in triplicate at 3 levels at low (0.1 µM), medium (0.5 µM) 
and high (3 µM). 
 
 
 
 
 
 
Low QC 
(0.1 µM) 
Medium QC 
(0.5 µM) 
High QC 
(3 µM) 
Assay 1 
Amount detected  (µM) 0.09 0.51 3.01 
Variance of accuracy (%) -13.00 2.12 0.50 
Variance of precision (%) 13.51 7.41 6.18 
Assay 2 
Amount detected (µM) 0.11 0.52 3.18 
Variance of accuracy (%) 10.27 4.89 5.91 
Variance of precision (%) 2.68 1.34 1.73 
Assay 3 
Amount detected (µM) 0.11 0.51 3.01 
Variance of accuracy (%) 8.50 2.05 0.48 
Variance of precision (%) 8.75 1.37 4.53 
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5.3.3 Inducibility of CYP2B6 activity in Caco-2 cell lines  
CYP2B6 probe substrate metabolite was not detectable in Caco-2 cells with 
HPLC-UV after induction with 10 µM RIF for 72 h (data not shown), despite this 
treatment condition generating the highest level of CYP2B6 mRNA expression 
detected, as shown in Figure 5.1. The Caco-2 cell line was therefore inappropriate for 
use in optimising CYP2B6 activity detection by HPLC-UV for subsequent siRNA 
investigations.  However, minor CYP2B6 enzyme activity was detected in Caco-2 
cells by the P450-Glo™ assay in untreated and induction with 10 µM RIF treatment 
conditions as shown in Figure 5.4.  
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Effect of RIF on CYP2B6 enzyme activity in Caco-2 cell line 
determined by P450-Glo™ assay. Caco-2 cells were seeded at 3 x 105 per well 
and incubated with 10 µM RIF for 72 h. CYP2B6 P450-Glo™ assay was 
conducted to determine CYP2B6 activity. Data shows mean ± SD of three 
replicates from one independent experiment corrected for background 
luminescence, where *P<0.05 compared with untreated cells. 
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5.3.4 Optimisation of mRNA knockdown time-course and siRNA dosage 
Primary human hepatocytes were treated with varying concentrations of 
CYP2B6 siRNA for 15 h and then incubated over 120 h to determine the achievable 
level of mRNA knockdown and the optimum time-course for prolonged knockdown 
after a single dose of siRNA. CYP2B6 mRNA expression declined over time without 
any siRNA treatment, as shown in Figure 5.5. This decline in untreated primary 
human hepatocytes was utilized to calculate kdeg in subsequent experiments. 
 
 
 
 
 
 
 
 
Figure 5.5 Relative CYP2B6 mRNA expression in untreated samples incubated 
over 72 h. Cryopreserved primary human hepatocytes (Hu1824) were seeded at 1 x 
105 per well and incubated over 72 h with culture medium replaced every 24 h. 
Relative CYP2B6 mRNA expression was calculated by Pfaffl method and expressed 
as percentage expression of hepatocytes at time 0 with mean  ± SD across 3 
technical replicates with N=1 independent experiment. Unpaired t-test was 
performed between each incubation time point and T0 where *P<0.05, **P<0.01 
and ***P<0.001. 
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Figure 5.6 shows that in optimisation experiments a statistically significant 
level of mRNA knockdown was achieved with CYP2B6-targeting siRNA. Over 50% 
CYP2B6 mRNA knockdown was detected in hepatocytes between 48-72 h incubation 
at all siRNA concentrations, with the exception of 50 nM CYP2B6 siRNA at 72 h. 
CYP2B6 mRNA expression resumed to over 90% of corresponding untreated controls 
at 120 h, suggesting that at 10 and 50 nM, siRNA was no longer silencing mRNA 
expression after 120 h from initial dosing (data not shown). CYP2B6 mRNA 
expression in non-targeting control (NTC) samples remained high across all time 
points and siRNA concentrations; the expected high expression for control conditions 
confirm the validity of using siRNA for specific gene knockdown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 198 
 
 
 
 
Figure 5.6 Relative CYP2B6 mRNA expression after treatment with a single siRNA 
dose followed by incubation over 72 h. Data was analysed by Pfaffl method and 
CYP2B6 expression was normalised to GAPDH. NTC refers to the non-targeting 
siRNA negative control. CYP2B6 mRNA is expressed as the relative expression of 
untreated hepatocytes at each incubation time point. Data displayed as mean ±SD from 3 
technical replicates from 1 independent experiment from donor Hu1824. Unpaired t-test 
was performed between each treatment condition and corresponding untreated control, 
at each time point, where *P<0.05, **P<0.01 and ***P<0.001. 
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In order to optimise the siRNA concentration needed to achieve maximum 
mRNA knockdown, primary human hepatocytes were dosed with 10, 50 or 100 nM of 
CYP2B6 SMARTpool siRNA for 15 h before it was removed and cells were 
incubated over 120 h. Figure 5.7 shows that 100 nM of siRNA consistently achieved 
over 65% mRNA knockdown across all time-points from 24-72 h incubation. At 120 
h, CYP2B6 mRNA showed rebound and recovered to that of untreated control levels 
across all siRNA concentrations. Therefore, 100 nM CYP2B6 siRNA over the course 
of 60 h was selected as the optimum treatment conditions to derive CYP2B6 kdeg in 
subsequent protein and activity experiments.  
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Figure 5.7 Relative CYP2B6 mRNA expression after dosing with different siRNA 
concentrations and incubation over 72 h. Primary human hepatocytes (Hu1824) were 
seeded at 1 x 105 cells per well and dosed with 10, 50 or 100 nM CYP2B6 SMARTpool 
siRNA for 15 h. siRNA was then removed and hepatocytes were incubated with culture 
medium over 120 h. Data expressed as relative CYP2B6 expression to GAPDH control, 
calculated by Pfaffl method. Expression is shown as % of untreated at each time point 
with mean ± SD from 3 technical replicates of 1 independent experiment. Unpaired t-test 
was performed between each treatment condition and corresponding untreated control, at 
each time point, where *P<0.05, **P<0.01 and ***P<0.001. 
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5.3.5 Optimisation of Western blotting for CYP2B6 protein detection 
As discussed in Chapter 4, a positive control is required to identify the protein 
band of interest from other bands detected by non-specific binding in Western 
blotting. CYP2B6 BACULOSOME® plus reagent was included and blotted at 25 and 
250 nl to identify the optimum concentration to use as the positive control. Figure 5.8 
shows a strong protein band at around 50 kDa for CYP2B6 BACULOSOME® and 
this was likely to be for CYP2B6 protein expected at 56 kDa, however CYP2B6 
protein was not clearly detected in primary human hepatocytes as there were no 
corresponding bands shown for untreated primary human hepatocytes even at time 0 
where high levels of CYP2B6 would be expected. It is evident from Figure 5.8 that 25 
nl of CYP2B6 BACULOSOME® reagent was the more appropriate volume to use for 
positive control in subsequent blots.  
 
 
 
 
 
 
 
 
 
Figure 5.8 CYP2B6 protein expression in varying volumes of CYP2B6 
BACULOSOME® plus reagent and in untreated primary human hepatocytes 
(Hu1824) incubated over 96 h. Untreated control primary human hepatocytes were 
incubated over 96 h time course before total protein was extracted using CelLytic™ M 
and quantified by Bradford assay. Protein was detected after incubation with primary 
anti-CYP2B6 antibody (ab198870) at 1/500 and secondary antibody (ab97080) at 
1/2000 dilution. 
Baculosome (nl) Time (h) 
250 25 0 48 72 96 
50 kDa 
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Three different primary CYP2B6 antibodies (ab198870, ab140609 and 
VMA00171) were used for optimisation to blot for CYP2B6 protein. Figure 5.9 
shows that no corresponding CYP2B6 protein band to the baculosome control was 
detected with ab198870. With the same protein sample, VMA000171 was able to 
detect a corresponding protein band to baculosome that displayed a reduction in 
abundance across time-points as expected, whereas ab140609 did not detect this. Low 
expression at time 0 was detected with ab140609 where the highest CYP2B6 
expression was expected. VMA00171 was therefore used as the primary anti-
CYP2B6 antibody for all subsequent Western blotting for CYP2B6 protein. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Representative Western blots showing CYP2B6 protein expression in 
primary human hepatocytes detected by different primary monoclonal antibodies. 
250 nl baculosome (Bac) included as positive control. A. CYP2B6 protein detected by 
ab198870 antibody in hepatocytes following treatment with various siRNA and control 
conditions over 36 and 48 h. VC; vehicle control. B. CYP2B6 protein expression detected 
by ab140609 or C. VMA000171 antibody in hepatocytes following 100 nM CYP2B6 
siRNA treatment or no treatment and incubated over 0-60 h.  
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5.3.6 Magnitude of CYP2B6 knockdown 
Following incubation of primary human hepatocytes with 100 nM of CYP2B6 
SMARTpool siRNA for 0-60 h, 19 (± 20.5) %, 74 (± 13) % and 97 (± 4.7) % mRNA 
knockdown was achieved at 12, 24 and 60 hours, respectively. Figure 5.10 shows that 
at 36 and 48 hours of incubation, CYP2B6 mRNA was undetectable. Incubating 
primary human hepatocytes for 15 h with 100 nM CYP2B6 SMARTpool siRNA 
showed prolonged mRNA suppression following a single dose over the course of 60 
h. Figure 5.10 shows that at 60 h, CYP2B6 mRNA recovery was observed. 
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Figure 5.10 Impact of siRNA on CYP2B6 mRNA expression. Primary human 
hepatocytes were dosed and incubated with 100nM CYP2B6 SMARTpool siRNA 
for 15 h in reduced serum optiMEM™ I media. After siRNA incubation, media was 
replaced and cells were incubated for 12, 24, 36, 48 and 60 h in 37
o
C 5% CO
2
. 
CYP2B6 mRNA expression was determined by RT-PCR. The level of CYP2B6 
expression is given as a percentage of untreated control at each time point and time 0 
was taken after initial cell plating. Data represents mean ± SD from n=3 independent 
experiments. Unpaired t-test was performed between each incubation time point and 
T0 where *P<0.05, **P<0.01 and ***P<0.001. 
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5.3.7 Deriving CYP2B6 kdeg from protein expression after siRNA treatment 
The CYP2B6 protein degradation rate constant was derived with two methods, 
as described in 4.3.6; from tracking protein loss in untreated hepatocytes and in 
siRNA-treated hepatocytes over time. The relative CYP2B6 expression normalised to 
GAPDH was calculated (Figure 5.11) and the protein density at each time point 
compared to control (T0) was fit to a linear regression model as shown in Figure 5.12. 
The slope was taken as the rate of degradation, which is inversely proportional to  t1/2. 
NTC was not included in the blot shown in Figure 5.11A because there were not 
enough wells on the electrophoresis gel to accommodate all the NTC samples. 
Multiple protein bands were observed for CYP2B6 and possible explanations for this 
include degradation of the protein samples during handling or non-specificity of the 
primary detection antibody. Care was taken to reduce artefacts caused by protein 
degradation, including the use of protease inhibitors, keeping protein samples on ice 
during handling and minimising freeze-thaw cycles.  
The CYP2B6 protein kdeg values derived by the two methods are summarised 
in Table 5.5. The average kdeg from the 3 donors derived from untreated samples was 
calculated to be 0.048 (± 0.031) h-1 and t1/2 of 26.0 (± 26.7) h. The average kdeg 
derived from siRNA treated samples was 0.081 (± 0.009) h-1 and t1/2 of 8.63 (± 0.948) 
h. Overall, kdeg derived from untreated hepatocytes resulted in a longer average half-
life compared with siRNA-treated.  
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Figure 5.11 Determination of CYP2B6 degradation rate constant by protein 
analysis. A. Representative Western blot of donor Hu8241, CYP2B6 protein density 
was normalised to GAPDH. B. The CYP2B6 protein density ratio normalised to 
GAPDH shown for siRNA-treated hepatocytes and corresponding untreated control. 
Data represents mean ± SD of 1 replicate from N=3 donors. Unpaired t-test was 
performed between the siRNA-treated and corresponding untreated hepatocytes, at 
each time point. 
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Figure 5.12. Determination of CYP2B6 degradation rate constant by protein 
analysis. CYP2B6 protein degradation over time was quantified by Western blot. 
CYP2B6 protein density was normalized to GAPDH and is expressed as a 
percentage of T0. A. CYP2B6 kdeg derived from untreated hepatocytes. B. 
CYP2B6 kdeg derived from siRNA-treated hepatocytes. The natural logarithm of 
the percent of T0 is given and the slope of the loss of enzyme protein expression is 
used to calculate the protein half-life, which is equal to the rate of degradation. 
Data represents 1 replicate from N=3 donors. 
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5.3.8 Deriving CYP2B6 kdeg from P450-Glo™ activity assay  
CYP2B6 enzyme activity was determined by P450-Glo™ assay at 0, 12, 24, 
36, 48 and 60 h incubation following initial siRNA dosing. The percentage of activity 
at each time point compared to T0 was fit to linear regression models (Figure 5.13) 
based on first-order enzyme degradation kinetics. Kdeg was taken as the slope of the 
curve as described previously.  
Table 5.5 shows that the average kdeg from the 3 donors derived from 
untreated samples was 0.029 (± 0.007) h-1 and t1/2 of 24.6 (± 6.24) h. The average kdeg 
derived from siRNA treated samples were 0.058 (± 0.010) h-1 and t1/2 of 12.3 (± 2.26) 
h. Overall, kdeg derived from untreated hepatocytes resulted in a longer average half-
life compared with siRNA-treated.  
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Figure 5.13 Determination of CYP2B6 kdeg by CYP2B6 P450-Glo™ assay. 
Primary human hepatocytes were treated with siRNA and incubated over 0-60 h.  
CYP2B6 enzyme activity was quantified by Promega CYP2B6 P450-Glo™ assay 
at designated time points according to manufacturer’s protocol. A. CYP2B6 kdeg 
derived from untreated hepatocytes. B. CYP2B6 kdeg derived from siRNA-treated 
hepatocytes. The natural logarithm of the percent of T0 is given and the slope of 
the loss of activity curve is used to calculate the enzyme half-life, which is equal to 
the rate of degradation. Data represents 1 replicate from N=3 donors. 
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5.3.8 Deriving CYP2B6 kdeg from probe substrate metabolite formation  
CYP2B6 activity was measured by bupropion probe substrate turnover. The 
amount of (2S, 3S)-hydroxybupropion metabolite formation was measured at 12, 24, 
36, 48 and 60 hours after incubation with CYP2B6 targeting siRNA. Figure 5.14 
shows that concentration of (2S,3S)-hydroxybupropion detected was lower for 
CYP2B6 siRNA-treated hepatocytes compared with untreated and NTC-treated. 
However, statistically significant differences were not detected when unpaired t-test 
was performed between untreated and siRNA treated conditions.  
The percentage of activity at each time point compared to T0 was fit to linear 
regression models based on assumed first-order enzyme degradation kinetics as 
shown in Figure 5.15 to calculate kdeg. The CYP2B6 kdeg values were derived by 
tracking the decline of CYP2B6 activity in both untreated and siRNA-treated 
samples. The average kdeg from the 3 donors derived from untreated samples were 
calculated to be 0.036 (± 0.007) h-1 and t1/2 of 15.2 (± 3.81) h. The average kdeg 
derived from siRNA treated samples were 0.062 (± 0.006) h-1 and t1/2 of 11.3 (± 1.10) 
h. Overall, kdeg derived from untreated hepatocytes resulted in a longer average half-
life compared with siRNA-treated.  
A summary of the kdeg and t1/2 values calculated from protein and activity 
methods are given in Table 5.5. Mean values were derived from one experimental 
replicate of hepatocytes from three donors.  
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Figure 5.14 Determination of CYP2B6 activity by formation of probe 
substrate metabolite. Primary human hepatocytes were treated with CYP2B6 or 
non-targeting control (NTC) siRNA and incubated over 12, 24, 36, 48 and 60 h. 
Formation of (2S,3S)-hydroxybupropion after 2 h incubation with 500 µM 
buproprion was quanified with HPLC-UV. Data represents mean ± SD from n=3.  
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Figure 5.15 Determination of the CYP2B6 kdeg by (2S,3S)-hydroxybupropion 
formation. CYP2B6 activity was determined by formation of (2S,3S)-
hydroxybupropion. CYP2B6 activity is expressed as a percentage of T0. A. CYP2B6 
kdeg derived from untreated hepatocytes. B. CYP2B6 kdeg derived from siRNA-
treated hepatocytes. The natural logarithm of the percent of T0 is given and the slope 
of the loss of enzyme activity is used to calculate the protein half-life, which is equal 
to the rate of degradation. Data represents 1 replicate from N=3 donors. 
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Table 5.5 Summary of the kdeg and t1/2 values derived from protein and activity 
methods of analysis using untreated and siRNA treated samples. 
Parameter Donor 1 Donor 2 Donor 3 
t1/2 (h)  derived from protein determined by 
Western blot in untreated samples 
56.8 10.5 10.7 
kdeg (h-1) derived from protein determined by 
Western blot in untreated samples 
0.0122 0.066 0.065 
Average t1/2 (h) 26.0 (± 26.7 ) 
Average kdeg (h-1) 0.048 (± 0.031) 
t1/2 (h)  derived from protein determined by 
Western blot in siRNA treated samples 
9.50 7.62 8.77 
kdeg (h-1) derived from protein determined by 
Western blot in siRNA treated samples 
0.073 0.091 0.079 
Average t1/2 (h) 8.63 (± 0.948 ) 
Average kdeg (h-1) 0.081 (± 0.009) 
t1/2 (h)  derived from activity determined by P450 
Glo™ assay in untreated samples 
31.5 23.1 19.3 
kdeg (h-1) derived from activity determined by P450 
Glo™ assay in untreated samples 
0.022 0.030 0.036 
Average t1/2 (h) 24.6 (± 6.24 ) 
Average kdeg (h-1) 0.029 (± 0.007) 
t1/2 (h)  derived from activity determined by P450 
Glo™ assay in siRNA treated samples 
14.7 10.2 12.0 
kdeg (h-1) derived from activity determined by P450 
Glo™ assay in siRNA treated samples 
0.047 0.068 0.058 
Average t1/2 (h) 12.3 (± 2.26 ) 
Average kdeg (h-1) 0.058 (± 0.010) 
t1/2 (h)  derived from activity determined by probe 
substrate metabolite formation in untreated samples 
10.8 17.8 16.9 
kdeg (h-1) derived from activity determined by probe 
substrate metabolite formation in untreated samples 
0.028 0.039 0.041 
Average t1/2 (h) 15.2 (± 3.81 ) 
Average kdeg (h-1) 0.036 (± 0.007) 
t1/2 (h)  derived from activity determined by probe 
substrate metabolite formation in siRNA treated 
samples 
11.2 10.2 12.4 
kdeg (h-1) derived from activity determined by probe 
substrate metabolite formation in siRNA treated 
samples 
0.062 0.068 0.056 
Average t1/2 (h) 11.3 (± 1.10 ) 
Average kdeg (h-1) 0.062 (± 0.006) 
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5.4 Discussion 
Accurate CYP enzyme kdeg values are vital for the correct prediction of time-
dependent DDIs, but until now, most studies have focused on measuring the 
degradation rate of CYP3A4 (Table 1.3) with no consensus to the best approach. As 
CYP2B6 is highly polymorphic and inducible with an ever-growing list of new 
substrates, it is hypothesised that the enzyme has an important role in causing DDIs, 
especially in time-dependent induction interactions. In this Chapter, the siRNA-based 
methods used for deriving CYP3A4 kdeg, which was utilised in Chapter 4, was applied 
to measure CYP2B6 kdeg with the addition of a different method of detecting CYP2B6 
activity to further validate the approach.  
Previous work conducted from our laboratory reported that CYP2B6 and 
CYP3A4 mRNA were inducible after treatment with PB for 24 h in Caco-2 and 
HepG2 cell lines, respectively (Martin et al. 2008). Due to the expense of using 
primary human hepatocytes for initial protein and activity assay optimisations 
(Faucette et al. 2004), HepG2 and Caco-2 cell lines were incubated with known 
inducer compounds RIF and PB over a time-course of 72 h with the aim of increasing 
CYP2B6 expression to detectable levels of protein and activity for use in 
experimental optimisations. After induction with RIF and PB, CYP2B6 mRNA was 
undetectable in HepG2 cells at all inducer concentrations and across all time-points. 
This was inconsistent with the findings of Choi et al. (2015) who reported 8-fold 
induction of CYP2B6 mRNA after treatment with PB for 24 h. Li et al. (2010) 
reported detectable CYP2B6 activity in HepG2 when transfected with PXR vector, 
whilst other studies reported little or no induction after RIF or PB treatment (Gerets et 
al. 2012; Westerink & Schoonen 2007). In this study, a low level of CYP2B6 mRNA 
expression was detected in Caco-2 cells after induction with both RIF and PB and 
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after culture for 72 h, however, this was not in agreement with the much higher levels 
of CYP2B6 induction with PB reported by Martin et al (2008). The main disparity 
between the protocol published by Martin et al. (2008) and the methodology used 
here was that a lower seeding density was used (3 x 105 vs. 5 x 106 cells) and this 
difference in cell numbers may well give rise to the discrepancies observed. 
Furthermore, protein binding was not assessed and this could impact on overall free 
drug concentrations able to exert effects.  
Overall, insufficient levels of CYP2B6 expression was achieved after 
induction in both Caco-2 and HepG2 cell lines; therefore all protein and activity 
detection methods were optimised in primary human hepatocytes. In the wider 
context, Caco-2 and HepG2 are often used as cost-effective in vitro cell systems to 
study transporter activity and toxicity during human drug development (Brandon et al. 
2006) but are not used for studying metabolism and PK. Caco-2 cells express many 
transporters representative of the in vivo human gut and are routinely used to study 
absorption (Artursson & Karlsson 1991; Angelis & Turco 2011). HepG2 cells are 
highly differentiated hepatoma cells that display many genotypic similarities with 
liver cells; they express many hepatic enzymes and are often used as screening for 
toxicity of parent compound during drug development (Gerets et al. 2012). Both 
Caco-2 and HepG2 cells are not generally used to study metabolism due to the low 
expression of phase I DMEs (Prueksaritanont et al. 1996; Westerink & Schoonen 
2007) and caution must be exercised when using these cell systems as they may not 
be representative of the human situation or that of primary cells. 
To date, there are only two studies that have reported a t1/2 value for CYP2B6. 
Renwick et al. (2000) reported a t1/2 of 32 h estimated based on using immunoblot 
detection of decreasing protein levels in human liver slices in culture from a single 
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donor. Dixit et al. (2016) reported a t1/2 of 70 h and this was measured by induction of 
CYP2B6 in primary human hepatocytes to maximal levels then tracking the time 
taken to recover to basal pre-induced activity levels. The caveat to both approaches is 
that in order for the rates to be deemed accurate, it must be assumed that there was no 
further de novo synthesis during the time period investigated that would distort CYP 
abundance. The approach described in this study addresses this issue by introducing 
siRNA to impede de novo protein synthesis, thus rendering protein degradation as the 
rate-limiting step and therefore the loss of enzyme activity should be attributable to 
the t1/2 of the specific protein measured. Interestingly, the hepatic CYP2B6 kdeg values 
derived from untreated hepatocytes by protein expression loss and activity loss 
measured by P450-Glo™ assay generated kdeg vales of 0.048 h-1 and 0.029 h-1 with t1/2 
of 26.0 h and 24.6 h, respectively, which were in reasonable agreement with values 
obtained by Renwick et al. (2000).  
Overall, the kdeg values derived from untreated hepatocytes generated a longer 
t1/2 value compared with siRNA treated. This is unsurprising given the purpose of 
using siRNA to inhibit mRNA translation and therefore reducing downstream protein 
translation and activity. However, it must be noted that less variability was observed 
for both CYP3A4 (see Chapter 4) and CYP2B6 when kdeg was derived from siRNA 
treated hepatocytes and that kdeg cannot be consistently derived from untreated 
hepatcoyes, as with CYP3A4 activity where loss over time was not observed (see 
Figure 4.15). Moreover, CYP3A4 kdeg values of 0.0189 (± 0.0043) h-1 and 0.0202 (± 
0.0003) h-1 derived from siRNA treated hepatocytes in Chapter 4 were within the 
0.017 - 0.028 h-1 range recommended by Mao et al. (2013) and closer to the recently 
reported kdeg values of 0.019 h-1 and 0.03 h-1 (see Table 1.3) which were used in 
PBPK models to predict TDIs. The CYP3A4 and CYP2B6 kdeg values derived from 
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untreated hepatocytes were in reasonable agreement with Renwick et al. (2000), who 
tracked CYP apoprotein loss in non-treated liver slices. It would appear that the 
siRNA treatment approach generated more accurate kdeg values compared with non-
treated as de novo protein synthesis could be obscuring the true protein degradation 
rate. The kdeg values measured by all approaches ought to be incorporated into PBPK 
simulations of time-dependent CYP2B6 induction interactions and assessed in 
comparison to other available literature values, for DDI prediction accuracy to 
validate the physiological relevance and aid defining the best method. 
Interestingly, in agreement with findings in Chapter 4, using activity analysis 
to derive CYP2B6 kdeg appeared to be the more robust method compared with 
quantifying protein loss by Western blotting. There was a larger variation in CYP2B6 
kdeg calculated from protein compared to activity loss and this can be attributed to the 
semi-quantitative limitations of using Western blot to assess absolute protein 
abundance. Furthermore, there was good agreement of CYP2B6 kdeg 0.029 (± 0.007) 
h-1 and 0.036 (± 0.007) h-1 for untreated hepatocytes and 0.058 (± 0.010) h-1 and 0.062 
(± 0.006) h-1 for siRNA treated hepaotyctes, derived from two different activity 
measurement approaches. This suggests that tracking activity loss rather than protein 
may be the more robust approach for measuring kdeg.  
It should be noted that CYP2B6 is highly polymorphic and there can be large 
inter-individual variability in the expression and activity between donors (Zanger & 
Klein 2013) and this presents a limitation to the current study. Another potential 
limitation to our kdeg approach is that the quantification of a given protein with a long 
t1/2 in monocultured primary human hepatocytes is likely to be problematic. Although 
primary human hepatocytes are regarded as the gold standard in vitro model for 
assessing drug metabolism (Gerets et al. 2012), our studies showed that after 120 
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hours of incubation CYP2B6 mRNA expression reduced to 7.6% (± 1.3) of the 
expression level at time 0 and this differential decline in CYP2B6 expression is 
consistent with the well-documented parallel CYP decline over time in cultured 
human hepatocytes (Renwick et al. 2000; Rodriguez-Antona et al. 2002; Heslop et al. 
2016; LeCluyse 2001). Several studies have commented on the longevity and 
stabilisation of CYP expression in HepatoPac® model and indeed this model was 
used by Ramsden et al. (2015) and Dixit et al. (2016) to directly measure CYP kdeg. 
Thus, for proteins with t1/2 over 120 hours an alternative liver model with prolonged 
CYP expression, such as the HepatoPac® model may be preferred. There are several 
conflicting reports regarding the expression of CYPs in monocultured primary 
hepatocytes. For example, Rodriguez-Antona et al. (2002) reported significant mRNA 
decrease (to below 20%) after 24 hours of culture whereas protein levels were 
detectable at 72 hours. Heslop et al. (2016) were able to detect multiple CYP mRNA 
expression up to 168 hours in culture. Runge et al. (2000) showed detectable CYP 
protein expression at 30 days of culture. It is therefore clearly difficult to define a cut-
off; the current studies indicate that primary human hepatocytes can be used 
successfully up to 96 hours (in Chapter 4) but caution should be taken when 
investigating proteins beyond this time point. Where prior knowledge indicates that 
t1/2 is likely to be less than 96 hours, the use of monocultured primary hepatocytes 
offers a cost-effective and robust approach but variability across systems and 
experiments warrant validation for an appropriate cut-off for each experimental set-
up. In summary, a cost-effective and robust method for determination of protein 
degradation was validated by comparison to accepted values of CYP3A4 and 
employed to determine a value for CYP2B6. 
 
 219 
 
 
 
 
 
 
 
 
CHAPTER 6 
 
Exploring genetic polymorphisms in CYP3A4 
protein degradation machinery on substrate 
pharmacokinetics 
 
 
 
 
 
 
 
 
 
 220 
CONTENTS 
 
6.1 Introduction 
 
6.2 Materials and Methods 
6.2.1   Materials 
6.2.2 Patient samples 
6.2.3 DNA extraction and ATV plasma concentration quantification 
6.2.4 SNP genotyping 
6.2.5 Statistical analysis 
 
6.3 Results 
6.3.1 Patient characteristics 
6.3.2 Summary of genotype frequencies  
6.3.3 Assessment of compliance with Hardy-Weinberg equilibrium  
6.3.4 Non-association of SNPs with plasma ATV concentrations 
6.3.5 Univariate and multivariate analysis of SNP associations with plasma ATV 
concentrations in unboosted patient samples (cohort A) 
6.3.6 Univariate and multivariate analysis of SNP associations with plasma ATV 
concentrations in RTV boosted patient samples (cohort B) 
 
6.4 Discussion 
 
 
 
 
 
 
 
 221 
6.1 Introduction 
As discussed previously in chapter 1.6, much of what is known about the 
specific mechanisms of CYP3A4 protein degradation are derived from studies in 
Sacchromyces cerevisae and rat hepatocytes but there is a high degree of evolutionary 
conservation in degradation pathways between these systems (Wang et al. 2011). 
Consequently, they can be considered to provide reliable clues to the endogenous 
human pathways of degradation. CYP proteins are thought to undergo degradation via 
the ERAD-C pathway of degradation and different CYPs undergo varying degrees of 
ERAD/UPD or ERAD/ALD. Studies in cultured rat hepatocytes have revealed that 
CYP3A protein degradation occurs predominantly via the UPD pathway involving the 
Ub-mediated 26S proteasomal system, but the ALD pathway is likely to contribute to 
a smaller extent (Kim et al. 2016). 
CYP3A4 is an integral monotopic type I ER-anchored protein with a 
cytosolic-facing haem active site that carries out oxidative reactions with a propensity 
to generate ROS; this makes it a model candidate for ERAD-C targeted degradation 
(Wang et al. 2015; Kim et al. 2016). CYP3A4 first undergoes post-translational 
phosphorylation by PKA and PKC protein kinases (Wang et al. 2009), followed by 
synergistic ubiquitination by two cytosolic E2/E3 Ub-ligase complexes: UbcH5a-
CHIP-Hsc70-Hsp40 and UBC7-gp78/AMFR. Molecular recognition of CHIP 
substrates occurs though the Hsc70-Hsp40 co-chaperone complex (Pabarcus et al. 
2009). gp78/AMFR complex recognition involves ‘phosphodegrons’ which are Lys 
residues within a negatively charged cluster of phosphorylatable DEST residues along 
cytosol-exposed surface loops and/or disordered regions within the CYP3A4 protein 
(Wang et al. 2015). Following ubiquitination by E2/E3 Ub-ligase complexes, the 
p97/VCP-AAA ATPase-Npl4-Ufd1 chaperone complex extracts the ubiquitinated 
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CYP3A4 protein from the ER membrane and translocates it to the cytosolic 26S 
proteasome for degradation (Faouzi et al. 2007; Acharya et al. 2011). CYP3A4’s LIR 
motifs, which are hallmarks of ERAD/ALD, are concealed within the protein fold and 
have restricted cytosol accessibility for ERAD/ALD recognition. This is therefore 
consistent with the finding that the protein predominantly undergoes ERAD/UPD 
over ALD (Faouzi et al. 2007; Kim et al. 2016). A schematic for the current best 
hypothesis for the components involved in CYP3A4 protein ERAD/UPD pathway are 
shown in Figure 6.1. 
Figure 6.1 A schematic of CYP3A4 ERAD/UPD pathway of protein degradation 
(adapted from Kim et al 2016).  
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The gp78 (glycoprotein 78) protein, encoded by the AMFR gene, is an E2 
ubiquitin-protein ligase that is involved in the degradation processes of not only 
CYP3A4, but also of human CD3D (T-cell surface glycoprotein CD3 delta chain), 
CFTR (cystic fibrosis transmembrane conductance regulator) and APOB 
(apolipoprotein B) proteins. Over 3,600 single nucleotide polymorphisms (SNPs) 
have been identified for the AMFR gene yet their propensity to cause drug 
interactions is not well studied. A handful of SNPs have been cited in published 
literature; Choi et al. (2011) found 3 SNPs (rs2440467, rs2432540 and rs6499837) to 
be significantly associated with AMFR protein expression levels. Cha et al. (2014) 
found rs2440472 to be associated with coronary artery disease in Chinese 
populations. UBE2G1 (ubiquitin-conjugating enzyme E2 G1) is the human 
homologue to yeast ubiquitin-conjugating enzyme E2 7 (UBC7) that has been 
previously found to be involved in the CYP3A4 ERAD-C pathway. Evangelou et al. 
recently found a significant association of UBE2G1 SNP rs9906760 with type 1 
diabetes (Evangelou et al. 2014). As these SNPs identified in AMFR and UBE2G1 
were likely to cause functional alterations to the gene product, it was hypothesised 
that these polymorphisms could potentially impact on CYP3A4 degradation.  
SNPs are a single nucleotide variation within a gene sequence that can give 
rise to clinical interactions, by generating disease through a dysfunctional gene 
product or through alteration in response to drugs. For example, CYP3A4*22 has 
been linked to reduced hepatic expression (Okubo et al. 2013) and an altered response 
to statin drugs (D. Wang et al. 2011; Elens et al. 2011). CYP3A4*1B has been 
associated with enhanced CYP3A4 activity and affects tacrolimus PK in renal 
transplant patients (Shi et al. 2015). Clearly, SNPs that alter CYP3A4 expression 
levels can give rise to major clinical interactions, given its importance role in drug 
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metabolism. In theory, any SNP that elicits a significant impact on CYP3A4 protein 
degradation machinery may also alter its abundance and modify drug metabolism. 
Atazanavir (ATV) is a protease inhibitor (PI) used in the treatment of HIV 
subtype 1 (HIV-1) infections. It can be administered at a dosage of 400 mg once a day 
(unboosted) or 300 mg coupled with 100 mg dose of ritonavir (RTV) once per day 
(boosted; ATV/r) in treatment naïve patients (Bristol-Myers Squibb 2003). The use of 
unboosted ATV is not licensed in Europe and is currently not recommended but it 
remains the PI of choice for special populations of patients who are unable to tolerate 
ritonavir, such as in the case of hyperbilirubinaemia and moderate liver insufficiency 
(Siccardi et al. 2012; Achenbach et al. 2011). Atazanavir is predominantly 
metabolised by CYP3A isoenzymes (Goldsmith & Perry 2003; Bristol-Myers Squibb 
Company, 2004) and therefore quantifying plasma concentrations of ATV can be an 
indicator of the extent of CYP3A activity correlating with treatment response. The 
aim of this chapter was to investigate the impact of known functional SNPs in AMFR 
(rs2432540 A>G, rs6499837 C>T, rs2440472 A>G and rs2440467 C>T) and 
UBE2G1 (rs9906760 A>G) genes on ATV plasma concentration in two cohorts of 
patients; one given unboosted ATV and the other ATV/r. Plasma concentrations of 
ATV were therefore used as a surrogate measure of CYP3A4 activity.  
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6.2 Materials and methods 
6.2.1 Materials 
TaqMan® Genotyping Master Mix and TaqMan® SNP Genotyping assays for 
AMFR: rs2432540 A>G (C__16014493_10), rs6499837 C>T (C__29285325_10), 
rs2440472 A>G (C__26354979_10) and rs2440467 C>T (C__16240734_10) and 
UBE2G1 rs9906760 A>G (C__29654285_20) were purchased from ThermoFisher 
Scientific Inc. (Loughborough, UK). 96-well polymerase chain reaction (PCR) plates 
and Microseal® ‘B’ PCR plate sealing film were obtained from Bio-Rad (Watford, 
UK). Nuclease-free water (W4502) was purchased from Sigma-Aldrich (Dorset, UK). 
 
6.2.2 Patient samples 
Cohort A consisted of 47 patients administered with unboosted ATV and these 
patients were recruited in Torino. Cohort B included 50 patients administered with 
RTV-boosted ATV (ATV/r) recruited in Liverpool and Torino. Inclusion criteria for 
cohorts were as follows: receipt of unboosted ATV (400 mg once per day) for cohort 
A, receipt of ATV/r (300 mg ATV with 100 mg RTV once per day) for cohort B, age 
> 18 years and no receipt of other drugs known to affect plasma concentrations of 
ATV (except tenofovir). Data for age, sex, body weight, time after dose, concomitant 
antiretroviral drugs and other medications were collected for both cohorts. For cohort 
B, the plasma ATV concentrations taken at 24 (±4) h post dose were included. 
Sampling was performed after written informed consent was obtained in accordance 
with local ethics committee instructions. 
 
6.2.3 DNA extraction and atazanavir plasma concentration quantification 
Dr Marco Siccardi previously extracted genomic DNA and quantified ATV plasma 
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concentrations using UV-HPLC and HPLC-MS/MS in patient blood samples, as 
detailed in his publications (Siccardi et al. 2012; Schipani et al. 2010). The extracted 
genomic DNA was stored at -20oC until analysis. Upon analysis DNA was quantified 
using NanoDrop™ 1000 spectrophotometer (ThermoFisher Scientific Inc., Delaware, 
USA) to determine sample concentration and purity ratio. Only DNA samples with a 
260:280 absorbance of >1.4 and concentration of >2 ng/µl were included in the 
analysis. 
 
6.2.4 SNP genotyping 
Real-time polymerase chain reactions (qPCR) were made up to a final volume of 25 
µl per well on 96-well PCR plates. Each well consisted of 12.5 µl of 2X TaqMan® 
Genotyping Master Mix, 1.25 µl of 20X gene assay, 9.25 µl nuclease-free water and 2 
µl of genomic DNA (at least 2 ng/µl concentration). Negative controls were included 
for each gene assay where 2 µl of nuclease-free water was added in place of genomic 
DNA. Each sample was completed in duplicates. The 96-well plates were then 
covered with Microseal® adhesive PCR plate sealing film and centrifuged briefly up 
to 2000 rpm to mix the reaction contents and to allow all reagents to collect at the 
bottom of the well to eliminate air bubbles from the solution mix.  
  Genotyping was performed using real-time PCR allelic discrimination assay 
on a DNA Engine Chromo4 system (Bio-Rad Laboratories, California, USA). Four 
AMFR polymorphisms rs2432540 A>G, rs6499837 C>T, rs2440472 A>G and 
rs2440467 C>T, and one UBE2G1 polymorphism rs9906760 A>G were assessed in 2 
cohorts of patient samples (see Table 6.2). The PCR heat cycling protocol involved an 
initial enzyme activation step at 95oC for 10 min, followed by 40 cycles of 
amplification with denaturation at 95oC for 15 s, followed by final annealing at 60oC 
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for 1 min. Allelic discrimination plots (Figure 6.2) and genotype assignments were 
performed using Opticon Monitor, version 3.1 (Bio-Rad Laboratories Inc., UK) 
according to VIC® and FAM™ fluorescence.  
 
 
 
 
Figure 6.2 Representative allelic discrimination plot. Red dots indicate blanks with 
no expression. Green dots represent homozygous genotype for allele associated with 
VIC® dye. Blue dots represent heterozygous genotype. Orange dots represent 
homozygous genotype for allele associated with FAM™ dye. 
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Table 6.1 Applied Biosystem Assay IDs and sequence for selected SNPs (VIC® 
and FAM™ are TaqMan® reporter dyes) 
Assay ID SNP ID Gene SNP 
alleles 
Assay sequence ([VIC/FAM]) 
     
C__16014493_10 rs2432540 AMFR A/G GTGTTCAGAAAAGGTTAGATTATCC[A/G]C
CACAGAAATAAAATGAACGTTTCA 
 
C__29285325_10 rs6499837 AMFR C/T CCCTTCCAGAATGGTTCTACTCTTC[C/T]A
CTGGAGAAAACAGAAACTAAATTA 
 
C__26354979_10 rs2440472 AMFR A/G GCAGTTTACAAACATACATTCTGAC[A/G]T
ACTCTGGGATCTGCTGTTATTAAA 
 
C__16240734_10 rs2440467 AMFR C/T AGCTCCCACTCATTTCAATCTACCA[C/T]A
ATCTACTGTCCAACCCCTCGGGCA 
 
C__29654285_20 rs9906760 UBE2G1 A/G GGTCCTGTTGAGGTGGAAGAGTTGC[A/G]T
GGTGTGAACACTAAATCAAGTAAG 
 
 
 
6.2.5 Statistical analysis 
All genotypes were assigned 0 or 1 binary coding based on homozygous for common 
allele, or carrier of at least one variant allele, respectively, for regression analyses. 
Patient characteristics were analysed and categorical variables were described using 
relative frequencies, whilst continuous variables were described using median and 
range. Compliance with Hardy-Weinberg equilibrium was tested by χ2 test of 
observed and predicted genotype frequencies using an online Hardy-Weinberg 
equilibrium calculator (Rodriguez et al. 2009). The distribution of ATV plasma 
concentrations for both cohorts was determined individually by Shapiro-Wilk test for 
normality with P<0.05 considered significant. Categorical genotype data were 
compared using the Kruskal Walis one-way analysis of variance (ANOVA) and 
Mann-Whitney U test; P<0.05 was considered a significant association.  
A univariate linear regression analysis was carried out to identify patient 
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demographic variables associated with mean ATV plasma concentrations. 
Independent variables with a P-value up to 0.2 in the univariate analysis were carried 
through to a multivariate stepwise linear regression analysis where P<0.05 was 
considered significant. Because no significant associations were detected for any of 
the demographic variables or genotypes against ATV plasma concentrations in both 
cohorts, further statistical analyses were not conducted. All statistical analyses were 
performed with SPSS Statistics Software, version 22 (IBM) and charts were produced 
using GraphPad Prism 6 (GraphPad Software, CA, USA). 
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6.3 Results 
6.3.1 Patient characteristics 
A total of 47 patients of cohort A and 50 patients of cohort B met the inclusion 
criteria. The data available for characteristics for patients included were assessed and 
are presented in Table 6.2. 
Table 6.2 Patient characteristics for Cohorts A and B (values shown as median 
(range) or % of subjects). 
 
6.3.2 Summary of genotype frequencies 
Genotype was characterised for cohorts A and B for the 5 chosen SNPs and 
population frequencies were in agreement with published data, as shown in Table 6.3. 
Table 6.3 Summary of genotype frequencies (EUR = European population)	
 
Gene SNP EUR population 
allele frequency from 
1000Genome 
Cohort A 
genotype 
frequencies 
Cohort B 
genotype 
frequencies 
     
AMFR rs2432540 C 0.53 : T 0.47 C 0.53 : T 0.47 C 0.59 : T 0.41 
AMFR rs6499837 T 0.45 : C 0.55 T 0.42 : C 0.58 T 0.35 : C 0.65 
AMFR rs2440472 C 0.53 : T 0.47 C 0.54 : T 0.46 C 0.59 : T 0.41 
AMFR rs2440467 T 0.45 : C0.55 T 0.43 : C 0.57 T 0.35 : C 0.65 
UBE2G1 rs9906760 A 0.68 : G 0.32 A 0.62 : G 0.38 A 0.63 : G0.37 
Characteristics Cohort A Total (n=47) Cohort B Total (n=50) 
   
Age (years) 45 (44) 45 (45) 
Caucasian (%) 100 100 
Gender: Female (%) 40 28 
Weight (kg) 65 (47) 72 (70) 
Height (cm) 168 (35) 172 (38) 
BMI 23.74 (13.7) 23.81 (17.8) 
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6.3.3 Assessment of compliance with Hardy-Weinberg equilibrium 
The genotypes characterised for cohorts A and B were assessed for fit with the 
Hardy-Weinberg equilibrium by χ2 test of observed and predicted genotype 
frequencies. This data is presented in Table 6.4. All genotypes characterised for the 5 
SNPs in both cohorts displayed a P-value of >0.0001 and were therefore in 
compliance with the Hardy-Weinberg equilibrium.   
 
Table 6.4 Compliance of patient samples with Hardy-Weinberg equilibrium 
 
Gene SNP Cohort A (n=47) Cohort B (n=50) 
χ2 P-value χ2 P-value 
      
AMFR rs2432540 0.58 P > 0.05 1.98 P > 0.05 
AMFR rs6499837 0.43 P > 0.05 1.74 P > 0.05 
AMFR rs2440472 0.24 P > 0.05 1.98 P > 0.05 
AMFR rs2440467 0.81 P > 0.05 1.76 P > 0.05 
UBE2G1 rs9906760 5.78 0.05>P<0.01 3.66 P > 0.05 
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6.3.4 Non-association of SNPs with ATV plasma concentrations 
The Shapiro-Wilk test for normality for ATV plasma concentration (dependent 
variable) displayed a significant P-value of P=7.4x10-7 for cohort A and P=3.4x10-7 
for cohort B, therefore non-normal distributions were assumed. The effect of the 5 
SNPs on ATV plasma concentrations was determined by Kruskal Walis non-
parametric ANOVA test. No significant associations were found for all 5 SNPs for 
both cohorts (P>0.05) as depicted in Figures 6.3 and 6.4. Categorical data were 
assessed with Mann-Whitney U test for carrier and non-carrier genotype categories. 
No significance was detected for all 5 SNPs with Mann-Whitney U tests in both 
cohorts (P>0.05). Table 6.5 summarises the effect of the 5 selected SNPs on ATV 
plasma concentrations. 
 
Table 6.5 Effect of SNPs on ATV plasma concentration 
 
Gene SNP Cohort A Cohort B 
Kruskal 
Walis P-value 
Mann-Whitney 
U Test P-value 
Kruskal 
Walis P-value 
Mann-Whitney 
U Test P-value 
1-tailed 2-tailed 1-tailed 2-tailed 
        
AMFR rs2432540 0.44 0.11 0.22 0.36 0.18 0.37 
AMFR rs6499837 0.82 0.27 0.54 0.35 0.18 0.36 
AMFR rs2440472 0.65 0.22 0.44 0.59 0.29 0.60 
AMFR rs2440467 0.94 0.37 0.73 0.35 0.18 0.35 
UBE2G1 rs9906760 0.32 0.08 0.16 0.87 0.43 0.87 
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Figure 6.3 Comparison of ATV concentrations in carriers and non-carrier of selected 
SNPs in patient cohort A administered with unboosted ATV. A. AMFR A>G rs2432540, 
B. AMFR C>T rs6499837, C. AMFR A>G rs2440472, D. AMFR C>T rs2440467 and E. 
UBE2G1 A>G rs9906760. Statistical significance determined by Kruskal Walis ANOVA.  
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Figure 6.4 Comparison of ATV concentrations (24 ±4 h post dose) in carriers and non-
carrier of selected SNPs in patient cohort B administered with boosted ATV/r. A. AMFR 
A>G rs2432540, B. AMFR C>T rs6499837, C. AMFR A>G rs2440472, D. AMFR C>T 
rs2440467 and E. UBE2G1 A>G rs9906760. Statistical significance determined by Kruskal 
Walis ANOVA.  
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6.3.5 Univariate and multivariate analysis for associations with ATV plasma 
concentrations in unboosted patient samples (cohort A)  
Univariate regression analysis showed associations of gender (P=0.20), height 
(P=0.15) and rs9906760 (P=0.18) to ATV plasma concentrations for cohort A. 
Therefore, these characteristics were included in a stepwise multivariate regression 
analysis. Patient characteristics including age (P=0.97), weight (P=0.78) and body 
mass index (BMI; P=0.53) were not correlated to ATV concentrations in univariate 
analysis. No significant associations of gender, height or rs9906760 carrier/non-
carrier status to ATV concentrations were found (P>0.05) upon multivariate analysis, 
so no further statistical analyses were conducted. 
 
Table 6.6 Univariate and multivariate analysis of patient demographics and 
physical characteristics with plasma ATV concentrations for cohort A. 
 
 
 
Characteristics Univariate linear regression Multivariate linear regression 
P-value β-value (95% CI) P-value β-value (95% CI) 
     
Age (years) 0.970 0.000 (-0.014 – 0.014) - - 
Gender 0.201 0.167 (-0.092 – 0.426) 0.627 0.073 (-0.228 – 0.374) 
Weight (kg) 0.779 -0.002 (-0.013 - 0.010) - - 
Height (cm) 0.146 -0.012 (-0.029 – 0.005) 0.146 -0.012 (-0.029 – 0.005) 
BMI 0.526 0.013 (-0.027 – 0.053) - - 
rs2432540 0.248 -0.170 (-0.462 – 0.122) - - 
rs6499837 0.509 -0.091 (-0.367 – 0.185) - - 
rs2440472 0.447 -0.109 (-0.397 – 0.178) - - 
rs2440467 0.697 -0.055 (-0.337 – 0.227) - - 
rs9906760 0.177 -0.189 (-0.466 – 0.088) 0.259 -0.159 (-0.438 – 0.121) 
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6.3.6 Univariate and multivariate analysis for associations with ATV plasma 
concentrations in RTV boosted patient samples (cohort B)  
Univariate regression analysis showed no significant associations with 
demographics or physical characteristics including: age (P=0.72), gender (P=0.62), 
weight (P=0.82), height (P=0.33), BMI (P=0.38), tenofovir dose (P=0.99) and time 
post dose (P=0.85) to ATV plasma concentrations for cohort B (P>0.2). No 
significant associations were found with the 5 selected SNPs; therefore multivariate 
regression and further statistical analyses were not conducted for cohort B data. 
 
Table 6.7 Univariate analysis of patient demographics and physical 
characteristics with plasma ATV concentrations for cohort B.  
Characteristics Univariate linear regression 
P-value β-value (95% CI) 
   
Age (years) 0.722 0.002 (-0.009 – 0.013) 
Gender 0.617 -0.055 (-0.275 – 0.165) 
Weight (kg) 0.817 0.126 (-0.962 – 1.215) 
Height (cm) 0.327 -0.006 (-0.017 – 0.006) 
BMI 0.378 0.010 (-0.013 – 0.033) 
Tenofovir dose 0.992 0.001 (-0.208 – 0.210) 
Time post dose (h) 0.845 -0.005 (-0.059 – 0.048) 
rs2432540 0.466 -0.077 (-0.289 – 0.134) 
rs6499837 0.548 -0.060 (-0.261 – 0.140) 
rs2440472 0.729 -0.037 (-0.250 – 0.176) 
rs2440467 0.548 -0.060 (-0.261 – 0.140) 
rs9906760 0.979 -0.003 (-0.198 – 0.193) 
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6.4 Discussion 
Alterations to CYP3A4 abundance, whether through inhibition/induction or 
modulation of protein expression through genetic polymorphisms, can have 
significant impact on substrate drug metabolism and disposition. It was therefore 
hypothesised that any disruption to the CYP3A4 protein degradation machinery will 
alter overall protein abundance and subsequently impact on substrate PK. To test this 
hypothesis, four SNPs in the AMFR gene and one SNP in UBE2G1 gene, where both 
gene products were speculated to be involved in the human CYP3A4 ERAD/UPD 
pathway, were assessed for associations with substrate ATV plasma concentrations in 
two cohorts of HIV-1 infected patients. This study found that the 5 selected SNPs had 
no effect on plasma ATV concentrations in both cohorts of patients.  
Cohort B included patients given RTV-boosted ATV regimens. RTV is a PI 
class drug and a potent inhibitor of CYP3A4. It is often prescribed with additional PI 
drugs to boost concomitant drug exposure. Its rationale for use as a ‘booster’ is due to 
its ability to inhibit CYP3A4, resulting in reduced metabolism and increased exposure 
of concomitant drugs and therefore a ‘boosted’ therapeutic effect (Zeldin & 
Petruschke 2004; Hull & Montaner 2011; Boffito 2004). Less significant associations 
of SNPs to ATV PK were expected in cohort B as RTV’s effect on CYP3A4 and 
ATV PK could mask any effect of the AMFR or UBE2G1 SNPs. Both cohorts were 
included in this study with the ATV/r cohort B intended as a comparison with cohort 
A. However, no significant associations were found in either cohort. Our group had 
previously characterized an association of the PXR SNP rs2472677 C>T to reduced 
concentrations of unboosted ATV (cohort A) (Siccardi et al. 2008), however, 
associations CYP3A4*22 (rs35599367 C>T), a well-known polymorphism resulting 
in reduced CYP3A4 expression, was not analysed for these cohorts. 
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Several sources have documented that altered states of protein degradation 
have been a principal cause of pharmacogenetic related loss of function of different 
DMEs. Enhanced proteasomal degradation has been reported as a principal 
mechanism for thiopurine S-methyltrasnferase (TPMT) deficiency in mutant TPMT*2 
and TPMT*3 alleles (Tai et al. 1999).  Li et al. (2008) reported on the importance of 
SNPs in autophagic machinery for the protein degradation of TPMT*3A, which is a 
well-characterised variant allozyme known to cause clinical pharmacogenetic 
interactions. Additionally, the human N-acetyltrasnferase 2 (NAT2) enzyme 
polymorphism NAT2*5 allozyme yields large reduction in NAT2 protein due to 
enhanced protein degradation, which results in a slow acetylator phenotype (Zang et 
al. 2004). For the sulfotransferase (SULT) 1A1*2 allozyme, enhanced proteasomal 
degradation can be attributed for reduced metabolism of carcinogens and increased 
risk of urinary tract cancer (Nagar et al. 2006). More recently, altered proteasomal 
degradation in p.P187S polymorphism of NADPH quinone oxidoreductase 1 (NQO1) 
has been identified as a mechanism contributing to loss of function and non-activation 
of cancer pro-dugs (Encarnación et al. 2016). Nakagawa et al. (2011) reviewed the 
impact of protein degradation on ABC transporter protein expression and consequent 
effects on drug disposition. It is evident that protein degradation mechanisms should 
be considered amongst mechanisms responsible for the effects of 
pharmacogenetically significant polymorphisms. 
Polymorphisms in genes involved in protein degradation mechanisms give rise 
to clinical manifestations and disease. Deregulation of the UPD has been implicated 
in the pathology of many neurodegenerative disorders such as Alzheimer’s disease, 
Parkinson’s disease and Huntington disease, where inadequate degradation leads to 
aggregation of misfolded and dysfunctional proteins (Paul 2008; Schmidt & Finley 
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2014). Stintzing et al. (2015) reported that polymorphisms in genes involved in 
epidermal growth factor receptor (EGFR) turnover could be predictors of efficacy of 
cetuximab in colorectal cancer patients. This is the only published study, at the time 
of writing, which has validated a SNP in protein degradation machinery that is 
associated with disposition of a clinically used drug. Although polymorphisms in 
degradation proteins are a plausible mechanism for causing clinical interactions, 
clearly this area is under studied.  This is perhaps due to the complexity of the 
signaling and protein cascades involved in the degradation process and paucity in the 
understanding of molecular interactions and mechanisms for target recognition.  
To date, there are no published pharmacogenetic effects of protein degradation 
machinery on CYP degradation despite well-established associations of CYP protein 
abundance to clinical interactions (Nebert et al. 2013). This is perhaps due to 
insufficient understanding of the exact mechanisms of CYP protein degradation and 
further elucidation is needed to identify specific markers of degradation. CYP3A4 and 
CYP2E1 are the most extensively studied in terms of protein degradation and the 
pathways identified for these CYP proteins have provided clues to elucidate 
mechanisms for other CYPs. Human CYPs 3A4, 3A5 and 2B6 are likely to 
predominantly undergo ERAD/UPD whereas CYPs 2E1, 2C9, 2D6 showed biphasic 
turnover involving both UPD and ALD (Kim et al. 2016). As discussed previously 
gp78, the AMFR gene product, is involved in the ERAD/UPD degradation of many 
proteins other than CYP3A4, thus gp78 is specific but not limited to the CYP3A4 
degradation pathway (Chen et al. 2012; Zhang et al. 2015). UBE2G1 is a human 
homologue of UBC7 and is a speculated component of the human CYP3A4 
degradation pathway, however, the evidence of involvement of this protein is scarce 
compared with gp78. SNPs in UBE2G2 could be investigated instead, as it is another 
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UBC7 homologue and some studies have found this E2 protein to be clearly 
implicated in ERAD (Chen et al. 2006). As human CYP3A4 degradation is 
understudied, it is perhaps unsurprising that no associations of SNPs to ATV PK were 
found in this study. It must be noted that analysis for both cohorts across all 5 SNPs 
were also carried out using an additive model of inheritance, whereby alleles were 
coded as 0 (homozygous WT), 1 (heterozygous) and 2 (homozygous variant). 
However no significant associations were found correlating to ATV plasma 
concentrations and therefore the data was not presented. As the relative contributions 
of the identified components of the CYP3A4 degradation machinery to overall protein 
degradation are unknown, a limitation to this investigation was that only 5 SNPs in 2 
genes were studied. More SNPs in more genes of the recognised degradation 
machinery is likely to be needed to find any significant associations, such as in the 
study by Stintzing et al. where they analysed 20 SNPs in 7 genes. However, this 
machinery is involved in degradation of many proteins and a high-impact genetic 
abnormality would therefore likely impact many biological processes. For this reason, 
one might expect these systems to be well conserved. 
Characterising clinically relevant polymorphisms in the degradation process 
can provide predictive biomarkers of disease, provide new targets in treatments or 
inform treatment regimen design. The protein degradation pathway as a potential 
pathway for pharmacogenetics is a relatively new concept (Nakagawa et al. 2011). 
The UPD has been increasingly recognised as a potential pathway for biomarker and 
drug development but it is a field that requires further evaluation. Better elucidation 
of processes specific to CYP isozyme degradation will provide new targets for 
treatment and increase the likelihood of identifying significant pharmacogenetic 
relationships.  
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DDIs may result in serious clinical consequences and therefore the potential of 
a NME causing or being a victim of an interaction needs to be carefully studied. The 
ability to quantitatively predict DDIs early in the drug development process is 
essential to reduce risks of adverse effects manifesting during clinical studies. The 
potential for a DDI interaction can be assessed using in vitro, in vivo and in silico 
methods. In early preclinical drug development, in vitro methods are used to 
determine the metabolic pathways involved in the clearance of a NME and for 
screening interaction potential, then IVIVE can be used for predicting the risk of 
clinical DDIs of the compound and where signs of interaction potential based on in 
vitro and in silico studies are identified, full drug interaction investigations may be 
carried out (Jones et al. 2012).  
In silico approaches to predicting DDI potential can be applied at different 
points in the drug development process to aid drug candidate selection, inform drug 
trials and dosing regimen selection. The use of in silico approaches can reduce the 
costs of drug development considerably and in several instances simulations from 
PBPK models have been used in lieu of clinical studies (Bjornsson et al. 2003; Jones 
et al. 2012; Jamei 2016; Park et al. 2017).  
The use of PBPK models to replace clinical studies has been particularly 
prevalent when the mechanism of DDI is due to competitive inhibition of CYP 
substrates (particularly when the CYP isozyme involved is CYP3A4). In irreversible 
or quasi-irreversible inhibition where manifestation and reversal of the interaction is 
slow and time-dependent, such as in the case of MBI interactions, accurate 
predictions of DDI potential and magnitude is problematic due to the lack of data for 
some parameters that are critical for prediction. In MBI, the perpetrator drug 
irreversibly binds to the enzyme forming an inactivated drug-enzyme complex that 
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permanently removes the enzyme from the pool of active enzymes and recovery of 
enzyme activity is gained only by re-synthesis of the enzyme protein. Therefore, the 
consequences of MBI persist longer and can be more profound than reversible 
inhibition. To predict MBI interactions, specific parameters such as kinact and kdeg of 
the inhibited enzyme are essential for IVIVE. Using values only sufficient for 
reversible inhibition have resulted in under prediction or failure to identify MBI 
interactions. Although progress has also been made in predicting drug interactions 
caused by changes in the level of DMEs such as induction and MBI (Wagner et al. 
2015), there is still more work that needs to be done to improve the accuracy of DDI 
predictions for these mechanisms (Jones et al. 2015). 
The kdeg of CYP enzymes, characterising the in vivo turnover, is essential for the 
IVIVE of interactions caused by MBI. The first-order (where the rate is dependent on 
enzyme concentration) enzyme degradation rate is a physiological value depending on 
the enzyme, individual and species concerned. Ideally CYP kdeg ought to be derived in 
vivo in humans for effective IVIVE of human drug interactions. However, kdeg of 
DMEs cannot be easily measured directly in vivo therefore surrogate measures using 
in vitro systems have been used to obtain estimates. For many years, the prediction 
accuracy of MBI interactions have been hampered by the lack of a physiologically-
relevant enzyme kdeg values and where they are available, the values vary widely 
because they are generated from many different in vitro approaches with no 
consensus as to the best method. As the half-lives of CYPs vary between species, for 
example they are shorter in rats compared to humans, using preclinical species to 
derive kdeg values can under predict the risk and magnitude of MBI interactions. One 
of the major aims of this thesis was to develop a robust in vitro method for measuring 
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DME kdeg in primary human hepatocytes as an accurate representation of the in vivo 
human condition.  
Initially, the simplest and most widely used in vitro approach for measuring 
protein degradation was explored and this involved using pharmacological 
interference by protein synthesis inhibitor compounds to stop de novo protein 
synthesis followed by tracking protein expression decline over time. However, protein 
synthesis inhibitor drugs exert their effects through inhibiting fundamental 
components of the universal protein synthesis pathway, therefore cytotoxicity was 
expected with prolonged use. Four commonly used protein synthesis inhibitor 
compounds including actinomycin D, cycloheximide, emetine and puromycin, were 
assessed as single agents and also in two-, three- and four-agent combinations for 
their capacity to stop de novo protein synthesis without producing overt cytotoxicity. 
However, all four inhibitor drugs in all combinations were found to be unsuitable for 
further use in deriving CYP kdeg due to cytotoxicity determined through several 
different toxicity assays, that was frequently observed at lower concentrations than 
required for protein synthesis inhibition. Therefore, a different approach for stopping 
de novo protein synthesis was required. The protein synthesis inhibitor agents 
investigated are commonly used in vitro for analysis of protein or mRNA stability 
with applications in many fields of cellular biology and the concentrations used in 
these studies far exceed the toxic concentrations reported here (Table 2.1). Work 
herein shows that for proteins that are likely to have longer half-lives (over 24 h), the 
use of pharmacological interference is unsuitable for determining protein turnover. 
Caution should be exercised when using other protein synthesis inhibitor compounds 
in in vitro cellular systems and ideally, drug concentrations should first be optimised 
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and deemed non-toxic through the use of appropriate toxicity assays prior to being 
used in downstream applications. 
It was hypothesised that introducing DME-specific siRNA to an in vitro culture 
system would exclusively knockdown expression of target gene mRNA and 
subsequent de novo protein synthesis with minimal cytotoxicity due to specificity of 
the siRNA target. A time-course of mRNA knockdown was validated in primary 
human hepatocytes and siRNA methods were found to be considerably less cytotoxic 
than using protein synthesis inhibitor agents. The CYP protein expression and activity 
decline through time was tracked by Western blotting and probe substrate metabolite 
formation, respectively, and the kdeg value was derived from the degradation curves 
assuming first-order kinetics in untreated and siRNA treated hepatocytes. The 
CYP3A4 kdeg values derived using the siRNA treated approach were found to be 
similar to recently published values (Ramsden et al 2015; Dixit et al 2016; Takahashi 
et al 2017) and within the range described by Mao et al. (2013). Therefore the same 
approach was applied to measure CYP2B6 kdeg, which is a less-well characterised 
CYP enzyme. There have only been two previous studies, at the time of writing, that 
have reported on the kdeg of CYP2B6 and both studies did not account for de novo 
protein synthesis during assessment of degradation and consequently the values 
varied widely. The CYP2B6 kdeg  values derived in this study was closer to 0.022 h-1 
(t1/2 of 26 h) reported by Renwick et al (2000) than 0.010 h-1 (t1/2 of 68 h) reported by 
Dixit et al (2016). The CYP2B6 kdeg values can now be incorporated into PBPK 
predictions of DDIs involving mechanism-based inactivators of CYP2B6 such as 
clopidogrel, ticlopidine (Richter et al. 2004; Nishiya et al. 2009), monoamine oxidase 
inhibitors (Sridar et al. 2012; Nirogi et al. 2015) and components of medicinal herbs 
(Cao et al. 2015; Ji et al. 2015; Lu et al. 2016). 
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A limitation to the use of cryopreserved primary hepatocytes as the in vitro model 
for deriving CYP kdeg is that several sources have documented significant decline of 
CYP expression over time in monolayer culture and thus they may not be 
representative of the endogenous human state. However, primary human hepatocytes 
are still regarded as the ‘gold standard’ for in vitro metabolism studies because they 
possess the full complement of DMEs and they have been found to be better 
predictors of in vivo drug clearance compared with liver microsome preparations in 
some studies. Moreover, cryopreserved hepatocytes express CYP proteins at levels 
comparable to freshly isolated hepatocytes (Smith et al. 2012). Indeed, better cell 
models that mimic the endogenous human liver will improve drug research and 
several models are under development to address this need. For example, 3D 
hepatocyte culture systems involving sandwich culture between an extracellular 
matrix and a scaffold-free approach in the self-aggregation of cells into spheroids 
with or without nutrient perfusion, have reported stable hepatocyte phenotype for 
longer duration (over weeks) compared with monoculture systems (Soldatow et al. 
2013; Zeilinger et al. 2016). Other methods include co-culturing hepatocytes with 
non-parenchymal cells such as Kuppfer and endothelial cells, which promote cell-to-
cell adhesion and have resulted in reduced de-differentiation during in vitro culture 
(Bhatia et al. 1999; Shulman & Nahmias 2013). Using such long-lived liver cell 
models to measure kdeg of hepatic proteins with long t1/2 (days) may be more 
appropriate than the current monoculture hepatocyte system and indeed, drug 
metabolism studies have increasingly come away from using monocultured 
hepatocytes in favour of the 3D culture models, especially in transporter studies.  
Of all the identified CYP enzymes, CYP3A4 is also the most extensively studied 
for its precise mechanisms of protein degradation. CYP3A4 predominantly undergoes 
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degradation via the ERAD/UPD degradation pathway that involves several 
components including the gp78 glycoprotein (encoded by AMFR gene) and the 
UBE2G1 enzyme (Correia et al. 2014). It was postulated that any dysregulation of the 
CYP enzyme degradation machinery would have an overall impact on steady-state 
protein abundance and therefore capacity to facilitate metabolism. Four SNPs in the 
AMFR gene and one in UBE2G1 were selected based on their reported likelihood of 
affecting the gene product function and were assessed for associations with CYP3A4-
mediated PK changes in the known substrate ATV plasma concentrations in two 
cohorts of HIV-1 infected patients. Significant associations were not observed with 
any of the 5 SNPs. The ERAD/UPD pathway for CYP enzymes has been more 
extensively studied compared with the ERAD/ALD pathway; the factors targetting 
CYP proteins to be degraded by ALD pathway remains mostly obscure (Kim et al. 
2016). Further elucidation of the precise mechanisms that target DME proteins for 
degradation may identify new targets to measure to better characterise DME kdeg 
values. Stintzing et al. (2015) identified associations between polymorphisms in the 
EGFR degradation machinery and PK of cetuximab in colorectal cancer patients. This 
presents the only study, at the time of writing, to identify associations between SNPs 
of proteins involved in protein degradation to drug disposition. Clearly, dysregulation 
of the protein degradation machinery offers a plausible mechanism for altering drug 
disposition but the magnitude of effect and whether they contribute to significant 
changes in PK remains understudied.   
Confidence in the prediction of DDIs for drugs eliminated via CYP enzymes, 
especially those mediated by CYPs 1A2, 2C8, 2C9, 2C19, 2D6 and 3A4, is generally 
high compared with those for transporter-based DDIs and non-CYP enzymes (Fowler 
et al. 2017). Significant challenges are still present in the prediction of complex drug 
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interactions where perpetrator drugs and metabolites affect both transporter and 
enzyme-mediated disposition processes, where multiple forms of interaction such as 
time-dependent inhibition, active uptake and enzyme induction occur simultaneously 
(Varma et al. 2014; Fowler et al. 2017). The HIV drug ritonavir, is one such example 
of a complex case where as well as being a CYP3A4 substrate, it inhibits, inactivates 
and induces CYP3A4 and also inhibits and induces other DMEs. Model validation for 
accurate prediction of DDIs is more difficult concerning non-CYP enzymes such as 
aldehyde oxidase (AO), flavin monooxygenases (FMO) and UGTs because PK data 
for specific substrates and in vivo interactions with inhibitors are lacking. Currently, 
much effort is focused on dissecting the relative contributions of DMEs and drug 
transporters on drug PK and therefore the potential for the DMEs and transporters to 
mediate DDIs. Increased knowledge in enzymology and better cellular models to 
investigate DDIs will overcome some of these problems. The methods presented in 
this thesis can be used to characterise kdeg for less well-characterised CYPs or non-
CYP DMEs. The data and discussions presented in this thesis will hopefully 
contribute to improving prediction accuracy of DDIs in the near future. 
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